PF-[ADDRESS_465370] -IN-HUMAN  STUDY 
TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND  
PHARMACODYNAMICS OF SINGLE ASCENDING ORAL DOSES OF 
PF-07328948  ADMINISTERED  TO HEALTHY  ADULT  PARTICIPANTS  
 
Study  Intervention  Number:  PF-07328948  
Study  Intervention  Name:  [CONTACT_219912]:  CCI  
EudraCT Number:  NA 
ClinicalTrials.gov ID:  NA 
Pediatric Investigational Plan Number:  NA 
Protocol Number:  C4921001  
Phase:  1 
Brief  Title:  A Phase  1 Study  of Single  Ascending  Doses  of PF-07328948  in Healthy 
Adult Participants  
 
 
 
This document  and accompanying  materials  contain  confidential  information  belonging  to [COMPANY_007].  Except  as 
otherwise agreed to in writing, by [CONTACT_22788], you agree to hold this 
information  in confidence  and not copy  or disclose  it to others  (except  where  required  by [CONTACT_61285]) or 
use it for unauthorized purposes. In the event of any actual or suspected breach of this obligation, [COMPANY_007] 
must be promptly notified.  

PF-[ADDRESS_465371]  of country  health  authorities  and IRBs/ECs  and any protocol  administrative  change 
letter(s).  
Protocol  Amendment  Summary  of Changes  Table 
Amendment 2 (24 Jan 2023)  
Overall Rationale for the Amendment: The protocol is being amended to add pre - and 
post-dose neurological examinations to the Schedule of Activities and to extend CRU 
confinement  of participants  for an additional  [ADDRESS_465372]-dose. These changes are prompted by [CONTACT_371995] 1.  
 
Section  # and 
Name  [CONTACT_372017] 1.1 
(Synopsis), 1.3 
(Schedule of 
Activities),  2.3.1 
(Risk 
Assessment),  
2.3.2  (Benefit  
Assessment),  4.2 
(Scientific 
Rationale for 
Study Design), 
8.3.2  
(Neurological 
Examinations),  
9.3.1  (Safety 
Endpoints)  Updated to include 
neurological 
examinations pre - and 
post-dose,  with relevant 
rationale.  A SAE of “possible 
seizure”  occurred  during 
follow -up in 1 
participant in Cohort 1. 
Although  not considered 
related to blinded study 
intervention by [CONTACT_371996], out of an 
abundance of caution, 
participants  in this study 
will be monitored 
closely with serial 
physical exams directed 
at identifying any 
neurological signs or 
symptoms.  Substantial  
PF-07328948  
Protocol  C4921001  
Final  Protocol  Amendment  2, 24 Jan 2023  
PFIZER  CONFIDENTIAL  
Page  3  
  
Section  # and 
Name  [CONTACT_372018]  4.1 
(Overall 
Design),  
Section 4.2 
(Scientific 
Rationale for 
Study  Design), 
Section 4.3.1 
(Human PK 
Predictions)  The participants in each 
treatment period will be 
confined in CRU for an 
additional day and 
discharged on Day 4 of 
Cohort 2 and optional 
Cohort 3 (changed from 
discharge on Day 3 in 
Cohort 1) to collect PK 
samples at [ADDRESS_465373] - 
dose.  The preliminary  PK 
data emerging from 
Cohort 1 suggested the 
terminal half -life could  
be longer than this 
predicted 4 hours.  The emerging PK data 
from  Cohort  1 suggested 
the terminal t 1/[ADDRESS_465374] -dose.  Substantial  
Section 1.3 
(Schedule of 
Activities), 
Section  5.3.2 
(Meals and 
Dietary 
Restrictions)  CRU discharge, 
contraception check, 
physical exam, 
urinalysis, and safety 
laboratory tests removed 
from  Day 3, and replaced 
as pre -discharge 
activities on Day 4; 
added “Day 4 (if 
applicable)” for meals 
and dietary resctrictions  As a result for one 
additional day 
confinement  in CRU  and 
discharge changed to 
Day 4, some  
assessments scheduled 
on Day 3 are moved to 
prior to discharge on 
Day 4.  Nonsubstantial  
Section 1.3 
(Schedule  of 
Activities)  PK sample  collection  at 
[ADDRESS_465375]  OF FIGURES  ................................ ................................ ................................ ....................  9 
1. PROTOCOL  SUMMARY  ................................ ................................ ................................ ... 10 
1.1. Synopsis  ................................ ................................ ................................ ...................  10 
1.2. Schema ................................ ................................ ................................ .....................  16 
1.3. Schedule  of Activities  ................................ ................................ ..............................  17 
2. INTRODUCTION  ................................ ................................ ................................ ................  24 
2.1. Study  Rationale  ................................ ................................ ................................ ........  24 
2.2. Background  ................................ ................................ ................................ ..............  24 
2.2.1.  Nonclinical  Pharmacology  ................................ ................................ ..........  24 
2.2.2.  Nonclinical  Pharmacokinetics  and Metabolism  ................................ ..........  25 
CCI  
2.2.4.  Nonclinical  Safety  ................................ ................................ .......................  26 
2.3. Benefit/Risk Assessment  ................................ ................................ .........................  27 
2.3.1.  Risk Assessment  ................................ ................................ .........................  28 
2.3.2.  Benefit Assessment  ................................ ................................ .....................  30 
2.3.3.  Overall Benefit/Risk Conclusion  ................................ ................................  30 
3. OBJECTIVES  AND  ENDPOINTS  ................................ ................................ .....................  30 
4. STUDY  DESIGN  ................................ ................................ ................................ .................  31 
4.1. Overall  Design  ................................ ................................ ................................ .........  31 
4.2. Scientific Rationale for Study  Design  ................................ ................................ ..... 32 
4.2.1.  Choice  of Contraception/Barrier  Requirements  ................................ ..........  34 
4.2.2.  Collection  of Retained  Research  Samples  ................................ ...................  34 
4.3. Justification for Dose  ................................ ................................ ...............................  34 
CCI  
4.3.2.  Predicted  Efficacious  Concentration  and Human  Dose  ..............................  35 
4.3.3.  Human Exposure Stoppi[INVESTIGATOR_336241]  ................................ ..............................  35 
4.3.4.  Rationale  for Dose Selection  ................................ ................................ ....... 36 
4.4. End of Study  Definition  ................................ ................................ ...........................  37 
5. STUDY POPULATION  ................................ ................................ ................................ ...... 37 
PF-07328948  
Protocol  C4921001  
Final  Protocol  Amendment  2, 24 Jan 2023  
PFIZER  CONFIDENTIAL  
Page  5  
 5.1. Inclusion  Criteria  ................................ ................................ ................................ .... 38 
5.2. Exclusion Criteria  ................................ ................................ ................................ ... 38 
5.3. Lifestyle  Considerations  ................................ ................................ .........................  41 
5.3.1.  Contraception  ................................ ................................ .............................  41 
5.3.2.  Meals and Dietary  Restrictions  ................................ ................................ .. 41 
5.3.3.  Caffeine,  Alcohol,  and Tobacco  ................................ ................................ . 43 
5.3.4.  Activity  ................................ ................................ ................................ ...... 43 
5.4. Screen  Failures  ................................ ................................ ................................ ........  44 
6. STUDY  INTERVENTION(S)  AND  CONCOMITANT  THERAPY  ................................ . 44 
6.1. Study  Intervention(s)  Administered  ................................ ................................ ........  44 
6.1.1.  Administration  ................................ ................................ ............................  45 
6.2. Preparation, Handling, Storage, and Accountability  ................................ ..............  45 
6.2.1.  Preparation  and Dispensing  ................................ ................................ ........  46 
6.3. Assignment to Study Intervention  ................................ ................................ ..........  47 
6.4. Blinding  ................................ ................................ ................................ ..................  47 
6.4.1.  Blinding  of Participants  ................................ ................................ ..............  47 
6.4.2.  Blinding  of Site Personnel  ................................ ................................ ..........  47 
6.4.3.  Blinding of the Sponsor  ................................ ................................ .............  48 
6.4.4.  Breaking  the Blind  ................................ ................................ .....................  48 
6.5. Study  Intervention  Compliance  ................................ ................................ ..............  48 
6.6. Dose  Modification  ................................ ................................ ................................ .. 48 
6.6.1.  Dose  Escalation  and Stoppi[INVESTIGATOR_14123]  ................................ ..........................  49 
6.7. Continued  Access to  Study  Intervention After  the End  of the Study  .....................  50 
6.8. Treatment of Overdose  ................................ ................................ ...........................  50 
6.9. Prior  and Concomitant  Therapy  ................................ ................................ ..............  51 
6.9.1.  Rescue  Medicine  ................................ ................................ ........................  51 
7. DISCONTINUATION OF STUDY INTERVENTION AND PARTICIPANT  
DISCONTINUATION/WITHDRAWAL  ................................ ................................ ...........  51 
7.1. Discontinuation of Study  Intervention  ................................ ................................ .... 51 
7.1.1.  ECG  Changes  ................................ ................................ .............................  52 
7.1.2.  Potential Cases of Acute Kidney  Injury  ................................ .....................  52 
7.1.3.  COVID -19 ................................ ................................ ................................ .. 53 
PF-07328948  
Protocol  C4921001  
Final  Protocol  Amendment  2, 24 Jan 2023  
PFIZER  CONFIDENTIAL  
Page  6  
 7.2. Participant Discontinuation/Withdrawal From the Study  ................................ ....... [ADDRESS_465376] to Follow -up ................................ ................................ ................................ .... 55 
8. STUDY  ASSESSMENTS  AND  PROCEDURES  ................................ ...............................  55 
8.1. Administrative  Procedures  ................................ ................................ .......................  55 
8.2. Efficacy  Assessments  ................................ ................................ ..............................  56 
8.3. Safety Assessments  ................................ ................................ ................................ .. 56 
8.3.1.  Physical  Examinations  ................................ ................................ ................  57 
8.3.2.  Neurological Examinations  ................................ ................................ .........  57 
8.3.3.  Vital  Signs  ................................ ................................ ................................ ... 57 
[IP_ADDRESS].  Blood Pressure and Pulse Rate ................................ ..................  57 
[IP_ADDRESS].  Respi[INVESTIGATOR_82218] ................................ ................................ ........  58 
8.3.4.  Electrocardiograms  ................................ ................................ ......................  58 
[IP_ADDRESS].  Continuous  Cardiac  Monitoring  by [CONTACT_336258]  ..........................  59 
8.3.5.  Clinical  Safety  Laboratory  Assessments  ................................ .....................  59 
8.4. Adverse  Events,  Serious  Adverse  Events,  and Other  Safety  Reporting  ..................  60 
8.4.1.  Time Period and Frequency  for Collecting AE and SAE Information  ....... 61 
[IP_ADDRESS].  Reporting SAEs to [COMPANY_007] Safety  ................................ ...............  61 
[IP_ADDRESS].  Recording  Nonserious  AEs and SAEs  on the CRF ...................  61 
8.4.2.  Method  of Detecting  AEs and SAEs  ................................ ...........................  62 
8.4.3.  Follow -Up of AEs and SAEs  ................................ ................................ ...... 62 
8.4.4.  Regulatory  Reporting Requirements for SAEs  ................................ ...........  62 
8.4.5.  Environmental Exposure, Exposure During Pregnancy  or 
Breastfeeding, and Occupational Exposure  ................................ .....................  63 
[IP_ADDRESS].  Exposure During Pregnancy  ................................ ......................  63 
[IP_ADDRESS].  Exposure  During  Breastfeeding  ................................ .................  65 
[IP_ADDRESS].  Occupational Exposure  ................................ ..............................  65 
8.4.6.  Cardiovascular  and Death  Events  ................................ ................................  65 
8.4.7.  Disease -Related  Events  and/or  Disease -Related  Outcomes  Not 
Qualifying  as AEs or SAEs  ................................ ................................ ..............  [ADDRESS_465377]  ................................ .............................  65 
[IP_ADDRESS].  Lack of Efficacy  ................................ ................................ ........  66 
PF-07328948  
Protocol  C4921001  
Final  Protocol  Amendment  2, 24 Jan 2023  
PFIZER  CONFIDENTIAL  
Page  7  
 8.4.9.  Medical  Device  Deficiencies  ................................ ................................ ...... 66 
8.4.10.  Medication  Errors  ................................ ................................ ......................  66 
8.5. Pharmacokinetics  ................................ ................................ ................................ ..... 67 
8.5.1.  Plasma  for Analysis  of PF-07328948  Concentrations  ................................ . 67 
8.6. Genetics  ................................ ................................ ................................ ...................  68 
8.6.1.  Specified  Genetics  ................................ ................................ .......................  68 
8.6.2.  Retained  Research  Samples  for Genetics  ................................ ....................  68 
8.7. Pharmacodynamics  ................................ ................................ ................................ .. 68 
8.7.1.  Biomarkers  ................................ ................................ ................................ .. 68 
[IP_ADDRESS].  Specified Gene Expression (RNA) Research  ............................  68 
[IP_ADDRESS].  Specified  Protein  Research  ................................ ........................  69 
[IP_ADDRESS].  Specified  Metabolomic  Research  ................................ ...............  69 
[IP_ADDRESS].  Retained  Research  Samples  for Biomarker  ................................  69 
8.7.2.  Pharmacodynamics  Assessments  ................................ ................................  69 
CCI  
8.8. Immunogenicity  Assessments  ................................ ................................ .................  70 
8.9. Health  Economics  ................................ ................................ ................................ .... 71 
9. STATISTICAL  CONSIDERATIONS  ................................ ................................ .................  71 
9.1. Statistical Hypothesis  ................................ ................................ ..............................  71 
9.2. Analysis  Sets ................................ ................................ ................................ ............  71 
9.3. Statistical Analyses  ................................ ................................ ................................ .. 72 
9.3.1.  Safety Endpoints  ................................ ................................ .........................  72 
[IP_ADDRESS].  Electrocardiogram Analyses  ................................ ......................  72 
9.3.2.  PK Endpoints  ................................ ................................ ..............................  73 
[IP_ADDRESS].  Derivation  of PF-07328948  PK Parameters  ..............................  73 
[IP_ADDRESS].  Statistical  Methods  for PK Data ................................ ................  74 
9.3.3.  Tertiary/Exploratory  Endpoint(s)  Analysis  ................................ .................  74 
9.3.4.  Other  Analyses  ................................ ................................ ............................  74 
9.4. Interim  Analyses  ................................ ................................ ................................ ...... 74 
9.5. Sample Size Determination  ................................ ................................ .....................  74 
PF-07328948  
Protocol  C4921001  
Final  Protocol  Amendment  2, 24 Jan 2023  
PFIZER  CONFIDENTIAL  
Page  8  
 10. SUPPORTING   DOCUMENTATION   AND   OPERATIONAL  
CONSIDERATIONS  ................................ ................................ ................................ ..........  75 
10.1. Appendix  1: Regulatory,  Ethical, and  Study  Oversight Considerations  ...............  75 
10.1.1.  Regulatory  and Ethical Considerations  ................................ ....................  75 
[IP_ADDRESS].  Reporting of Safety Issues and Serious Breaches of the  
Protocol  or ICH GCP  ................................ ................................ ........  75 
10.1.2.  Financial Disclosure  ................................ ................................ .................  76 
10.1.3.  informed  Consent  Process  ................................ ................................ ........  76 
10.1.4.  Data  Protection  ................................ ................................ .........................  77 
10.1.5.  Committees  Structure  ................................ ................................ ...............  77 
[IP_ADDRESS].  Data  Monitoring  Committee  ................................ ...................  77 
10.1.6.  Dissemination  of Clinical Study  Data ................................ ......................  77 
10.1.7.  Data  Quality  Assurance  ................................ ................................ ............  79 
10.1.8.  Source Documents  ................................ ................................ ...................  80 
10.1.9.  Study  and Site Start and Closure  ................................ ..............................  80 
10.1.10.  Publication Policy  ................................ ................................ ..................  81 
10.1.11.  Sponsor’s Medically  Qualified Individual  ................................ .............  82 
10.2. Appendix 2: Clinical Laboratory  Tests  ................................ ................................  83 
10.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording,  
Evaluating,  Follow -Up, and Reporting  ................................ ................................ ..... 85 
10.3.1.  Definition  of AE ................................ ................................ .......................  85 
10.3.2.  Definition  of an SAE ................................ ................................ ................  86 
10.3.3.  Recording/Reporting  and Follow -Up of AEs and/or  SAEs During  
the Active Collection Period  ................................ ................................ ...........  87 
10.3.4.  Reporting of SAEs  ................................ ................................ ...................  91 
10.4. Appendix  4: Contraceptive  and Barrier  Guidance  ................................ ................  92 
10.4.1.  Male Participant Reproductive Inclusion Criteria  ................................ ... 92 
10.4.2.  Female Participant Reproductive Inclusion Criteria  ................................  92 
10.4.3.  Woman  of Childbearing  Potential  ................................ ............................  92 
10.4.4.  Contraception  Methods  ................................ ................................ ............  93 
10.5. Appendix 5: Genetics  ................................ ................................ ...........................  95 
10.6. Appendix  6: Liver  Safety:  Suggested  Actions  and Follow -Up Assessments  ....... 96 
10.7. Appendix 7: Kidney  Safety: Monitoring Guidelines  ................................ ............  98 
PF-07328948  
Protocol  C4921001  
Final  Protocol  Amendment  2, 24 Jan 2023  
PFIZER  CONFIDENTIAL  
Page  9  
 10.7.1.  Laboratory  Assessment of Change  in Kidney  Function  and 
Detection of Kidney Injury  ................................ ................................ .............  98 
10.7.2.  Age-Specific  Kidney  Function  Calculation Recommendations  ...............  98 
[IP_ADDRESS].  Adults  (18 Years  and Above) —2021 CKD -EPI 
[INVESTIGATOR_185560]  ................................ ................................ ..........................  98 
10.7.3.  Adverse  Event  Grading  for Kidney  Safety  Laboratory  
Abnormalities  ................................ ................................ ................................ .. 98 
10.8. Appendix  8: ECG  Findings  of Potential  Clinical  Concern  ................................ ... 99 
10.9. Appendix  9: Protocol  Amendment  History  ................................ ........................  101 
10.10.  Appendix  10: Abbreviations  ................................ ................................ .............  [ADDRESS_465378] OF TABLES  
Table  1. Study  Schedule of Assessment  ................................ ................................ . 17 
Table  2. Schedule of Activities for PK, PD, Vitals, and ECGs on Day  1 (and 
Day -1 if Applicable)  ................................ ................................ ...............  [ADDRESS_465379]  OF FIGURES  
Figure  1. Study  Design Schemaa,b,c,d  ................................ ................................ ................................ .............  16 
PF-07328948  
Protocol  C4921001  
Final  Protocol  Amendment  2, 24 Jan 2023  
PFIZER  CONFIDENTIAL  
Page  10  
 1. PROTOCOL  SUMMARY  
1.1. Synopsis  
Protocol Title: A Phase 1, Randomized, Double -Blind, Sponsor -Open, Placebo -Controlled, 
4-Period, Crossover, First -in-Human Study to Evaluate the Safety, Tolerability, 
Pharmacokinetics,  and Pharmacodynamics  of Single  Ascending  Oral Doses  of PF-07328948 
Administered to Healthy Adult Participants  
Brief  Title:  A Phase  1 Study  of Single  Ascending  Doses  of PF-07328948  in Healthy  Adult 
Participants  
Regulatory  Agency  Identification  Number(s):  
 
US IND Number:  CCI  
EudraCT  Number:  NA 
ClinicalTrials.gov  ID: NA 
Pediatric  Investigational  Plan  Number:  NA 
Protocol  Number:  C4921001  
Phase:  1 
Rationale: This study is the first clinical study with PF -07328948. The safety, tolerability, 
and plasma  PK and PD of PF-07328948  after administration  of escalating,  single,  oral doses 
will be evaluated.  
PF-07328948  
Protocol  C4921001  
Final  Protocol  Amendment  2, 24 Jan 2023  
PFIZER  CONFIDENTIAL  
Page  11  
 Objectives  and Endpoints:  
 
 
Primary:  Objectives   
Primary:  Endpoints  
• To evaluate the safety and tolerability of single 
ascending  doses  of PF-07328948  administered  orally  to 
healthy adult participants.  
 
Secondary:  
• To evaluate the pharmacokinetics of PF -07328948 
following  single  doses  of PF-07328948  administered 
orally to healthy adult participants.  
Tertiary/Exploratory:  
• To evaluate  additional  pharmacokinetic  parameters  of 
PF-07328948  following  single  doses  of PF-07328948 
administered orally to healthy adult participants.  • Assessment of adverse events, clinical safety 
laboratory tests, vital signs, continuous cardiac 
monitoring,  12-lead electrocardiograms,  and physical 
examinations.  
Secondary:  
• PK parameters derived from plasma PF -07328948 
concentrations:  Cmax, Tmax, AUC last, and if data permit, 
AUC inf, and t ½. 
Tertiary/Exploratory:  
• Additional  PK parameters  derived  from  plasma  
PF-07328948  concentrations:  Cmax(dn),  AUC last(dn) 
and if data permit AUC inf(dn), CL/F and V z/F. 
• CCI 
 
 
 
 
 
 
 
 
 
 
 
• To evaluate  the effect  of food (eg, a protein -rich meal 
such as MMTT),  if administered,  on the plasma  PK of 
PF-07328948 following single dose of PF -07328948 
administered orally to healthy adult participants.  . 
• PK parameters derived from plasma PF -07328948 
concentrations  after MMTT:  Cmax, Tmax, AUC last, and 
if data permit, AUC inf, and t ½. 
 
 
Overall  Design:  
This is a randomized, investigator - and participant -blind, sponsor -open, placebo -controlled, 
first-in-human study to assess safety, tolerability, PK and PD of single ascending oral doses 
of PF -07328948 administered to healthy adult participants in 2 planned cohorts (Cohort 1 
and Cohort 2). Each cohort will be a [ADDRESS_465380] dose for each cohort.  
Based  on the review  of emerging  safety,  tolerability,  and PK, 1 optional  cohort  of 
8 participants may be enrolled (crossover, placebo -controlled design) to explore additional 
doses,  to repeat  a dose,  to evaluate  split dosing,  or to investigate  food effects  on PK and PD 
biomarkers.  
 
Number of Participants: A total of up to approximately 16 (Cohorts 1 and 2) or 24 (with 
optional  Cohort  3) healthy  adult  participants  (approximately  8 participants  per cohort)  will be 
enrolled in the study.  
Note: "Enrolled" means a participant's agreement to participate in a clinical study following 
completion of the informed consent process and randomization to study intervention. A 
participant will be considered enrolled if the informed consent is not withdrawn prior to 
participating in any study activity  after screening. Potential participants who are screened for 
the purpose  of determining  eligibility  for the study,  but do not participate  in the study,  are not 
considered enrolled, unless otherwise specified by [CONTACT_760].  
Study Population:  Key inclusion and exclusion criteria are listed  below:  
Inclusion  Criteria  
Participants  must  meet  the following  key inclusion  criteria  to be eligible  for enrollment  into 
the study:  
1. Female  participants  of non-childbearing  potential  and males  must  be 18 to 60 years  of 
age, inclusive, at the time of signing the ICD.  
2. Female participants of non -childbearing potential and males who are overtly healthy 
as determined  by [CONTACT_371997],  physical  examination, 
laboratory tests, and cardiac monitoring.  
3. Participants  who are willing  and able to comply  with all scheduled  visits,  treatment 
plan, laboratory tests, lifestyle considerations, and other study procedures.  
Exclusion  Criteria  
Participants  with any of the following  characteristics/conditions  will be excluded:  
1. Evidence or history of clinically significant hematological, renal, endocrine, 
pulmonary,  gastrointestinal,  cardiovascular,  hepatic,  psychiatric,  neurological,  or 
PF-07328948  
Protocol  C4921001  
Final  Protocol  Amendment  2, 24 Jan 2023  
PFIZER  CONFIDENTIAL  
Page  13  
 allergic  disease  (including  drug allergies,  but excluding  untreated,  asymptomatic, 
seasonal allergies at the time of dosing).  
• Any condition  possibly  affecting  drug absorption  (eg, gastrectomy, 
cholecystectomy).  
• History  of HIV infection,  hepatitis  B, or hepatitis  C; positive  testing  for HIV, 
HBsAg, HBcAb, or HCVAb. Hepatitis B vaccination is allowed.  
2. Other medical or psychiatric condition including recent (within the past year) or 
active suicidal ideation/behavior or laboratory abnormality or other conditions or 
situations related to COVID -19 pandemic that may increase the risk of study 
participation  or, in the investigator’s  judgment,  make  the participant  inappropriate  for 
the study.  
3. Use of prescription  or nonprescription  drugs  and dietary  and herbal  supplements 
within  7 days or 5 half-lives  (whichever  is longer)  prior  to the first dose of study 
intervention.  
4. Receipt of a COVID -[ADDRESS_465381]  (drug  or vaccine) within  
30 days (or as determined  by [CONTACT_219873])  or [ADDRESS_465382] 
dose of study intervention used in this study (whichever is longer).  
6. Screening  supi[INVESTIGATOR_145972] ≥140  mm Hg (systolic)  or ≥90 mm Hg (diastolic),  following  at 
least [ADDRESS_465383].  
7. Renal  impairment  as defined  by [CONTACT_371998]  <75 mL/min/1.73m2 calculated  using 
CKD -EPI [INVESTIGATOR_371973].  
8. Standard [ADDRESS_465384] participant safety or interpretation of study results (eg, QTcF >[ADDRESS_465385] -degree AV 
block, or serious bradyarrhythmias or tachyarrhythmias). If the uncorrected QT 
interval  is >[ADDRESS_465386], if deemed necessary:  
• AST  or ALT  level  ≥1.25×  ULN;  
• Total bilirubin level ≥1.5 × ULN; participants with a history of Gilbert’s 
syndrome  may have  direct  bilirubin  measured  and would  be eligible  for this study 
provided the direct bilirubin level is ≤ULN.  
10. History of alcohol abuse or binge drinking and/or any other illicit drug use or 
dependence within 6 months of Screening. Binge drinking is defined as a pattern of 
5 (male)  and 4 (female)  or more  alcoholic  drinks  in about  2 hours.  As a general  rule, 
alcohol  intake  should  not exceed  14 units  per week  (1 unit = 8 ounces  (240 mL) beer, 
1 ounce (30 mL) of 40% spi[INVESTIGATOR_17040], or 3 ounces (90 mL) of wine).  
11. Investigator site staff directly involved in the conduct of the study and their family 
members,  site staff otherwise  supervised  by [CONTACT_093],  and sponsor  and sponsor 
delegate employees directly involved in the conduct of the study and their family 
members.  
Study Arms and Duration:  
PF-07328948  and placebo  will be provided  by [CONTACT_371999].  
 
Study  Intervention(s)  
Intervention  Name  [INVESTIGATOR_16335]-07328948  Placebo  
Arm  Name  
(group  of participants  receiving  a specific  treatment  or 
no treatment)  PF-07328948  Placebo  
Unit  Dose  Strength(s)  10-3000 mg 0 mg 
Route  of Administration  Oral Oral 
Use Experimental  Placebo  
IMP or NIMP/AxMP  IMP IMP 
PF-07328948  
Protocol  C4921001  
Final  Protocol  Amendment  2, 24 Jan 2023  
PFIZER  CONFIDENTIAL  
Page  15  
  
Study  Arm(s)  
Arm  Title  Cohort 1 Cohort 2 Cohort 3 (Optional)  
Arm  Type  Experimental  Experimental  Experimental  
Arm Description  Participants  will receive  up to 
4 dose levels  of PF-07328948 
and up to 2 doses  of matching 
placebo. Doses will be 
administered as oral  
suspensions  as escalating  single 
doses to be determined.  Participants  will receive  up to 
4 dose levels  of PF-07328948 
and up to 2 doses  of matching 
placebo. Doses will be 
administered as oral 
suspensions as escalating 
single  doses  to be determined.  Participants  will receive  up to 
4 dose levels  of PF-07328948 
and up to 2 doses  of matching 
placebo. Doses will be 
administered as oral 
suspensions as escalating 
single  doses  to be determined.  
 
Statistical  Methods:  
The sample size has been chosen based on the need to minimize first exposure to humans of  
a new chemical  entity  and the requirement  to conduct  adequate  safety,  toleration, PK  and PD 
assessments at each dose level. All safety analyses will be performed on the safety analysis 
set, which  is defined  as all participants  randomly  assigned  to study  intervention  and who take 
at least 1 dose of study intervention. Participants will be analyzed according to the study 
intervention they actually received. Safety data will be presented in tabular and/or graphical 
format and summarized descriptively, where appropriate. The plasma PK parameters for 
PF‑07328948 following oral dose administration will be derived from the plasma 
concentration‑time profiles. Plasma PK parameters and concentrations of PF -07328948 will 
be descriptively summarized by [CONTACT_2715] (and fasting condition, if appropriate) and nominal 
time, as appropriate.  
Ethical Considerations:  
The participants in this study are not expected to obtain any specific benefit beyond 
contributing to the process of developi[INVESTIGATOR_336243]. They  will 
receive close monitoring of their safety via study procedures undertaken (eg, physical 
examinations, neurological examinations, 12 -lead ECGs, vital signs) which will occur as 
outlined in this protocol. Based on the totality of available nonclinical data, and taking into 
account the measures to minimize risk to study participants, the overall benefit/risk profile 
supports  clinical  testing  of PF-[ADDRESS_465387]  of food  (eg, a protein -rich meal  such as MMTT) may  be evaluated  in at least 1 period  of Cohort  2 (eg, P3) and/or 
Cohort [ADDRESS_465388] period in each cohort (with red box) and the first period of assessment of food effect in any cohort (eg, P3 in 
Cohort  2 with red box),  participants  will be admitted  on Day -2 and time-matched  biomarker  assessment  will be collected  on 
Day -1. 
d. Precautionary  sentinel  dosing  will be used in any period  evaluating  escalating  doses  of PF-07328948.  For such periods,  2 
participants (1 receiving  PF-07328948 and 1 receiving placebo) will be dosed initially before the remaining participants of 
that period are dosed. Safety and tolerability data through at least [ADDRESS_465389] -dose for the sentinel participants will be 
reviewed prior to dosing the remaining participants of that period. Sentinel dosing may be omitted when repeating a dose 
level or administering a lower dose level than previously evaluated.  
PF-07328948  
Protocol  C4921001  
Final  Protocol  Amendment  2, 24 Jan 2023  
PFIZER  CONFIDENTIAL  
Page  17  
  
1.3. Schedule of Activities  
The SoA table provides an overview of the protocol visits and procedures. Refer to the STUDY ASSESSMENTS AND  
PROCEDURES  section  of the protocol  for detailed  information  on each procedure  and assessment  required  for compliance  with the 
protocol.  
The investigator  may schedule  visits  (unplanned  visits)  in addition  to those  listed  in the SoA table,  in order  to conduct  evaluations  or 
assessments required to protect the well -being of the participant.  
 
Table  1. Study  Schedule  of Assessment  
 
Visit  Identifier  
Abbreviations used in this 
table  may be found  in 
Appendix 10 . Screen  Period  1 to Period  4 
In-patient  Follow -Up ET Notes  
Days  Relative  to Day 1 Day -28 to 
Day -3 Day 
-2 Day 
-1 Day 
1 Day 
2 Day 
3 Day 
4 Visit: 
Day 
8±[ADDRESS_465390]: 
28-35 
days  All screening  should  be done  ≤[ADDRESS_465391] dose. 
Day relative to start of study intervention (Day 1).  
Day 1 activities  at time=0  hour are prior  to the dose,  except 
for study intervention administration.  
On-site follow -up visit occurs on Day 8±[ADDRESS_465392] occur  
28 to 35 days after administration  of the final dose of study 
intervention.  Hours  After  Dose     0 24 36 48 72 
Informed consent  X           Informed  consent  should  be obtained  prior  to undergoing 
any study -specific procedures.  
See Section  10.1.3  for additional information.  
CRU  confinement   X X → → → → X    Admission  on Day -[ADDRESS_465393] in any cohort,  
if applicable  
Inclusion/exclusion criteria  X X          Period  1 only.  Review  any changes  from  Screening.  
Medical/medication history  X X          
History  of alcohol,  tobacco, 
and illegal drug use  X X          
Review  concomitant 
treatments  X → → → → → → → → X X See Section  6.9 for additional  information.  
Demography  X            
PF-07328948  
Protocol  C4921001  
Final  Protocol  Amendment  2, 24 Jan 2023  
PFIZER  CONFIDENTIAL  
Page  18  
  
Table  1. Study  Schedule  of Assessment  
 
Visit Identifier 
Abbreviations  used in this 
table may be found in  
Appendix 10. Screen  Period  1 to Period  4 
In-patient  Follow -Up ET Notes  
Days  Relative  to Day 1 Day -28 to 
Day -3 Day 
-2 Day 
-1 Day 
1 Day 
2 Day 
3 Day 
4 Visit: 
Day 
8±[ADDRESS_465394]: 
28-35 
days  All screening  should  be done  ≤[ADDRESS_465395] dose. 
Day relative to start of study intervention (Day 1).  
Day 1 activities  at time=0  hour are prior  to the dose,  except 
for study intervention administration.  
On-site follow -up visit occurs on Day 8±[ADDRESS_465396] occur  
28 to 35 days after administration  of the final dose of study 
intervention.  Hours  After  Dose     0 24 36 48 72 
Contraception  check  X X X     X X X X Contraception  only required  for male  study  participants. 
Contraceptive guidance is outlined in Appendix 4 . 
If performed  on Day -2 at admission,  assessment  is not 
needed on Day -1 
COVID -19 related  measures   X X X X  X X X  X Per CRU procedures.  
CRU  discharge         X    Participants may be asked to remain at the CRU after 
completion  of Day 4 activities  at the discretion  of the 
investigator  or if safety,  tolerability,  or PK data dictate  the 
need to prolong inpatient stay at the CRU  
Serious  and nonserious  AE 
monitoring  X → → → → → → → → X X See Section  8.4.3  for follow -up AE and SAE  assessments.  
Physical exam  X X  
See Table  2 X   X X  X Complete PE at Screening or upon admission for a 
participant’s  first period  in the study;  at all other  time points, 
brief PE performed for findings during previous exam or 
new/open AEs, at investigator discretion.  
Including  height  and weight  only at screening 
See Section 8.3.1  for additional information.  
Neurological  examination     X    X  X Complete neurological exam for timepoints on Day 1 (see 
Table  2) and 24 hours  after dosing  on Day 1. At other  time 
points, neurological exam at investigator discretion.  
See Section  8.3.2  for additional  information.  
Respi[INVESTIGATOR_2842]    X  X X X  X Single assessment at all timepoints  
See Section  8.3.3  for additional  details.  
PF-07328948  
Protocol  C4921001  
Final  Protocol  Amendment  2, 24 Jan 2023  
PFIZER  CONFIDENTIAL  
Page  19  
  
Table  1. Study  Schedule  of Assessment  
Visit Identifier 
Abbreviations  used in this 
table may be found in 
Appendix 10 . Screen  Period  1 to Period  4 
In-patient  Follow -Up ET Notes  
Days  Relative  to Day 1 Day -28 to 
Day -3 Day 
-2 Day 
-1 Day 
1 Day 
2 Day 
3 Day 
4 Visit: 
Day 
8±[ADDRESS_465397]: 
28-35 
days All screening  should  be done  ≤[ADDRESS_465398] dose. 
Day relative to start of study intervention (Day 1).  
Day 1 activities  at time=0  hour are prior  to the dose,  except  
Hours  After  Dose  
 
 
 
 
 
Supi[INVESTIGATOR_371974]  X 
pulse rate  
 
 
 
12-Lead  ECG  X 
 
 
Continuous  cardiac  telemetry 
Study intervention 
administration  
Standardized meal/snack  
Blood samples for: 
PF-07328948  plasma 
pharmacokinetics  
CCI 
CCI 0 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X See Table  2 24  36 48 72 
 
 
 
 
 
X X X X 
 
 
 
 
X X X X 
 
 
 
 
 
X X 
 
X X X X 
 
C 
C for study  intervention  administration.  
On-site follow -up visit occurs on Day 8±[ADDRESS_465399]  occur 
28 to 35 days after administration  of the final dose of study 
intervention.  
X Single assessment at Screening, Day 1 at 0 hour, follow -up 
visit and ET. Triplicate assessments at all other times. 
Triplicate  measures  are collected  approximately  2-4 minutes 
apart.  
See Section  8.3.3  for additional  details.  
X Single 12 -lead ECG at Screening, follow -up visit and ET. 
Triplicate  12-lead ECGs  at all other  times.  See Section  8.3.4  
for additional details.  
 
Dosing  under  fasted  or fed conditions  (eg, MMTT)  is to 
occur as outlined in Section 5.3.2.  
See Section  5.3.2  for detailed  instruction.  
 
X See Section  8.5.1  for additional  details.  
 
 
Samples on Day 2 and Day 3 ([ADDRESS_465400] -dose) 
and at follow -up visit (Day  8±1)  after the final dose will be 
collected after fast overnight for at least 8 hours.  
See Section  8.7.2  for additional  information.  See Table  2 
See Table  2 
PF-07328948  
Protocol  C4921001  
Final  Protocol  Amendment  2, 24 Jan 2023  
PFIZER  CONFIDENTIAL  
Page  20  
  
Table  1. Study  Schedule  of Assessment  
 
Visit Identifier 
Abbreviations  used in this 
table may be found in  
Appendix 10. Screen  Period  1 to Period  4 
In-patient  Follow -Up ET Notes  
Days  Relative  to Day 1 Day -28 to 
Day -3 Day 
-2 Day 
-1 Day 
1 Day 
2 Day 
3 Day 
4 Visit: 
Day 
8±[ADDRESS_465401]: 
28-35 
days  All screening  should  be done  ≤[ADDRESS_465402] dose. 
Day relative to start of study intervention (Day 1).  
Day 1 activities  at time=0  hour are prior  to the dose,  except 
for study intervention administration.  
On-site follow -up visit occurs on Day 8±[ADDRESS_465403] 4 hours  prior  to sample 
collection.  
If performed  on Day-2 at admission,  safety  lab tests are not 
needed on Day -1. Results of any pre -dose safety labs  
should  be reviewed  and confirmed  acceptable  prior  to 
dosing.  
Retained  Research  Sample  for 
Genetics (Prep D1.5)     X        Collected in first period only. If not collected on the 
designated collection day, collect at the next available time 
point  when  biospecimens  are being  collected  in conjunction 
with a participant visit. See Section 8.6.2  for additional 
details.  
[COMPANY_007]  Prep B1.5  retained 
research sample     X X       Samples to be collected as outlined in Section [IP_ADDRESS] . 
Samples  will be collected  in Period  1 and Period  4 only for 
each cohort  [COMPANY_007]  Prep B2.5  retained 
research sample     X X       
HIV,  HBsAg,  HBsAb,  
HBcAb,  HCVAb  X           See Appendix  2: Clinical  Laboratory  Tests . 
FSH X           Only  for females  who have  been  amenorrheic  for at least 12 
months.  
Urine  samples  for: 
Urine drug testing  X X X         If performed  on Day-2 at admission,  urine  drug testing  is not 
needed on Day -1. Results of any pre -dose testing should be 
reviewed and confirmed acceptable prior to dosing.  
See Appendix  2: Clinical  Laboratory  Tests  
PF-07328948  
Protocol  C4921001  
Final  Protocol  Amendment  2, 24 Jan 2023  
PFIZER  CONFIDENTIAL  
Page  21  
  
Table  1. Study  Schedule  of Assessment  
 
Visit Identifier 
Abbreviations  used in this 
table may be found in  
Appendix 10. Screen  Period  1 to Period  4 
In-patient  Follow -Up ET Notes  
Days  Relative  to Day 1 Day -28 to 
Day -3 Day 
-2 Day 
-1 Day 
1 Day 
2 Day 
3 Day 
4 Visit: 
Day 
8±[ADDRESS_465404]: 
28-35 
days  All screening  should  be done  ≤[ADDRESS_465405] dose. 
Day relative to start of study intervention (Day 1).  
Day 1 activities  at time=0  hour are prior  to the dose,  except 
for study intervention administration.  
On-site follow -up visit occurs on Day 8±[ADDRESS_465406] occur  
28 to 35 days after administration  of the final dose of study 
intervention.  Hours  After  Dose     0 24 36 48 72 
Urinalysis  (with  microscopy, 
if needed)  X X X  X   X X  X Participant  should  fast for at least 4 hours  prior  to sample 
collection.  
If performed  on Day-2 at admission,  urinalysis  not needed 
on Day -1. Results of any pre -dose testing should be  
reviewed  and confirmed  acceptable  prior  to dosing.  See 
Appendix 2: Clinical Laboratory Tests  
PF-07328948  
Protocol  C4921001  
Final  Protocol  Amendment  2, 24 Jan 2023  
PFIZER  CONFIDENTIAL  
Page  22  
  
Table 2. Schedule  of Activities  for PK, PD, Vitals,  and ECGs  on Day 1 (and  Day -1 if Applicable)  
 
Visit  Identifier  
Abbreviations  used in this table  may 
be found in Appendix 10 .  Notes  
 Day 1, Day -1 (if applicable)  Applies  to Day 1 for Periods  1-4, and for Day -1 when  admission 
occurs on Day -2 
Hours  Relative  to Dosing  at 0 hour  -1.0 -0.5 0 0.5 1 1.5 2 3 4 8 10 12 Day 1 activities  at time = 0 hour are prior  to the dose,  except  for study 
intervention administration.  
Study  intervention  administration 
(Day 1 only)    X          Dosing  under  fasted  or fed conditions  (eg, MMTT)  is to occur  as outlined 
in Section 5.3.2 . 
Standardized meal/snack          X  X  See Section  5.3.2  for detailed  instruction.  
Participants will be provided the same lunch, dinner and snacks at same 
times on Day -1 when time -matched biomarker assessment is collected 
and on Day 1 of each period. If administered on Day -1, MMTT will be 
administered  at the same  time as planned  for administration  on Day 1 (ie, 
20 minutes prior to 0 hour).  
High  protein  meal  (eg, MMTT)    X          Administered only in periods where food effect is assessed.  See 
Section  5.3.2  for detailed  instruction.  High  protein  meal  to be provided 
approximately 20 minutes prior to 0 hours, and consumed within 10 
minutes such that study intervention is administer approximately 10 
minutes after completion of meal.  
Continuous  cardiac  telemetry 
(Day 1 only)    X → → → → → → X   To establish a baseline, telemetry should be recorded for at least a 2 -hour 
interval  before  dosing  in Period  1, either  immediately  prior  to dosing  or at 
some 2 -hour continuous interval in the 24 hours prior to dosing when the 
participant is awake. See Section [IP_ADDRESS] . 
Assessment  on Day 1 initiate  at time=[ADDRESS_465407] 
dose.  
Neurological examination    X    X      Day 1 only.  The pre-dose assessment  (at time =0 hr) can be completed  at 
any time within 24 hours prior to the dose on Day 1 in each period.  
12-Lead  ECG  (Day  1 only)  X X X  X  X X X X  X Triplicate  measures  are collected  approximately  2-4 minutes  apart.  
See Section  8.3.4  for additional  details.  
Supi[INVESTIGATOR_371975] (Day  1 
only)    X  X  X X X X  X Single measurement only at 0 hour; triplicate measurement at other 
timepoints.  Triplicate  measures  are collected  approximately  2-4 minutes 
apart.  
See Section  8.3.3  for additional  details.  
Respi[INVESTIGATOR_697] (Day 1 only)    X  X  X X X X  X Single assessment at all timepoints  
See Section  8.3.3  for additional  details.  
PF-07328948  
Protocol  C4921001  
Final  Protocol  Amendment  2, 24 Jan 2023  
PFIZER  CONFIDENTIAL  
Page  23  
  
Table 2. Schedule  of Activities  for PK, PD, Vitals,  and ECGs  on Day 1 (and  Day -1 if Applicable)  
Visit  Identifier  
Abbreviations  used in this table  may 
be found in Appendix 10 .  
 
 
Day 1, Day -1 (if applicable)  Notes  
 
 
Applies  to Day 1 for Periods  1-4, and for Day -1 when  admission 
occurs on Day -2 
Hours  Relative  to Dosing  at 0 hour  
PF-07328948 plasma 
pharmacokinetics  (Day  1 only)  
CCI 
CCI -1.0 -0.5  0 
X 0.5 
X 1  1.5 2 3 4 
X  X X  X  X 8 10 
X Day 1 activities  at time = 0 hour are prior  to the dose,  except  for study  
12  intervention  administration.  
X  See Section  8.5.1  for additional information.  
PF-07328948  
Protocol  C4921001  
Final  Protocol  Amendment  2, 24 Jan 2023  
PFIZER  CONFIDENTIAL  
Page  24  
 2. INTRODUCTION  
PF-07328948  is a small  molecule  allosteric  inhibitor/degrader  of BDK  that is currently  being 
developed as an oral therapy to treat heart failure.  
2.1. Study Rationale  
This study  will be the first time PF-07328948  is administered  to humans.  The purpose  of the 
study is to evaluate the safety, tolerability, plasma PK and PD of PF -07328948 following 
administration of escalating, single, oral doses to healthy adult participants.  
2.2. Background  
Tissue and/or plasma BCAA and/or BCKA levels are elevated in various disease states 
including heart failure, type 2 diabetes mellitus, NAFLD/NASH, and obesity.1,2,3,[ADDRESS_465408], dose - 
and time -dependent BCAA and BCKA lowering in plasma and tissues in mouse, rat and/or  
 
These  improvements  were  concomitant  with reduced  pBCKDH  and BDK  levels  in heart  and 
kidney tissue as well as reduced plasma BCAA and BCKA levels.  
2.2.1.  Nonclinical Pharmacology  
PF-[ADDRESS_465409] of mouse, rat,  dog, and human BDK  CCI  
In human  skeletal  muscle  cells,  PF-07328948  treatment 
resulted in inhibition of BDK -dependent phosphorylation of BCKDHA. In HEK293 cells, 
PF-07328948 decreased both BDK protein and the ratio of pBCKDHA/BCKDHA protein. 
CCI 
 
 
. In 
diet-induced  obese  mice,  reductions  of plasma  BCAAs  and BCKAs  were  observed  following 
subchronic and chronic dosing. PF -07328948 reduced liver triglycerides, plasma insulin 
levels,  and plasma  non-esterified  free fatty acids  after chronic  dosing  compared  with vehicle - dog. In  addition,  CCI 
PF-07328948  
Protocol  C4921001  
Final  Protocol  Amendment  2, 24 Jan 2023  
PFIZER  CONFIDENTIAL  
Page  25  
 
CCI treated animals. These metabolic improvements were concomitant with decreases in BDK 
protein  levels  in gastrocnemius  muscle  and heart,  and decreased  phosphorylation  of BCKDH 
in muscle, heart, and liver. In the ZSF1 rat model of heart failure -preserved ejection, after 
chronic administration in food, PF -07328948 improved exercise capacity and increased 
systolic cardiac functional parameters, with a trend for reduced left atria hypertrophy 
compared to animals that were administered control chow. These improvements were 
concomitant with reduced pBCKDH and BDK levels in heart and kidney tissue as well as 
reduced plasma BCAA and BCKA levels.  
Details of the nonclinical pharmacology  are included in the IB. 
2.2.2.  Nonclinical  Pharmacokinetics  and Metabolism  
PF-07328948 was rapi[INVESTIGATOR_371976] V ss in rats, dogs, and monkeys. After IV administration of PF - 
07328948, renal excretion of unchanged PF‑07328948 was <1% in rats, dogs, and monkeys 
and biliary excretion of unchanged PF‑07328948 was ~1% in rats. In oral repeat -dose 
toxicity  studies in rats and dogs, the systemic exposure increased with increasing dose in a 
less than or approximately  dose proportional  manner  and there  were  no consistent  sex-related 
differences or accumulation observed.  
PF-[ADDRESS_465410] for induction in plasma, intestinal lumen, enterocytes, 
liver, and portal inlet.  cells.  CCI 
PF-07328948  
Protocol  C4921001  
Final  Protocol  Amendment  2, 24 Jan 2023  
PFIZER  CONFIDENTIAL  
Page  26  
 CCI  These  predictions  will be refined 
once human PK data are available for PF -07328948.  
Additional  details  are included  in the IB. 
CCI  
 
2.2.4.  Nonclinical Safety  
PF-07328948  was administered  orally  to rats and dogs  in toxicity  studies  up to 1 month  in 
 
 
 
 
 
 
 
 
 
 
 
 
Based  on a weight  of evidence,  PF-07328948  does not pose a risk for genotoxicity.  
Based  on the UV absorption  profile  of PF-07328948,  there  is a potential  for phototoxicity. 
Additional details of the nonclinical safety are provided in the IB.  
duration.  CCI 
The NOAEL  in the 1-month  GLP 
repeat -dose toxicity study in rats was 100 mg/kg/day,  CCI 
. The 
NOAEL  in the 1-month  GLP  repeat -dose toxicity  study  in dogs  was 100 mg/kg/day,  CCI 
PF-07328948  
Protocol  C4921001  
Final  Protocol  Amendment  2, 24 Jan 2023  
PFIZER  CONFIDENTIAL  
Page  27  
 2.3. Benefit/Risk  Assessment  
Study C4921001 is the first time that PF -[ADDRESS_465411] been identified; postulated risks 
based on nonclinical studies are summarized in Section  2.3.[ADDRESS_465412], intensive, inpatient monitoring of the participants following 
administration of single, oral doses of the study intervention.  
More  detailed  information  about  the known  and expected  benefits  and risks  and reasonably 
expected AEs of PF -07328948 may be found in the IB, which is the SRSD for this study.  
PF-07328948  
Protocol  C4921001  
Final  Protocol  Amendment  2, 24 Jan 2023  
PFIZER  CONFIDENTIAL  
Page  28  
  
2.3.1.  Risk  Assessment  
All study  intervention  risks  are communicated  through  the IB. 
 
Potential  Risk  of Clinical  Significance  Summary  of Data/Rationale  for Risk Mitigation  Strategy  
Study  Intervention  - PF-07328948  
Effects  on blood  pressure  Decreased BP was observed after single doses 
(≥ 20 mg/kg) of PF -07328948 in dogs in 
exploratory  toxicology  studies.  No BP changes 
were subsequently noted in GLP toxicology  
studies  after single  doses  of ≤ 100 mg/kg  in dogs.  • Participants  will be in a closely  monitored 
environment while in the CRU during the 
study.  
• Inpatient  monitoring  will include  serial 
assessment of blood pressure.  
Skin sensitivity  to light;  sunburn  Based  on light absorption  within  the UV range, 
PF-07328948 has a risk for phototoxicity.  • Participants  with a history  of phototoxicity  or 
photosensitivity are excluded from study.  
• Lifestyle and activity considerations have  
been added advising participant to use 
sunscreen and eye protection, and to avoid 
sunlight  and high-intensity  UV light exposure.  
Drug -drug interactions  resulting  in exposure  changes 
of background concomitant medications.  CCI • Use of prescription or nonprescription drugs 
and dietary and herbal supplements are 
prohibited within 7 days or 5 half -lives 
(whichever  is longer)  prior  to the first dose of 
study intervention through the last PK 
collection.  
Idiosyncratic  drug reaction  IADR  risk CCI  • Participants  will be in a closely  monitored 
environment while in the CRU during the 
study.  
• Risk of IADR  after single  dose of 
PF-07328948 is considered low.  
• Laboratory  safety  tests include  serial 
assessment of LFTs and CBCs.  
PF-07328948  
Protocol  C4921001  
Final  Protocol  Amendment  2, 24 Jan 2023  
PFIZER  CONFIDENTIAL  
Page  29  
  
Potential  Risk  of Clinical  Significance  Summary  of Data/Rationale  for Risk Mitigation  Strategy  
BCAA  deficiency  BCAAs  play a multifaceted  role in maintenance 
of health. Prolonged deficiency of ≥ 1 BCAA 
caused by [CONTACT_372000] -function mutations in BDK gene in 
humans are associated with neurological 
sequelae.  • Single doses of PF -07328948 are not 
anticipated  to result  in prolonged  lowering  of 
BCAAs.  
• Risk of neurological  sequelae  from  magnitude 
and duration of BCAA lowering expected 
following single doses of PF -[ADDRESS_465413] -dose.  
Other  
The COVID -19 pandemic  may pose risks  to study 
participation.  During  the pandemic,  healthy  participants  could  be 
infected  with the SARS -CoV -2 virus  through  study 
participation, which could lead to increased health 
risks for this participant and others in the study.  
AEs could  be confounded.  • Inclusion  of COVID -19 specific  assessments 
according to the SoA. 
PF-07328948  
Protocol  C4921001  
Final  Protocol  Amendment  2, 24 Jan 2023  
PFIZER  CONFIDENTIAL  
Page  30  
 2.3.2.  Benefit  Assessment  
The participants in this study are not expected to obtain any specific benefit beyond 
contributing  to the process  of developi[INVESTIGATOR_371977].  They  will 
receive close monitoring of their safety via study procedures undertaken (eg, physical 
examinations, including neurological examinations, 12 -lead ECGs, vital signs) which will 
occur as outlined in this protocol.  
2.3.3.  Overall  Benefit/Risk  Conclusion  
Based on the totality of available nonclinical data, and taking into account the measures to 
minimize  risk to study  participants,  the overall  benefit/risk  profile  supports  clinical  testing  of 
PF-07328948 in this study as part of the clinical development for an indication of heart 
failure.  
3. OBJECTIVES  AND  ENDPOINTS  
 
 
Primary:  Objectives   
 
Primary:  Endpoints  
• To evaluate the safety and tolerability of single 
ascending  doses  of PF-07328948  administered  orally  to 
healthy adult participants.  
 
Secondary:  
• To evaluate the pharmacokinetics of PF -07328948 
following  single  doses  of PF-07328948  administered 
orally to healthy adult participants.  
Tertiary/Exploratory:  
• To evaluate  additional  pharmacokinetic  parameters  of 
PF-07328948  following  single  doses  of PF-07328948 
administered orally to healthy adult participants.  • Assessment of adverse events, clinical safety 
laboratory tests, vital signs, continuous cardiac 
monitoring,  12-lead electrocardiograms,  and physical 
examinations.  
Secondary:  
• PK parameters derived from plasma PF -07328948 
concentrations:  Cmax, Tmax, AUC last, and if data permit, 
AUC inf, and t ½. 
Tertiary/Exploratory:  
• Additional  PK parameters  derived  from  plasma  
PF-07328948  concentrations:  Cmax(dn),  AUC last(dn) 
and if data permit AUC inf(dn), CL/F and V z/F. 
• CCI 
 
 
 
 
 
 
 
 
 
 
 
• To evaluate  the effect of food (eg,  a protein -rich meal 
such as MMTT),  if administered,  on the plasma  PK of 
PF-07328948 following single dose of PF -07328948 
administered orally to healthy adult participants.  • PK parameters derived from plasma PF -07328948 
concentrations  after MMTT:  Cmax, Tmax, AUC last, and 
if data permit, AUC inf, and t ½. 
PF-[ADDRESS_465414]-in-human, single ascending oral dose, 4 -period, sequential, crossover study of  
PF-07328948 administered to healthy  adult participants. Approximately  24 healthy  adult 
participants  (up to 3 cohorts  of approximately  8 participants  each)  will be enrolled  in this 
study. The first [ADDRESS_465415] cohort is optional. In each period, 
participants will be randomized to either PF -07328948 or placebo in a ratio of 3:1. Each 
participant is planned to undergo up to 4 treatment periods receiving up to 4 doses of  
PF-07328948  and up to 2 placebo.  
Precautionary sentinel dosing will be used in any period evaluating escalating doses of PF - 
07328948 and may be omitted for periods when repeating a dose level or administering a 
lower  dose level  than previously  evaluated.  For periods  with sentinel  dosing,  2 participants  (1 
receiving PF -07328948 and 1 receiving placebo) will be dosed initially  before the remaining 
participants of that period are dosed. Safety and tolerability data through at least [ADDRESS_465416] food period  (if applicable)  within  a cohort.  For 
all other periods (ie, Periods [ADDRESS_465417] food period within each cohort), participants 
will be re-admitted  to the CRU  on Day -1. For each period  in this study,  on Day  1, following  
≥10-hour overnight fast, participants will receive a single oral dose of PF -[ADDRESS_465418] 7 
days will be introduced between subsequent doses. During the washout interval, emerging 
24-hour PK and 48 -hour safety data will be reviewed and the next dose will be determined. 
An on-site follow -up visit on Day 8±[ADDRESS_465419]  or an on- 
site visit at the discretion of the PI.  
Based  on the review  of emerging  safety,  tolerability,  and PK data (and PD data if available) 
in Cohorts [ADDRESS_465420] cohort may enroll 8 participants (crossover,  
placebo -controlled  design)  to explore  additional  doses,  to repeat  a dose,  to evaluate  split 
dosing, or to investigate food effects on PK and PD biomarkers.  
Dosing will occur in the fasted state for all periods for dose escalation. The effect of a 
high-protein meal on safety, tolerability, PK exposure, and PD biomarkers CCI  
may be assessed  in at 
least 1 period  within Cohort  2 and/or  Cohort 3. 
 
PF-07328948  
Protocol  C4921001  
Final  Protocol  Amendment  2, 24 Jan 2023  
PFIZER  CONFIDENTIAL  
Page  32  
 
CCI CCI  Participants 
should only need to undergo these time -matched assessments of PD biomarkers on Day -1 
once in the fasted state and/or once in the fed state in each cohort, unless there is any 
uncertainty regarding the reliability of the initial Day -1 assessment. In addition, if thought 
necessary  to achieve  study  objectives,  study  intervention  may be administered  in the fed state 
(eg, following a high -protein meal) during any of the study periods/cohorts.  
The total duration  of participation  from  the screening  visit to the telephone  follow -up contact 
[CONTACT_372001] 14 weeks.  
If a participant drops out before completing all study periods within a cohort, or withdraws 
for a reason unrelated to safety, the participant may be replaced at the discretion of the 
investigator and sponsor. The replacement participant(s) may or may not be required to 
complete all periods of the cohort in which they are participating at the discretion of the 
investigator  and sponsor.  Of note,  replacement  participants  may be required  to undergo  time- 
matched assessments of PD biomarkers during Day -[ADDRESS_465421] not been conducted. In 
male participants, appropriate measures are expected to be followed to minimize potential 
transfer of PF -07328948 via semen to partners (see Appendix 4 ). 
Because this is the first time PF -[ADDRESS_465422]  feasible  total daily  dose 
CCI . Furthermore, to permit an  unbiased  assessment  of safety, the administration of 
both PF -07328948 and placebo in each period will be double -blinded to both site staff 
(except those involved in preparation of doses) as well as participants. To permit real -time 
review of the safety, tolerability, and PK data, a limited number of sponsor study team 
members will be unblinded.  
 
. As a BDK  inhibitor/degrader,  
PF-07328948  
Protocol  C4921001  
Final  Protocol  Amendment  2, 24 Jan 2023  
PFIZER  CONFIDENTIAL  
Page  33  
 PF-07328948 is expected to inhibit BDK -mediated phosphorylation of BCKDH enzyme 
complex,  resulting  in an increase  in BCAA/BCKA  catabolism  and a decrease  in circulating 
BCAA and BCKA levels. As protein intake is known to impact plasma BCAA/BCKA 
levels,5 CCI 
 
. Lunch and dinner will be standardized when participants are 
confined  in the CRU;  additional  efforts  will be made  to ensure  lunch,  dinner  and snacks  are 
as identical as is feasible on Day 1 for each period and on Day -1 where time -matched  
CCI assessment  is performed  (Section  5.3.2 ). CCI 
 
 
 
 
 
Based on predicted half -life in human (~4 hours), PK samples were collected over [ADDRESS_465423] -dose. A washout interval of ≥7 days is proposed 
between  doses  within  an individual  participant;  this interval  should  be sufficient  based  on all 
emergent PK data to date, and the projections that CCI  levels  return  to 
baseline within approximately [ADDRESS_465424] -dose based on a PK/PD model developed with 
preclinical data and emergent PK/PD data in Cohort 1. In addition, this washout interval 
should offer sufficient opportunity to review safety, tolerability, and PK data after each 
dosing period prior required for decision on the PF -07328948 dose to be evaluated in the  
subsequent  period.  However,  sampling  times,  duration  of sampling,  and/or  the length  of the 
washout period may be modified and/or extended based on emerging PK and/or PD data.  
Participants may be asked to remain at the CRU after completion of Day 4 activities at the 
discretion  of the investigator  or if safety,  tolerability,  or PK data dictate  the need  to prolong 
inpatient stay in the CRU. The planned doses and assignment to study intervention in the 
escalation sequence (see Section 1.2 ) may be modified or repeated, as guided by [CONTACT_372002], tolerability, and PK data but will follow the dose -escalation rules defined in Section  
6.6.1 . 
Decreased blood pressure was observed after single doses (≥ 20 mg/kg) of PF -07328948 in 
dogs  in exploratory  toxicology  studies;  however,  no significant  blood  pressure  changes  were 
subsequently noted in GLP toxicology studies after single doses of ≤ 100 mg/kg in dogs.  
Serial triplicate assessment of blood pressure will be performed following single dose 
administration  as outlined  in SoA. Triplicate  12-lead ECGs  and continuous  cardiac  telemetry  
CCI 
PF-07328948  
Protocol  C4921001  
Final  Protocol  Amendment  2, 24 Jan 2023  
PFIZER  CONFIDENTIAL  
Page  34  
 also will be monitored  as outlined  in SoA. PF-07328948  effects  on the respi[INVESTIGATOR_371978] 100 mg/kg in the 
GLP -compliant pulmonary assessment study. The relevance of these transient effects of  
PF-07328948  on rat tidal and minute  volume  to humans  is unknown,  but respi[INVESTIGATOR_371979].  
One serious adverse event was reported during the follow -up period in 1 participant (out of 9 
participants) in the first cohort of this study. This participant completed [ADDRESS_465425] 7 days between doses. An adverse event of 
“loss  of consciousness,  possible  seizure”  was reported  in this participant  during  the follow -up 
period, [ADDRESS_465426] dose of blinded study  medication (PF -07328948 or placebo) 
administered in Period 4. The participant required assessment in the Emergency Department 
for this adverse event, but spontaneously resolved without intervention and did not require 
hospi[INVESTIGATOR_371980]. While the Principal Investigator [INVESTIGATOR_371981] (PF -07328948 or placebo) may have 
contributed to the adverse event of “loss of consciousness, possible seizure”, this event was 
also reviewed by [CONTACT_372003] a [COMPANY_007] Risk Management Committee, and 
these teams concluded that the event was unrelated to study intervention based on the 
prolonged duration between last dose of blinded study  medication and animal data indicating 
that PF -[ADDRESS_465427], as described in Section 5.3.4 . 
4.2.1.  Choice of Contraception/Barrier Requirements  
Human  reproductive  safety  data are not available  for PF-07328948.  Therefore,  the use of a 
highly effective method of contraception is required for male study participants and is 
recommended for partners of male study participants who are WOCBP (see Appendix 4 ). 
4.2.2.  Collection  of Retained  Research  Samples  
Retained  Research  Samples  will be collected  and stored  for further  analyses  which  may,  for 
example, provide greater understanding of the study intervention.  
4.3. Justification  for Dose  
The proposed  dose levels  of PF-07328948  were  derived  based  on cumulative  nonclinical 
data, including in vitro, in vivo, PK and PD data, and the completed nonclinical toxicity 
studies. Dose levels beyond the starting dose (in Period 1 of Cohort 1) may  be modified 
based on emerging human safety, tolerability, and PK data in the current study.  
PF-07328948  
Protocol  C4921001  
Final  Protocol  Amendment  2, 24 Jan 2023  
PFIZER  CONFIDENTIAL  
Page  35  
 CCI  
 
4.3.2.  Predicted  Efficacious  Concentration  and Human  Dose  
The desired degree of target modulation is  based  on published  human  metabolomic  data.3,4,7,8 
As BCAAs  are elevated  ~20%  on a population  level  in patients  with cardiometabolic  disease  
 
However,  due to uncertainty  around  the degree  of target  modulation  necessary  for efficacy  in 
patients with heart failure and the first -in-class nature of the mechanism of BDK inhibition, 
higher degrees of target modulation CCI  
is desired  to be evaluated  if permitted  by [CONTACT_372004]. 
4.3.3.  Human Exposure Stoppi[INVESTIGATOR_371982]  1-month  GLP  toxicity  studies  were 
which  correspond  to the  highest doses  tested in 
those  respective  studies.  
Therefore, the human exposure stoppi[INVESTIGATOR_371983] -[ADDRESS_465428] sensitive species.  
• The human  PF-07328948  Cmax limit  is CCI  
• The human  PF-07328948  AUC 24 limit  is CCI  relative  to healthy  individuals,  CCI 
CCI 
PF-07328948  
Protocol  C4921001  
Final  Protocol  Amendment  2, 24 Jan 2023  
PFIZER  CONFIDENTIAL  
Page  36  
 
Dose 
(mg) 
Cmax 
a 
 AUC 24 
a 
(ng/mL)  
 (ng.h/mL)  
Total  Free 
 Total  
 Free 
10 461 1 
30 1380  2 
100 4610  6 
300 [ZIP_CODE]  20 
750 [ZIP_CODE]  64 
1500  [ZIP_CODE]  173 
2990  
8910  
[ZIP_CODE]  
[ZIP_CODE]  
181000  
310000  
4 
11 
37 
C 
C  
C  
112 C  
286 C  
595 
 C  
CC 
I 
CCI 4.3.4.  Rationale for Dose Selection  
The safety, tolerability, and plasma PK of PF -07328948 after administration of single 
escalating oral doses across a wide dose/exposure range will be evaluated in this study. 
Dosing will occur in the fasted state, except in periods in which dosing may occur in the fed 
state to permit  exploratory  assessment  of the effect  of food on PF-07328948  PK and PD. The 
doses presented in Table 3 are projected based on nonclinical data and may be modified 
based on emerging human safety, tolerability, and PK data. Predicted human PK parameter 
estimates, toxicokinetic data, and projected efficacious concentrations were used to establish 
the initial range of planned doses in this study. The projected human exposures account for 
concentration -dependent protein binding within the planned dose range.  
 
Table 3.  Predicted  Human  Exposures,  Pharmacodynamic  Effects,  and Safety 
Margin at Proposed Single Doses of PF -07328948  
 
a. Human PK profiles were predicted using a 1 -compartment model with the projected human PK 
parameters  for PF-07328948  outlined  in Section  4.3.1 . Human  plasma  fu values  were  predicted  using  the 
linear equation ( CCI  and hepatic 
clearance was projected using the well -stirred model.  
b. Pharmacodynamic effects elucidated with Ile and KMV was simulated based on a PK/PD model 
developed  with preclinical  data and Ki for human  BDK  inhibition  and human  fasting  plasma  Ile and KMV 
baseline level. Ave reduction was calculated over 24 hours.  
c. SM, safety  margin  for unbound  exposure  (Cmax,u  and AUC24,u)  at the proposed  doses  were  calculated 
based on the NOAELs in the 1 -month GLP toxicity studies in both rats and dogs. The human exposure  
limits were defined as CCI  
observed at NOAEL in rat 1 -month GLP toxicity study.  
 
The PF-07328948  starting  dose level  of 10 mg is planned.  The predicted  PF-07328948  Cmax,u  
and AUC 24,u after single dose of 10 mg are CCI , respectively, 
below the exposure limits defined for PF -07328948 dose escalation in Section 4.3.3 . The 
maximum  reduction  for plasma  isoleucine  and ketoisoleucine  are predicted  to be 3% and 4%, 
respectively, suggesting little target modulation at this dose. A single dose of 1500 mg (the 
top dose in Table 3) is estimated to provide an exposure margin CCI   
, respectively,  relative  to the exposure  limits.  
PF-07328948  
Protocol  C4921001  
Final  Protocol  Amendment  2, 24 Jan 2023  
PFIZER  CONFIDENTIAL  
Page  37  
 The dose range  to be studied was  selected  to account for  uncertainties  in the projected  Ceff 
and the projected therapeutic dose, while also bracketing the expected clinically effective 
dose range  in humans  for clinically  relevant  pharmacological  activity  and providing  safety 
coverage for a wide range of PF -07328948 doses.  
Assessment of the safety, tolerability, and PK after each single dose level will be conducted 
before  escalating  to the next dose level.  The dose/exposure -escalation  increments  are planned 
to be up to approximately semi -logarithmic increases in exposure from the previous highest 
dose level that has been evaluated. If exposure exceeds the projected therapeutic range, or if 
changes in safety parameters are observed, smaller dose -escalation steps may be 
implemented.  
The actual dose levels, target exposures, and/or dose level increments may be adjusted 
(higher  or lower)  during  the study  based  on emerging  human  safety,  tolerability,  and PK 
data, but projected exposures will not exceed the predefined human exposure limits. If  
Cmax-related  adverse  events  are observed,  split dosing  (eg, the total dose will be divided  into 
2 or 3 parts on Day 1) may be used to potentially increase AUC without increasing C max. 
Dose levels may  also be repeated if warranted.  
When  the assessment  of the effect  of food on the PK and PD of PF-07328948  is conducted, 
the dose level will be selected based on emerging safety, tolerability, and PK data from 
previous periods of this study. The actual dose level used will be expected to achieve 
exposures similar to or greater than projected therapeutic exposures (as outlined in  
Section 4.3.2 ). 
4.4. End of Study Definition  
The end of the study  is defined  as the date of last scheduled  procedure  shown  in the SoA for 
the last participant in the trial.  
A participant  is considered  to have  completed  the study  if they have  completed  all periods  of 
the study, including the last scheduled procedure shown in the SoA. 
5. STUDY POPULATION  
This study can fulfill its objectives only if appropriate participants are enrolled, including 
participants across diverse and representative racial and ethnic backgrounds. Use of a 
prescreening tool is utilized for study recruitment purposes, it will include collection of 
information that reflects the enrollment of a diverse participant population including, where 
permitted  under  local  regulations,  age, sex, and race,  and ethnicity.  The following  eligibility 
criteria are designed to select participants for whom participation in the study  is considered 
appropriate. All relevant medical and nonmedical conditions should be taken into 
consideration when deciding whether a particular participant is suitable for this protocol.  
Prospective  approval  of protocol  deviations  to recruitment  and enrollment  criteria,  also 
known as protocol waivers or exemptions, is not permitted.  
PF-07328948  
Protocol  C4921001  
Final  Protocol  Amendment  2, 24 Jan 2023  
PFIZER  CONFIDENTIAL  
Page  38  
 5.1. Inclusion  Criteria  
Participants  are eligible  to be included  in the study  only if all of the following  criteria  apply:  
Age and Sex: 
1. Female  participants  of non-child  bearing  potential  and males  must  be 18 to 60 years 
of age, inclusive, at the time of signing the ICD.  
Refer  to Appendix  4 for reproductive  criteria  for male  (Section  10.4.1 ) and female 
(Section 10.4.2 ) participants.  
2. Female participants of non -child bearing potential and males who are overtly healthy 
as determined  by [CONTACT_371997],  physical  examination, 
laboratory tests, and cardiac monitoring.  
Other Inclusion  Criteria:  
3. BMI  of 17.5 to 30.5 kg/m2; and a total body  weight >50  kg (110 lb). 
4. Participants  who are willing  and able to comply  with all scheduled  visits,  treatment 
plan, laboratory tests, lifestyle considerations, and other study procedures.  
5. Capable of giving signed informed consent as described in Appendix 1 , which 
includes  compliance  with the requirements  and restrictions  listed  in the ICD and in 
this protocol.  
5.2. Exclusion  Criteria  
Participants  are excluded  from the  study  if any of the  following  criteria apply:  
Medical Conditions:  
1. Evidence or history of clinically significant hematological, renal, endocrine, 
pulmonary,  gastrointestinal,  cardiovascular,  hepatic, psychiatric,  neurological,  or 
allergic  disease  (including  drug allergies,  but excluding  untreated,  asymptomatic, 
seasonal allergies at the time of dosing).  
• Any condition  possibly  affecting  drug absorption  (eg, gastrectomy, 
cholecystectomy).  
• History  of HIV infection,  hepatitis  B, or hepatitis  C; positive  testing  for HIV, 
HBsAg, HBcAb, or HCVAb. Hepatitis B vaccination is allowed.  
• History  of phototoxicity  or photosensitivity.  
PF-07328948  
Protocol  C4921001  
Final  Protocol  Amendment  2, 24 Jan 2023  
PFIZER  CONFIDENTIAL  
Page  39  
 2. Other medical or psychiatric condition including recent (within the past year) or 
active suicidal ideation/behavior or laboratory abnormality or other conditions or 
situations related to COVID -19 pandemic that may increase the risk of study 
participation  or, in the investigator’s  judgment,  make  the participant  inappropriate  for 
the study.  
Prior/Concomitant Therapy:  
3. Use of prescription or nonprescription drugs and dietary and herbal supplements 
within 7 days or 5 half -lives (whichever is longer) prior to the first dose of study 
intervention through the last PK collection, with the exception of moderate/strong 
CYP3A  inducers  or time-dependent  inhibitors  which  are prohibited  within  [ADDRESS_465429] dose of study intervention. (Refer to Section 6.9  
Prior and Concomitant Therapy for additional details).  
4. Receipt of a COVID -19 vaccine within 7 days before screening or within 7 days 
before any visit in which a safety lab is planned. Vaccination with a COVID -19 
vaccine  that occurs  greater  than 7 days from  either  screening  or any visit in which  a 
safety lab is planned is permitted.  
Prior/Concurrent Clinical Study Experience:  
5. Previous  administration  with an investigational  product  (drug  or vaccine) within  
30 days (or as determined  by [CONTACT_219873])  or [ADDRESS_465430] 
dose of study intervention used in this study (whichever is longer).  
Diagnostic Assessments:  
6. A positive  urine  drug test. 
7. Screening  supi[INVESTIGATOR_145972] ≥140  mm Hg (systolic)  or ≥90 mm Hg (diastolic),  following  at 
least [ADDRESS_465431]. If BP is ≥140 mm Hg (systolic) or ≥90 mm Hg 
(diastolic), the BP should be repeated 2 more times and the average of the 3 BP 
values should be used to determine the participant’s eligibility.  
8. Renal impairment as defined by [CONTACT_371998] 75 mL/min/1.73m2 (based on serum 
creatinine).  Based  upon  participant  age at screening,  eGFR  is calculated  from  serum 
creatinine using the recommended CKD -EPI [INVESTIGATOR_371984] 10.7.[ADDRESS_465432] participant safety or interpretation of study results (eg, QTcF [ADDRESS_465433] -degree AV 
block, or serious bradyarrhythmias or tachyarrhythmias). If the uncorrected QT  
PF-07328948  
Protocol  C4921001  
Final  Protocol  Amendment  2, 24 Jan 2023  
PFIZER  CONFIDENTIAL  
Page  40  
 interval  is 450 ms, this interval  should  be rate-corrected  using  the Fridericia  method 
only and the resulting QTcF should be used for decision making and reporting. If 
QTcF exceeds 450 ms, or QRS exceeds 120 ms, the ECG should be repeated twice 
and the average of the 3 QTcF or QRS values used to determine the participant’s 
eligibility. Computer -interpreted ECGs should be overread by a physician 
experienced in reading ECGs before excluding a participant.  
10. Participants  with ANY  of the following  abnormalities  in clinical  laboratory  tests at 
screening, as assessed by [CONTACT_1758] -specific laboratory and confirmed by a single 
repeat test, if deemed necessary:  
• AST  or ALT  level  ≥1.25  × ULN;  
• Total bilirubin level ≥1.5 × ULN; participants with a history of Gilbert’s 
syndrome  may have  direct  bilirubin  measured  and would  be eligible  for this study 
provided the direct bilirubin level is ≤ ULN.  
Other Exclusion  Criteria:  
11. History of alcohol abuse or binge drinking and/or any other illicit drug use or 
dependence within 6 months of Screening. Binge drinking is defined as a pattern of 
5 (male)  and 4 (female)  or more  alcoholic  drinks  in about  2 hours.  As a general  rule, 
alcohol  intake  should  not exceed  14 units  per week  (1 unit = 8 ounces  (240 mL) beer, 
1 ounce (30 mL) of 40% spi[INVESTIGATOR_17040], or 3 ounces (90 mL) of wine).  
12. Blood  donation  (excluding  plasma  donations)  of approximately  1 pi[INVESTIGATOR_11731] (500 mL) or 
more within 60 days prior to dosing.  
13. History  of sensitivity  to heparin  or heparin -induced  thrombocytopenia.  
14. Use of tobacco  or nicotine -containing  products  in excess  of the equivalent  of 
5 cigarettes/day or 2 chews of tobacco/day.  
15. Unwilling  or unable  to comply  with the criteria  in the Lifestyle  Considerations  
section of this protocol.  
16. Investigator site staff directly involved in the conduct of the study and their family 
members,  site staff otherwise  supervised  by [CONTACT_093],  and sponsor  and sponsor 
delegate employees directly involved in the conduct of the study and their family 
members.  
PF-07328948  
Protocol  C4921001  
Final  Protocol  Amendment  2, 24 Jan 2023  
PFIZER  CONFIDENTIAL  
Page  41  
 5.3. Lifestyle Considerations  
The following  guidelines  are provided:  
5.3.1.  Contraception  
The investigator or their designee, in consultation with the participant, will confirm that the 
participant is utilizing an appropriate method of contraception for the individual participant 
and their partner(s) from the permitted list of contraception methods (see Appendix 4 , 
Section  10.4.4 ) and will confirm  that the participant  has been  instructed  in its consistent  and 
correct use. At timepoints indicated in SoA, the investigator or designee will inform the 
participant of the need to use highly effective contraception consistently and correctly and 
document the conversation and the participant’s affirmation in the participant’s chart.  
Participants need to affirm their consistent and correct use of at least [ADDRESS_465434] the participant to call immediately  if the 
selected contraception method is discontinued and document the requirement to use an 
alternate protocol -specified method, including if the participant will no longer use abstinence 
as the selected  contraception  method,  or if pregnancy  is known  or suspected  in the participant 
or partner.  
5.3.2.  Meals  and Dietary  Restrictions  
• Participants must abstain from all food and drink (except water) at least [ADDRESS_465435] 10 hours  prior  to the collection  of the 
pre-dose PK and PD biomarker samples on Day 1 (and on Day -1 if relevant for that 
period), and at least 8 hours prior to PD biomarker collection on Day  2, Day  3, Day  4 
(if applicable) and Day 8 ±1 visit (following final dose of study intervention).  
• Noncaffeinated  drinks  (except  grapefruit  or grapefruit -related  citrus  fruit juices -see 
below) may be consumed with meals and the evening snack.  
• Dosing under fasted conditions:  
• Following  an overnight  fast of at least 10 hours,  participants  will receive  study 
intervention.  
• Water  is permitted  until 1 hour prior  to study  intervention  administration.  Water 
may be consumed without restriction beginning 1 hour after dosing.  
• No food or drink  (other  than water)  is permitted  until lunch  approximately  [ADDRESS_465436] been 
completed.  
PF-07328948  
Protocol  C4921001  
Final  Protocol  Amendment  2, 24 Jan 2023  
PFIZER  CONFIDENTIAL  
Page  42  
 • Dosing  when  an effect  of a protein -rich meal  (eg, MMTT)  is investigated,  if 
performed:  
• Following an overnight fast of at least 10  hours, participants will be provided a 
protein -rich meal as 16 ounces of Ensure Plus® breakfast approximately 20 
minutes prior to administration of study intervention. The entire Ensure Plus® 
meal  is to be consumed  within  10 minutes  with study  intervention  administered 
approximately  10 minutes after completion of the meal at 0 hour. There are no 
water restrictions prior to dosing for participants dosed under fed conditions. 
Water may be consumed without restriction beginning 1 hour after dosing.  
• MMTT  on Day -1, if administered:  
• Following  an overnight  fast of at least 10 hours,  participants  will be provided  a 
protein -rich meal as 16 ounces of Ensure Plus® breakfast; the timing of 
administration of the protein -rich meal on Day -1 will be at approximately the 
same time as planned for administration on Day 1.  
• Lunch will be provided approximately 4 hours after dosing and after the 4 -hour 
postdose  samples  (or time-match  sample  on Day -1 if applicable)  have  been  collected.  
• Dinner  will be provided  approximately  10 hours  after dosing  and after  the 10-hour 
postdose samples (or time -matched sample on Day -1 if applicable) have been 
collected.  
• An evening  snack  may be permitted.  Participants  will receive  the same  evening  snack 
at approximately the same time (± 30 minutes) on Day -1 and Day 1, as well as on 
any Day -2 if applicable.  
• Participants  will be provided  the same  lunch,  dinner  and snacks  on Day -1 when  time- 
matched biomarker assessment is collected and on Day 1 of each period (with or 
without a MMTT) to strive for as similar food intake as is feasible on these days 
across periods.  
• Participants will be encouraged to consume their entire meals on Day 1 during all 
periods. In addition, participants will be encouraged to consume their entire evening 
snack  (if applicable)  on Day  -2 and entire  meals  on Day -1 if a MMTT  is planned  for 
Day -1; if participants  do not consume  their entire  meal  on Day -1 where  a MMTT  is 
performed, they  will be instructed to consume the same amount of food (±10%, with 
similar uptake of optional snacks) on following Day [ADDRESS_465437] meals on other study days.  
PF-07328948  
Protocol  C4921001  
Final  Protocol  Amendment  2, 24 Jan 2023  
PFIZER  CONFIDENTIAL  
Page  43  
 • Participants will refrain from consuming red wine, grapefruit, or grapefruit -related 
citrus  fruits  (eg, Seville  oranges,  pomelos,  fruit juices)  from  [ADDRESS_465438] 
dose of study intervention until collection of the final PK blood sample.  
• While participants are confined, their total daily nutritional composition should be 
approximately  55% carbohydrate,  30% fat, and 15% protein.  The daily  caloric  intake 
per participant should not exceed approximately 3200 kcal. However, these 
guidelines may  be adapted to facilitate meal and dietary  restrictions required for Day 
1 in each period and for Day -1 when time -matched biomarker assessment is 
collected with or without a MMTT.  
5.3.3.  Caffeine,  Alcohol,  and Tobacco  
• Participants  will abstain  from  caffeine  -containing  products  for 24 hours  prior  to the 
start of dosing until collection of the final PK sample of each study period.  
• Participants  will abstain  from  alcohol  for 24 hours  prior  (or as specified  above  for red 
wine) to admission to the CRU and continue abstaining from alcohol until collection 
of the final PK sample of each study period. Participants may undergo an alcohol 
breath test or blood alcohol test at the discretion of the investigator.  
• Participants  will abstain  from  the use of tobacco - or nicotine -containing  products  for 
24 hours prior to dosing and during confinement in the CRU.  
5.3.4.  Activity  
• Participants will abstain from strenuous exercise (eg, heavy lifting, weight training, 
calisthenics,  aerobics)  for at least 48 hours  prior  to each blood  collection  for clinical 
laboratory tests. Walking at a normal pace will be permitted.  
• In order to standardize the conditions on PK sampling days, participants will be 
required  to refrain  from  lying  down  (except  when  required  for BP, pulse  rate, and 
ECG  measurements),  eating,  and drinking  beverages,  other  than water,  during  the 
first 4 hours after dosing.  
• Participants  will be confined  to the procedure  room  for the first 4 hours  after dosing 
on Day 1 during continuous cardiac monitoring, except to use the bathroom. After 
this, if the equipment setup allows, participants may  be ambulatory  during the ECG 
monitoring period, but should not engage in strenuous activities. If equipment does 
not allow  ambulation,  appropriate  accommodations  will be made  by [CONTACT_372005] (eg, bedside urinals should be provided to 
accommodate participants’ excretory needs).  
• Participants will be advised to avoid direct sunlight exposure or any high intensity 
UV light exposure, from admission in Period [ADDRESS_465439]. In 
addition,  participants  will be instructed  to apply  sun cream/lotion  with an SPF of ≥50, 
and wear eye -protective sunglasses as appropriate.  
PF-07328948  
Protocol  C4921001  
Final  Protocol  Amendment  2, 24 Jan 2023  
PFIZER  CONFIDENTIAL  
Page  44  
 5.4. Screen  Failures  
Screen  failures  are defined  as participants  who consent  to participate  in the clinical  study  but 
are not subsequently enrolled in the study. Screen failure data are collected and remain as 
source and are not reported on the CRF.  
Individuals  who do not meet  the criteria  for participation  in this study  (screen  failure)  may be 
rescreened.  
6. STUDY  INTERVENTION(S)  AND  CONCOMITANT  THERAPY  
Study interventions are all prespecified investigational and noninvestigational medicinal 
products/auxiliary  medicinal  products,  medical  devices,  and other  interventions  (eg, surgical 
and behavioral) intended to be administered to the study participants during the study 
conduct.  
For the purposes  of this protocol,  study  intervention  refers  to: 
• PF-07328948;  
• Placebo  for PF-07328948.  
6.1. Study  Intervention(s)  Administered  
 
Study Intervention(s)  
Intervention  Name  [INVESTIGATOR_16335]-07328948  Placebo  
Arm  Name  
(group  of participants  receiving  a 
specific treatment or no 
treatment)  PF-07328948  Placebo  
Type  Drug  Drug  
Dose  Formulation  Bulk  powder  for extemporaneous 
preparation of oral suspensions  Bulk  powder  for extemporaneous 
preparation of oral suspensions  
Unit  Dose  Strength(s)  10-3000 mg 0 mg 
Dosage  Level(s)  Single  ascending doses 10 -3000  mg 0 mg 
Route  of Administration  Oral Oral 
Use Experimental  Placebo  
IMP or NIMP/AxMP  IMP IMP 
Sourcing  Provided by [CONTACT_372006].  Study  intervention  will be provided 
as bulk powder for  
extemporaneous  preparation  of oral 
suspensions.  
PF-07328948  
Protocol  C4921001  
Final  Protocol  Amendment  2, 24 Jan 2023  
PFIZER  CONFIDENTIAL  
Page  45  
  
Study  Arm(s)  
Arm  Title  Cohort  1 Cohort  2 Cohort  3 (Optional)  
Arm  Type  Experimental  Experimental  Experimental  
Arm  Description  Participants  will receive 
up to 4 dose levels of 
PF-07328948 and up to 
2 matching placebo.  
Doses will be 
administered as oral 
suspensions as 
escalating  single  doses 
to be determined  Participants  will receive 
up to 4 dose levels of 
PF-07328948 and up to 
2 matching placebo.  
Doses will be 
administered as oral 
suspensions as 
escalating  single  doses 
to be determined  Participants will receive 
up to 4 dose levels  of PF- 
07328948 and up to 2 
matching placebo. Doses 
will be administered as 
oral suspensions as 
escalating  single  doses  to 
be determined  
Associated  Intervention 
Labels  PF-07328948;  Placebo  PF-07328948;  Placebo  PF-07328948;  Placebo  
PF-07328948  and placebo  will be provided  by [CONTACT_371999].  
PF-07328948  and placebo  will be presented  to the participants  in individual  dosing 
containers.  
6.1.1.  Administration  
For fasted  period(s):  
• Following an overnight fast of at least 10 hours, participants will receive study 
intervention  at approximately  0800  hours  (plus  or minus  2 hours)  without  breakfast 
on Day 1.  
For period(s)  when  an effect  of protein -rich meal  (ie, MMTT)  is investigated:  
• Following an overnight fast of at least 10 hours, participants will be provided a 
protein -rich meal  as 16 ounces  of Ensure  Plus®  breakfast  approximately  20 minutes 
prior to administration of study intervention. The entire Ensure Plus® meal is to be 
consumed within 10 minutes with study intervention administered approximately  
10 minutes after completion of the meal at 0 hour on Day 1 ( Section 5.3.2 .) 
For all periods, investigator site personnel will administer a single oral dose of study 
intervention  on Day [ADDRESS_465440] confirm that appropriate conditions (eg, 
temperature)  have  been  maintained  during  transit  for all study  interventions  received 
and any discrepancies  are reported  and resolved  before  use of the study  intervention.  
PF-07328948  
Protocol  C4921001  
Final  Protocol  Amendment  2, 24 Jan 2023  
PFIZER  CONFIDENTIAL  
Page  46  
 2. Only  participants  enrolled  in the study  may receive  study  intervention  and only 
authorized site staff may  supply, prepare, and/or administer study  intervention.  
3. All study interventions must be stored in a secure, environmentally controlled, and 
monitored (manual or automated recording) area in accordance with the labeled 
storage conditions with access limited to the investigator and authorized site staff. At 
a minimum, daily  minimum and maximum temperatures for all site storage locations 
must be documented and available upon request. Data for nonworking days must 
indicate  the minimum  and maximum  temperatures  since  previously  documented  upon 
return to business.  
4. Any excursions from the study intervention label storage conditions should be 
reported to [COMPANY_007] upon discovery  along with actions taken. The site should actively 
pursue  options  for returning  the study  intervention  to the labeled  storage  conditions, 
as soon as possible. Once an excursion is identified, the study intervention must be 
quarantined and not used until [COMPANY_007] provides permission to use the study 
intervention. Specific details regarding the excursion definition and information to 
report for each excursion will be provided to the site in the PCRU site procedures.  
5. Any storage  conditions  stated  in the SRSD  will be superseded  by [CONTACT_78254].  
6. Study  interventions  should  be stored  in their original  containers.  
7. The investigator,  institution,  head  of the medical  institution  (where  applicable),  or 
authorized site staff is responsible for study intervention accountability, 
reconciliation, and record maintenance (ie, receipt, reconciliation, and final 
disposition records), such as the IPAL or sponsor -approved equivalent. All study 
interventions will be accounted for using a study intervention accountability 
form/record.  
8. Further guidance and information for the final disposition of unused study 
interventions are provided in the PCRU’s site procedures. All destruction must be 
adequately documented. If destruction is authorized to take place at the investigator 
site, the investigator must ensure that the materials are destroyed in compliance with 
applicable  environmental  regulations,  institutional  policy,  and any special  instructions 
provided by [CONTACT_4618].  
Upon  identification  of a product  complaint,  notify  the sponsor  within  1 business  day of 
discovery.  
6.2.1.  Preparation  and Dispensing  
Within  this protocol,  preparation  refers  to the investigator  site activities  performed  to make 
the study  intervention ready  for administration or dispensing to the participant by  [CONTACT_216479]. Dispensing is defined as the provision of study  intervention, concomitant treatments, 
and accompanying information by [CONTACT_22806](s) to a healthcare provider,  
PF-[ADDRESS_465441].  Prepared  doses  will be provided  in unit dose containers  and labeled  in 
accordance with [COMPANY_007] regulations and the investigator site’s labeling requirements.  
PF-[ADDRESS_465442]. Blinded study intervention will be administered in a blinded fashion to the 
participant.  
6.3. Assignment  to Study  Intervention  
The investigator will assign participant numbers to the participants as they are screened for 
the study.  [COMPANY_007]  will provide  a randomization  schedule  to the investigator  and, in accordance 
with the randomization numbers, the participant will receive the study treatment regimen 
assigned to the corresponding randomization number.  
6.4. Blinding  
This is a double -blind  (sponsor -unblinded) study.  
6.4.1.  Blinding  of Participants  
Participants  will be blinded  to their assigned  study  intervention.  
6.4.2.  Blinding of Site Personnel  
Investigators  and other  site staff will be blinded  to participants’  assigned  study  intervention.  
Participants  will be assigned  to receive  study  intervention  according  to the assigned  treatment 
group  from  the randomization  scheme.  Investigators  will remain  blinded  to each participant’s 
assigned study intervention throughout the course of the study.  
In order  to maintain  this blind,  an otherwise  uninvolved  third  party  will be responsible  for the 
preparation  and dispensing  of all study  intervention  and will endeavor  to ensure  that there  are 
no differences in time taken to dispense or visual presentation, following randomization or 
dispensing.  
In the event of a Quality Assurance audit, the auditor(s) will be allowed access to unblinded 
study  intervention  records  at the site(s)  to verify  that randomization/dispensing  has been  done 
accurately.  
PCRU Pharmacy staff responsible for preparing all study  intervention will be unblinded. 
PCRU  site staff providing  technical  system  support  to the Pharmacy  staff,  and supporting 
blinded laboratory data processes will be unblinded. These site staff providing system 
support are not involved in any data collection or clinic floor activities.  
PF-07328948  
Protocol  C4921001  
Final  Protocol  Amendment  2, 24 Jan 2023  
PFIZER  CONFIDENTIAL  
Page  48  
 6.4.3.  Blinding of the Sponsor  
As this is a sponsor -open  study,  a limited  number  of the sponsor’s  team  members  (excluding 
site staff) may conduct unblinded reviews of the data during the course of the study for the 
purpose of safety and tolerability assessment, facilitating doseescalation decisions, 
facilitating  PK/PD  modeling,  and/or  supporting  clinical  development.  Unblinded  results  will 
be reviewed by a designated limited number of sponsor colleagues within the study team.  
6.4.4.  Breaking the Blind  
The method  for breaking  the blind  in this study  will be manual. In  case of an emergency,  the 
investigator has the sole responsibility for determining if unblinding of a participant’s 
treatment assignment is warranted. Participant safety must always be the first consideration 
in making such a determination. If the investigator decides that unblinding is warranted, the 
investigator should make every effort to contact [CONTACT_185604] a participant’s treatment assignment unless this could delay  further management 
of the participant. If a participant’s treatment assignment is unblinded, the sponsor must be 
notified within [ADDRESS_465443] be fully documented in a CRF.  
Blood specimens will be obtained from all participants for PK analysis to maintain the study 
blind at the investigator site. Only the investigator site staff will be blinded to study 
treatment. Other [COMPANY_007] personnel will be unblinded to participant treatments in order to 
permit real -time interpretation of the safety and PK data; and provide information necessary 
to potentially  alter the dose -escalation sequence. The blinded study  monitor, if assigned, will 
remain  blinded  to treatment  until all monitoring  for the study  has been  completed.  Specimens 
from participants randomized to placebo will not be routinely analyzed. To minimize the 
potential for bias, treatment randomization information will be kept confidential by [CONTACT_372007].  
6.5. Study  Intervention  Compliance  
When  the individual  dose for a participant  is prepared  from  a bulk supply,  the preparation  of 
the dose will be confirmed by a second qualified member of the study site staff.  
When  participants  are dosed  at the site, they will receive  study  intervention  directly  from  the 
investigator or designee, under medical supervision. The date and time of each dose 
administered  in the clinic  will be recorded  in the source  documents  and recorded  in the CRF. 
Study site personnel will examine each participant’s mouth to ensure that the study 
intervention was ingested.  
6.6. Dose Modification  
The decision to proceed to the next dose level of PF -07328948 (either an increase or a 
decrease)  will be made  by [CONTACT_372008],  tolerability, 
and preliminary PK data obtained in at least 6 participants (including at least 1 placebo  
PF-07328948  
Protocol  C4921001  
Final  Protocol  Amendment  2, 24 Jan 2023  
PFIZER  CONFIDENTIAL  
Page  49  
 participant)  at the prior  dose level.  Safety  data and PK data through  at least [ADDRESS_465444] -dose, respectively, will be reviewed.  
The dosing schedule may also be adjusted to expand a dosing cohort to further evaluate 
safety,  tolerability,  PK, and/or PD findings at a given dose level or to add cohorts to evaluate 
additional dose levels or repeat dose levels. The study procedures for these additional 
participant(s)/cohort(s)  will be the same  as that described  for other  study  participants/cohorts.  
6.6.1.  Dose  Escalation  and Stoppi[INVESTIGATOR_371985]-07328948 
will be evaluated and may be omitted when repeating a dose level or administering a lower 
dose level than previously evaluated. Two participants (1 receiving PF -07328948 and 1 
receiving  placebo)  within  a period  will be dosed  initially  before  the remaining  participants  of 
that period are dosed. Safety and tolerability data through at least [ADDRESS_465445] -dose for the 
sentinel participants will be reviewed prior to dosing the remaining participants of that 
period.  
Dose  escalation  stoppi[INVESTIGATOR_371986].  Dose  escalation  may be stopped  if it is determined  that the limits  of safety 
and/or tolerability have been reached. This decision will be made after a discussion takes 
place between the sponsor study  team and the investigator. The sponsor study  team may  not 
overrule the investigator’s decision to stop dose escalation. If dose escalation is stopped 
because of any of these criteria, additional cohorts may receive the same or lower doses of 
the study intervention.  
The dose escalation  will be  terminated based  on the  following criteria:  
• If 50% or more of the participants receiving active drug at a given dose level (but not 
participants  receiving  placebo)  develop  similar  clinically  significant  laboratory,  ECG, 
or vital sign abnormalities, in the same organ class, indicating dose -limiting 
intolerance.  
• Severe nonserious AEs, considered as, at least, possibly  related to study  intervention 
administration, in 2 participants at a given dose level (but not participants receiving 
placebo),  independent  of within  or not within  the same  system  organ  class,  indicating 
dose-limiting intolerance.  
• Dosing will be paused for any SAE that occurs in a participant receiving active 
treatment until causality  is fully  assessed by  [CONTACT_978] [INVESTIGATOR_38107]. Dosing may  resume 
if the SAE is determined to be not drug -related by [CONTACT_978] [INVESTIGATOR_38107]. If the SAE is 
determined  to be either  drug-related  or unknown,  either  dosing  will cease  or the SAE 
will be evaluated by [CONTACT_456]’s protocol review committee (or similar review 
group), which is independent of the study team and investigators. If the protocol 
review committee determines that dosing may resume, a plan that mitigates risks to 
participants with the resumption of dosing will be implemented. Such a plan could  
PF-07328948  
Protocol  C4921001  
Final  Protocol  Amendment  2, 24 Jan 2023  
PFIZER  CONFIDENTIAL  
Page  50  
 include  a revision  of inclusion/exclusion  criteria,  repeating  or reducing  the dose,  or 
adding appropriate safety monitoring.  
• It is determined  that the limit  of safety  and/or  tolerability  has been  reached. This 
decision will be made following discussions between the study team and the 
investigator.  
• Other  findings  that, at the discretion  of the study  team  and investigator,  indicate  that 
dose escalation should be halted.  
• If, at any dose level,  the average  exposure  reaches  or exceeds  the PK stoppi[INVESTIGATOR_371987]: 
Unbound C max of 285 ng/mL; or unbound AUC 24 of 3250 ng•h/mL.  
• If, based  on the observed  data,  the group  mean  Cmax,u  or AUC 24,u of the next planned 
dose is projected to exceed the escalation limits, that dose will not be explored. 
Modified doses may be explored if they are not expected to exceed PK stoppi[INVESTIGATOR_31732].  
Progression  to the next dose level  will occur  if the last dose level  is well tolerated  and after 
satisfactory review of the available safety and PK data.  
6.7. Continued  Access  to Study  Intervention  After  the End of the Study  
No study intervention will be provided to participants at the end of their study participation. 
It is expected  that participants  will be treated  as required  with standard -of-care treatments,  as 
advised by [CONTACT_219875].  
6.8. Treatment  of Overdose  
For this study, any  dose of PF-07328948  greater  than 3000  mg within  a 24-hour time period 
will be considered an overdose.  
There  is no specific treatment for an overdose.  
In the event  of an overdose,  the investigator  or treating  physician  should:  
1. Contact  [CONTACT_219876] 24 hours.  
2. Closely  monitor  the participant  for any AEs/SAEs  and laboratory  abnormalities  as 
medically appropriate and at least until the next scheduled follow -up. 
3. Document  the quantity  of the excess  dose as well as the duration  of the overdose  in 
the CRF.  
4. Overdose is reportable to [COMPANY_007] Safety  only when associated with an SAE.  
PF-[ADDRESS_465446] dose of 
study intervention if requested by [CONTACT_138830] (determined on a  
case-by-case basis).  
Decisions regarding dose interruptions or modifications will be made by [CONTACT_219878].  
6.9. Prior  and Concomitant  Therapy  
Use of prescription or nonprescription drugs and dietary and herbal supplements are 
prohibited  within  7 days or 5 half-lives  (whichever  is longer)  prior  to the first dose of study 
intervention through the last PK collection, with the exception of moderate/strong CYP3A 
inducers or time -dependent inhibitors which are prohibited within [ADDRESS_465447] participant safety or the overall results of the study may be 
permitted on a case -by-case basis following approval by [CONTACT_456] . 
Acetaminophen/paracetamol  may be used at doses of  ≤1 g/day.  
Females  taking  hormone  replacement  therapy  may be eligible  to participate  in this study  if 
they are willing to discontinue therapy at least [ADDRESS_465448] dose of study  intervention 
will be documented as concomitant treatments.  
6.9.1.  Rescue  Medicine  
There  is no rescue  therapy  to reverse  the AEs observed  with PF-07328948;  standard  medical 
supportive care must be provided to manage the AEs.  
7. DISCONTINUATION  OF STUDY  INTERVENTION  AND  PARTICIPANT 
DISCONTINUATION/WITHDRAWAL  
7.1. Discontinuation  of Study  Intervention  
It may  be necessary  for a participant  to permanently  discontinue  study  intervention. Reasons 
for permanent  discontinuation  of study  intervention  include  the following:  adverse  events,  or 
some other (administrative) reasons.  
Note  that discontinuation  of study  intervention  does not represent  withdrawal  from  the study. 
If study intervention is permanently discontinued, the participant should remain in the study 
to be evaluated for ongoing AEs. See the SoA for data to be collected at the time of  
PF-[ADDRESS_465449] be documented on the 
appropriate CRF/in the medical records whether the participant is discontinuing further 
receipt  of study  intervention  or also from  study  procedures,  posttreatment  study  follow -up, 
and/or future collection of additional information.  
7.1.1.  ECG  Changes  
A participant  who meets  either  of the following  bulleted  criteria  based  on the average  of 
triplicate ECG readings will be withdrawn from the study intervention.  
• QTcF  500 ms. 
• Change  from baseline:  QTcF  60 ms. 
If a clinically significant finding is identified (including, but not limited to, changes from 
baseline in QTcF after enrollment), the investigator or qualified designee will determine if 
the participant can continue in the study and if any change in participant management is 
needed.  This review  of the ECG  printed  at the time of collection  must  be documented.  Any 
new clinically relevant finding should be reported as an AE.  
7.1.2.  Potential  Cases  of Acute  Kidney Injury  
Participants exposed to study intervention demonstrating transient or sustained increase in 
SCr (with decrease in SCr -based eGFR or eCrCL) require expedited evaluation to 
differentiate  AKI from  DICI.  DICI  is defined  as transporter -mediated  effect  related  to altered 
renal tubular creatinine handling without histological injury.  
Differentiating  Acute  Kidney  Injury  from  Drug -Induced  Creatinine  Increase: 
Both AKI and DICI are associated with  
• confirmed  Scr increase  ≥0.3 mg/dL  (≥26.5  µmol/L)  within  48 hours 
OR 
• confirmed  Scr increase  ≥1.5 times  baseline  (known  or suspected  to have  occurred 
within the prior 7 days).  
AKI is associated  with 
• simultaneous,  confirmed  SCys  increase  and confirmed  Scr increase  AND  decrease  in 
Scr-based eGFR and combined Scr -Scys -based eGFR (where applicable),  
OR 
PF-07328948  
Protocol  C4921001  
Final  Protocol  Amendment  2, 24 Jan 2023  
PFIZER  CONFIDENTIAL  
Page  53  
 • confirmed  albuminuria  increase 
OR 
• urine  volume  <0.5mL/kg/h  for 6 consecutive  hours. 
DICI is associated with  
• confirmed  Scr increase  without  confirmed  increase  in reflex  SCys 
AND  
• confirmed  Scr-based  eGFR  decrease  without  confirmed  combined  Scr-Scys -based 
eGFR decrease (where applicable).  
Confirmed post -baseline decrease in kidney function should be assessed individually based 
on clinical  judgment.  Cases  wherein  uncertainty  remains,  the investigator  can review  the case 
with the sponsor. Consult the Kidney Safety Council if such a situation occurs during the 
study for support if needed.  
The participant should return to the site for evaluation as soon as possible, preferably within 
48 hours of awareness of the abnormal results. Evaluation should include physical 
examination,  laboratory  tests,  detailed  medical  and surgical  history,  review  of all medications 
(including recreational drugs and supplements [herbal]), family  history, sexual history, travel 
history, blood transfusion, and potential occupational exposure to chemicals. If appropriate, 
nephrology consultation may be recommended to facilitate differentiation of renal 
parenchymal disease, pre -renal azotemia, and post -renal obstruction. All confirmed cases of 
clinically relevant decrease in kidney function should be considered potential cases of DIKI  
if no other reason for the kidney function abnormalities has been found.  
If ≥2 healthy  participants  in a given  period/treatment  arm are noted  to have  confirmed  AKI, 
an assessment  of whether  the finding  may be considered  an adverse  drug reaction  should  be 
undertaken.  
7.1.3.  COVID -19 
If a participant  has COVID -19 during  the study,  this should  be reported  as an AE or SAE  (as 
appropriate) and appropriate medical intervention provided. Study treatment may continue 
unless the investigator/treating physician is concerned about the safety of the participant, in 
which case temporary or permanent discontinuation may be required.  
It is recommended  that the investigator  discuss  temporary  or permanent  discontinuation  of 
study intervention with the study medical monitor.  
PF-07328948  
Protocol  C4921001  
Final  Protocol  Amendment  2, 24 Jan 2023  
PFIZER  CONFIDENTIAL  
Page  54  
 7.2. Participant  Discontinuation/Withdrawal  From  the Study  
A participant  may withdraw  from  the study  at any time at their own request.  Reasons  for 
discontinuation from the study include the following:  
• Refused  further  study  procedure;  
• Lost to follow -up; 
• Death;  
• Study  terminated by  [CONTACT_3211];  
• Discretion of the investigator or sponsor for safety or behavioral reasons, or the 
inability  of the participant  to comply  with the protocol  required  schedule  of study 
visits or procedures.  
At the time of discontinuing  from  the study,  if possible,  an early  discontinuation  visit should 
be conducted. See the SoA for assessments to be collected at the time of study 
discontinuation and follow -up and for any further evaluations that need to be completed.  
The early  discontinuation  visit applies  only to participants  who are enrolled/randomized  and 
then are prematurely  withdrawn  from  the study.  Participants  should  be questioned  regarding 
their reason for withdrawal.  
The participant  will be permanently  discontinued from  the study  intervention  and the study  at 
that time.  
If a participant withdraws from the study, they may request destruction of any remaining 
samples  taken  and not tested,  and the investigator  must  document  any such requests  in the 
site study records and notify the sponsor accordingly.  
If the participant  withdraws  from  the study  and also withdraws  consent  (see Section  7.2.1) 
for disclosure of future information, no further evaluations will be performed and no 
additional data will be collected. The sponsor may retain and continue to use any data 
collected before such withdrawal of consent.  
7.2.1.  Withdrawal of  Consent  
Participants  who request  to discontinue  receipt  of study  intervention  will remain  in the study 
and must continue to be followed for protocol -specified follow -up procedures. The only 
exception  to this is when  a participant  specifically  withdraws  consent  for any further  contact 
[CONTACT_219879].  
Participants should notify the investigator in writing of the decision to withdraw consent 
from future follow -up, whenever possible. The withdrawal of consent should be explained in 
detail in the medical records by [CONTACT_093], as to whether the withdrawal is only from 
further  receipt  of study  intervention  or also from  study  procedures  and/or  posttreatment  study  
PF-07328948  
Protocol  C4921001  
Final  Protocol  Amendment  2, 24 Jan 2023  
PFIZER  CONFIDENTIAL  
Page  55  
 follow -up, and entered on the appropriate CRF page. In the event that vital status (whether 
the participant  is alive  or dead)  is being  measured,  publicly  available  information  should  be 
used to determine vital status only as appropriately directed in accordance with local law.  
7.3. Lost  to Follow -up 
A participant  will be considered  lost to follow -up if the participant  repeatedly  fails to return 
for scheduled visits and is unable to be contact[CONTACT_9298].  
The following  actions  must  be taken  if a participant  fails to return  to the clinic  for a required 
study visit:  
• The site must attempt to contact [CONTACT_14315]. Counsel the participant on the importance of maintaining the 
assigned  visit schedule  and ascertain  whether  the participant  wishes  to and/or  should 
continue in the study;  
• Before a participant is deemed lost to follow -up, the investigator or designee must 
make  every  effort  to regain  contact  [CONTACT_6635]  (where  possible,  3 telephone 
calls and, if necessary, a certified letter to the participant’s last known mailing 
address  or local  equivalent methods). These contact [CONTACT_219880]’s medical record;  
• Should  the participant  continue  to be unreachable,  the participant  will be considered 
to have withdrawn from the study.  
8. STUDY ASSESSMENTS AND  PROCEDURES  
8.1. Administrative  Procedures  
The investigator  (or an appropriate  delegate  at the investigator  site) must  obtain  a signed  and 
dated ICD before performing any study -specific procedures.  
Study  procedures  and their timing  are summarized  in the SoA. Protocol  waivers  or 
exemptions are not allowed.  
Adherence  to the study  design  requirements,  including  those  specified  in the SoA, is essential 
and required for study conduct.  
All screening evaluations must be completed and reviewed to confirm that potential 
participants  meet  all eligibility  criteria.  The investigator  will maintain  a screening  log to 
record  details  of all participants  screened  and to confirm  eligibility  or record  reasons  for 
screening failure, as applicable.  
Participants  will be screened  within  28 days prior  to administration  of the study  intervention 
to confirm that they meet the study population criteria for the study. If the time between 
screening and dosing exceeds 28 days as a result of unexpected delays (eg, delayed drug  
PF-07328948  
Protocol  C4921001  
Final  Protocol  Amendment  2, 24 Jan 2023  
PFIZER  CONFIDENTIAL  
Page  56  
 shipment),  then participants  do not require  rescreening  if the laboratory  results  obtained  prior 
to first dose administration meet eligibility criteria.  
A participant  who qualified  for this protocol  but did not enroll  from  an earlier  cohort/group 
may be used in a subsequent cohort/group without rescreening, provided laboratory  results 
obtained prior to the first dose administration meet eligibility criteria for this study. In 
addition, other clinical assessments or specimen collections, eg, retained research samples, 
may be used without repeat collection, as appropriate.  
Every effort should be made to ensure that protocol -required tests and procedures are 
completed as described. However, it is anticipated that from time to time there may be 
circumstances outside the control of the investigator that make it unfeasible to perform the 
test. In these cases, the investigator must take all steps necessary to ensure the safety and 
well-being of the participant. When a protocol -required test cannot be performed, the 
investigator  will document  the reason  for the missed  test and any corrective  and preventive 
actions that they have taken to ensure that required processes are adhered to as soon as 
possible. The study team must be informed of these incidents in a timely manner.  
Any safety, laboratory, or analyte results that have been collected for the purposes of this 
study  and could  unblind  the study  will not be reported  to investigative  sites or other  blinded 
personnel until the study has been unblinded.  
If an IV catheter  is utilized  for blood  sample  collections,  ECGs  and vital sign assessments 
(pulse rate and BP) should be collected prior to the insertion of the catheter.  
For samples being collected and shipped, detailed collection, processing, storage, and 
shipment  instructions  and contact  [CONTACT_219881].  
The total blood sampling volume for individual participants in this study is approximately 
515-550 mL. The actual collection times of blood sampling may change. Additional blood 
samples may  be taken for safety assessments at times specified by [CONTACT_4618], provided the total 
volume  taken  during  the study  does not exceed  550 mL during  any period  of 56 consecutive 
days.  
To prepare  for study  participation,  participants  will be instructed  on the information  in the 
Lifestyle Considerations  and Prior and Concomitant Therapy  sections of the protocol.  
8.2. Efficacy  Assessments  
No efficacy  assessments are being conducted in this study.  
8.3. Safety  Assessments  
Planned  time points  for all safety  assessments  are provided  in the SoA. Unscheduled  safety 
measurements may  be obtained at any  time during the study  to assess any  perceived safety 
issues.  
PF-07328948  
Protocol  C4921001  
Final  Protocol  Amendment  2, 24 Jan 2023  
PFIZER  CONFIDENTIAL  
Page  57  
 8.3.1.  Physical Examinations  
Physical  examinations  are to be performed  at the nominal  timepoints  specified  in the SoA. 
Additional physical examinations will be permitted, as necessary, to ensure appropriate 
collection of safety data.  
A complete  physical  examination  will include,  at a minimum,  head,  ears, eyes,  nose,  mouth, 
skin, heart and lung examinations (including lung auscultation), lymph nodes, and 
gastrointestinal, musculoskeletal, and neurological systems.  
A brief  physical  examination  will include,  at a minimum,  assessments  of general  appearance, 
the respi[INVESTIGATOR_696] (including lung auscultation) and cardiovascular systems, and  
participant -reported  symptoms.  
Physical  examinations  may be conducted  by a physician,  trained  physician’s  assistant,  or 
nurse practitioner as acceptable according to local regulation.  
Height  and weight  will also be measured  and recorded  as per the SoA. For measuring  weight, 
a scale with appropriate range and resolution is used and must be placed on a stable, flat 
surface. Participants must remove shoes, bulky layers of clothing, and jackets so that only 
light clothing remains. They must also remove the contents of their pockets and remain still 
during measurement of weight.  
Physical  examination  findings  collected  during  the study  will be considered  source  data and 
will not be required to be reported, unless otherwise noted. Any untoward physical 
examination findings that are identified during the active collection period and meet the 
definition of an AE or SAE ( Appendix 3 ) must be reported according to the processes in 
Sections 8.4.1  to 8.4.3 . 
8.3.2.  Neurological Examinations  
Neurological examinations as part of the physical exam may be conducted by a physician, 
trained  physician's  assistant,  or nurse  practitioner  as acceptable  according  to local  regulation. 
The neurological exam will consist of assessment of higher cortical function, the cranial 
nerves, motor function, deep tendon reflexes, sensory exam, and coordination and gait. The 
exam should be done to the extent needed to assess the participant for any potential changes 
in neurological status, as determined by [CONTACT_093] (or designee).  
8.3.3.  Vital Signs  
[IP_ADDRESS].  Blood  Pressure  and Pulse  Rate  
Supi[INVESTIGATOR_219848]’s  arm supported  at the level  of the heart,  and 
recorded to the nearest mm Hg after approximately [ADDRESS_465450]. The same arm 
(preferably the dominant arm) will be used throughout the study. Participants should be 
instructed not to speak during measurements. When triplicate measurements of supi[INVESTIGATOR_371988], measurements should be collected 2 -4 minutes apart.  
PF-07328948  
Protocol  C4921001  
Final  Protocol  Amendment  2, 24 Jan 2023  
PFIZER  CONFIDENTIAL  
Page  58  
 The same  properly  sized  and calibrated  BP cuff will be used to measure  BP each time.  The 
use of an automated device for measuring BP and pulse rate is acceptable; however, when 
done manually, pulse rate will be measured in the brachial/radial artery for at least  
30 seconds.  When  the timing  of these  measurements  coincides  with a blood  collection,  BP 
and pulse rate should be obtained prior to the nominal time of the blood collection.  
[IP_ADDRESS].  Respi[INVESTIGATOR_371989] [ADDRESS_465451]  vital sign findings  that are identified  during  the active  collection  period  and 
meet the definition of an  AE or SAE ( Appendix 3 ) must be reported according to the 
processes in Sections 8.4.[ADDRESS_465452] 12 -lead ECGs utilizing limb leads (with a 10 -second rhythm strip) should be 
collected at times specified in the SoA section of this protocol using an ECG machine that 
automatically calculates the HR and measures PR interval, QT interval, QTcF, and QRS 
complex. Alternative lead placement methodology using torso leads (eg, Mason -Likar) 
should not be used given the potential risk of discrepancies with ECGs acquired using 
standard  limb lead placement.  All scheduled  ECGs  should  be performed  after the participant 
has rested quietly for at least 5 minutes in a supi[INVESTIGATOR_2547].  
Triplicate  12-lead ECGs  will be obtained  approximately  2-4 minutes  apart;  the average  of the 
triplicate ECG measurements collected at -1.0, -0.5, and 0 hours pre -dose on Day 1 of each 
period will serve as each participant’s baseline QTcF value for that period.  
To ensure safety of the participants, a qualified individual at the investigator site will make 
comparisons  to baseline  measurements.  Additional  ECG  monitoring  will occur  if a) the mean 
value from the triplicate measurements for any postdose QTcF interval is increased by  
≥60 ms from the baseline and is >450 ms; or b) an absolute QT value is ≥[ADDRESS_465453] hourly until QTcF values from 2 successive ECGs fall below the threshold 
value that triggered the repeat measurement.  
For single ECG collections, additional ECG monitoring will occur if a) a postdose QTcF 
interval  is increased  by ≥60 ms from  the baseline  and is >450  ms; or b) an absolute  QT value 
is ≥[ADDRESS_465454] hourly  until QTc values  from  2 successive 
ECGs fall below the threshold value that triggered the repeat measurement.  
If a) a postdose QTcF interval remains ≥60 ms from the baseline and is >450 ms; or b) an 
absolute  QT value  is ≥500  ms for any scheduled  ECG  for greater  than 4 hours  (or sooner,  at 
the discretion  of the investigator);  or c) QTcF  value  get progressively  longer,  the participant 
shoul d undergo continuous ECG monitoring. A cardiologist should be consulted if QTcF 
values do not return to less than the criteria listed above after 8 hours of monitoring (or 
sooner, at the discretion of the investigator).  
In some cases, it may be appropriate to repeat abnormal ECGs to rule out improper lead 
placement  as contributing  to the ECG  abnormality.  It is important  that leads  be placed  in the 
same positions each time in order to achieve precise ECG recordings. If a machine -read 
QTcF value is prolonged, as defined above, repeat measurements may not be necessary if a 
qualified medical provider’s interpretation determines that the QTcF values are in the 
acceptable range.  
ECG  values  of potential  clinical  concern  are listed  in Appendix 8. 
[IP_ADDRESS].  Continuous  Cardiac  Monitoring  by [CONTACT_372009]. The time, duration, and description of the clinically 
significant  event  will be recorded  in the CRF. In  addition,  a printed  record  of the tracing(s)  of 
the clinically significant rhythm(s) will be made and retained with other source documents.  
Telemetry  should be collected using a centralized system that also allows  for the storage and 
advanced analysis of all recorded data in order to preserve important events for future 
evaluations. Holter monitoring should not be used in parallel with continuous telemetry, 
unless it is the only means of data storage available at the investigator site, or verifiable 
arrhythmia quantification is required. To establish a baseline, telemetry should be recorded 
for at least a [ADDRESS_465455] findings are those that are not associated with 
the underlying  disease,  unless  judged  by [CONTACT_219882]’s condition.  
All laboratory tests with values considered clinically significant and abnormal during 
participation  in the study  or within  [ADDRESS_465456] dose of study  intervention  should  be 
repeated until the values return to normal or baseline or are no longer considered clinically 
significant by [CONTACT_219883].  
If such values  do not return  to normal/baseline  within  a period  of time judged  reasonable  by 
[CONTACT_093], the etiology should be identified and the sponsor notified.  
See Appendix  [ADDRESS_465457]  be negative  for participants  to receive  study 
intervention.  
8.4. Adverse  Events,  Serious  Adverse  Events,  and Other  Safety  Reporting  
The definitions  of an AE and  an SAE  can be found  in Appendix 3. 
AEs may arise from symptoms or other complaints reported to the investigator by [CONTACT_2416] (or, when appropriate, by a caregiver, surrogate, or the participant’s legally 
authorized  representative),  or they may arise  from  clinical  findings  of the investigator  or 
other healthcare providers (clinical signs, test results, etc).  
The investigator  and any qualified  designees  are responsible  for detecting,  documenting,  and 
recording events that meet the definition of an AE or SAE and remain responsible to pursue 
and obtain adequate information both to determine the outcome and to assess whether the 
event meets the criteria for classification as an SAE or caused the participant to discontinue 
the study intervention (see Section 7.1 ). 
During  the active  collection  period  as described  in Section  8.4.1 , each participant  will be 
questioned about the occurrence of AEs in a nonleading manner.  
In addition,  the investigator  may be requested  by [CONTACT_219887] -up 
information in an expedited fashion.  
PF-07328948  
Protocol  C4921001  
Final  Protocol  Amendment  2, 24 Jan 2023  
PFIZER  CONFIDENTIAL  
Page  61  
 8.4.1.  Time  Period  and Frequency  for Collecting  AE and SAE  Information  
The time period for actively eliciting and collecting AEs and SAEs (“active collection 
period”)  for each participant  begins  from  the time the participant  provides  informed  consent, 
which is obtained before undergoing any study -related procedure and/or receiving study 
intervention), through and including a minimum of [ADDRESS_465458] SAE Report Form.  
[IP_ADDRESS].  Reporting  SAEs  to [COMPANY_007] Safety  
All SAEs occurring in a participant during the active collection period as described in 
Section  8.4.[ADDRESS_465459] SAE  Report  Form  immediately  upon 
awareness and under no circumstance should this exceed 24 hours, as indicated in 
Appendix 3 . The investigator will submit any updated SAE data to the sponsor within  
24 hours  of its being  available.  
[IP_ADDRESS].  Recording  Nonserious  AEs and SAEs  on the CRF  
All nonserious AEs and SAEs occurring in a participant during the active collection period, 
which  begins  after obtaining  informed  consent  as described  in Section  8.4.1,  will be recorded 
on the AE section of the CRF.  
The investigator  is to record  on the CRF  all directly  observed  and all spontaneously  reported 
AEs and SAEs reported by [CONTACT_2299].  
PF-[ADDRESS_465460]  to the CRF 
requirements as described in Section 5.4 . 
8.4.2.  Method  of Detecting  AEs and SAEs  
The method  of recording,  evaluating,  and assessing  causality  of AEs and SAEs  and the 
procedures for completing and transmitting SAE reports are provided in Appendix 3 . 
Care  will be taken  not to introduce  bias when  detecting  AEs and/or  SAEs.  Open -ended  and 
nonleading verbal questioning of the participant is the preferred method to inquire about 
AE occurrences.  
8.4.3.  Follow -Up of AEs and SAEs  
After the initial AE or SAE report, the investigator is required to proactively follow each 
participant at subsequent visits/contacts. For each event, the investigator must pursue and 
obtain  adequate  information  until resolution,  stabilization,  the event  is otherwise  explained, 
or the participant is lost to follow -up (as defined in Section 7.3 ). 
In general,  follow -up information  will include  a description  of the event  in sufficient  detail  to 
allow for a complete medical assessment of the case and independent determination of 
possible causality. Any information relevant to the event, such as concomitant medications 
and illnesses, must be provided. In the case of a participant death, a summary of available 
autopsy findings must be submitted as soon as possible to [COMPANY_007] Safety.  
Further  information  on follow -up procedures  is provided  in Appendix 3. 
8.4.4.  Regulatory  Reporting  Requirements  for SAEs  
Prompt notification by [CONTACT_219889] a 
study intervention under clinical investigation are met.  
The sponsor has a legal responsibility  to notify  both the local regulatory  authority  and other 
regulatory  agencies  about  the safety  of a study  intervention  under  clinical  investigation.  The 
sponsor will comply with country -specific regulatory requirements relating to safety 
reporting to the regulatory authority, IRBs/ECs, and investigators.  
Investigator  safety  reports  must  be prepared  for S[LOCATION_003]Rs  according  to local  regulatory 
requirements and sponsor policy and forwarded to investigators as necessary.  
PF-07328948  
Protocol  C4921001  
Final  Protocol  Amendment  2, 24 Jan 2023  
PFIZER  CONFIDENTIAL  
Page  63  
 An investigator who receives S[LOCATION_003]Rs or other specific safety information (eg, summary  or 
listing  of SAEs)  from  the sponsor  will review  and then file it along  with the SRSD(s)  for the 
study and will notify the IRB/EC, if appropriate according to local requirements.  
8.4.5.  Environmental  Exposure,  Exposure  During  Pregnancy  or Breastfeeding,  and 
Occupational Exposure  
Environmental exposure, occurs when a person not enrolled in the study as a participant 
receives unplanned direct contact [CONTACT_273478]. Such exposure 
may or may not lead to the occurrence of an AE or SAE. Persons at risk for environmental 
exposure  include  healthcare  providers,  family  members,  and others  who may be exposed.  An 
environmental exposure may include EDP, EDB, and occupational exposure.  
Any such exposures  to the study  intervention  under  study  are reportable  to [COMPANY_007]  Safety 
within 24 hours of investigator awareness.  
[IP_ADDRESS].  Exposure During Pregnancy  
An EDP  occurs  if: 
• A female  participant  is found  to be pregnant  while  receiving  or after discontinuing 
study intervention . 
• A male  participant  who is receiving  or has discontinued  study  intervention 
inseminates a female partner.  
• A female  nonparticipant  is found  to be pregnant  while  being  exposed  or having  been 
exposed to study intervention because of environmental exposure. Below are 
examples of environmental EDP:  
• A female  family  member  or healthcare  provider  reports  that she is pregnant  after 
having been exposed to the study intervention by [CONTACT_78262], inhalation, or skin 
contact.  
• A male  family  member  or healthcare  provider  who has been  exposed  to the study 
intervention by  [CONTACT_78262], inhalation, or skin contact [CONTACT_336270].  
The investigator must report EDP to [COMPANY_007] Safety within 24 hours of the investigator’s 
awareness,  irrespective  of whether  an SAE  has occurred.  The initial  information  submitted 
should include the anticipated date of delivery (see below for information related to 
termination of pregnancy).  
• If EDP  occurs  in a participant  or a participant’s  partner,  the investigator  must  report 
this information to [COMPANY_007] Safety on the CT SAE Report Form and an EDP 
Supplemental Form, regardless of whether an SAE has occurred. Details of the  
PF-[ADDRESS_465461] dose.  
• If EDP  occurs  in the setting  of environmental  exposure,  the investigator  must  report 
information  to [COMPANY_007]  Safety  using  the CT SAE  Report  Form  and EDP  Supplemental 
Form. Since the exposure information does not pertain to the participant enrolled in 
the study, the information is not recorded on a CRF; however, a copy of the 
completed CT SAE Report Form is maintained in the investigator site file.  
Follow -up is conducted to obtain general information on the pregnancy and its outcome for 
all EDP reports with an unknown outcome. The investigator will follow the pregnancy  until 
completion (or until pregnancy termination) and notify [COMPANY_007] Safety of the outcome as a 
follow -up to the initial EDP Supplemental Form. In the case of a live birth, the structural 
integrity  of the neonate  can be assessed  at the time of birth.  In the event  of a termination,  the 
reason(s) for termination should be specified and, if clinically possible, the structural 
integrity of the terminated fetus should be assessed by [CONTACT_4692] (unless 
preprocedure test findings are conclusive for a congenital anomaly and the findings are 
reported).  
Abnormal  pregnancy  outcomes  are considered  SAEs.  If the outcome  of the pregnancy  meets 
the criteria for an SAE (ie, ectopic pregnancy, spontaneous abortion, intrauterine fetal 
demise, neonatal death, or congenital anomaly in a live -born baby, a terminated fetus, an 
intrauterine fetal demise, or a neonatal death), the investigator should follow the procedures 
for reporting SAEs. Additional information about pregnancy outcomes that are reported to 
[COMPANY_007] Safety as SAEs follows:  
• Spontaneous  abortion  including  miscarriage  and missed  abortion  should  be reported 
as an SAE;  
• Neonatal  deaths  that occur  within  [ADDRESS_465462] 
to causality, as SAEs. In addition, infant deaths after 1 month should be reported as 
SAEs when the investigator assesses the infant death as related or possibly related to 
exposure to the study intervention.  
Additional information regarding the EDP may be requested by [CONTACT_456]. Further 
follow -up of birth outcomes will be handled on a case -by-case basis (eg, follow -up on 
preterm infants to identify developmental delays). In the case of paternal exposure, the 
investigator  will provide  the participant  with the Pregnant  Partner  Release  of Information  
Form to deliver to his partner. The investigator must document in the source documents that 
the participant  was given  the Pregnant  Partner  Release  of Information  Form  to provide  to his 
partner.  
PF-07328948  
Protocol  C4921001  
Final  Protocol  Amendment  2, 24 Jan 2023  
PFIZER  CONFIDENTIAL  
Page  65  
 [IP_ADDRESS].  Exposure During Breastfeeding  
An EDB  occurs  if: 
• A female  participant  is found  to be breastfeeding  while  receiving  or after 
discontinuing study intervention.  
• A female  nonparticipant  is found  to be breastfeeding  while  being  exposed  or having 
been exposed to study intervention (ie, environmental exposure). An example of 
environmental EDB is a female family member or healthcare provider who reports 
that she is breastfeeding after having been exposed to the study intervention by 
[CONTACT_78262], inhalation, or skin contact.  
The investigator must report EDB to [COMPANY_007] Safety within 24 hours of the investigator’s 
awareness, irrespective of whether an SAE has occurred. The information must be reported 
using  the CT SAE  Report  Form.  When  EDB  occurs  in the setting  of environmental  exposure, 
the exposure information does not pertain to the participant enrolled in the study , so the 
information is not recorded on a CRF. However, a copy of the completed CT SAE Report 
Form is maintained in the investigator site file.  
An EDB report is not created when a [COMPANY_007] drug specifically approved for use in 
breastfeeding women (eg, vitamins) is administered in accordance with authorized use. 
However,  if the infant  experiences  an SAE  associated  with such a drug,  the SAE  is reported 
together with the EDB.  
[IP_ADDRESS].  Occupational Exposure  
The investigator must report any  instance of occupational exposure to [COMPANY_007] Safety within 
24 hours of the investigator’s awareness using the CT SAE Report Form regardless of 
whether  there  is an associated  SAE.  Since  the information  about  the occupational  exposure 
does not pertain to a participant enrolled in the study, the information is not recorded on a 
CRF; however, a copy of the completed CT SAE Report Form must be maintained in the 
investigator site file.  
8.4.6.  Cardiovascular  and Death  Events  
Not applicable.  
8.4.7.  Disease -Related  Events  and/or  Disease -Related  Outcomes  Not Qualifying  as AEs 
or SAEs  
Not applicable.  
8.4.8.  Adverse  Events  of Special  Interest  
Not applicable.  
PF-07328948  
Protocol  C4921001  
Final  Protocol  Amendment  2, 24 Jan 2023  
PFIZER  CONFIDENTIAL  
Page  66  
 [IP_ADDRESS].  Lack  of Efficacy  
This section is not applicable because efficacy  is not expected in this study  population.  
8.4.9.  Medical  Device  Deficiencies  
Not applicable.  
8.4.10.  Medication  Errors  
Medication errors may result from the administration or consumption of the study 
intervention  by [CONTACT_219892],  or at the wrong  time,  or at the wrong  dosage  strength.  
Medication  errors  are recorded  and reported  as follows:  
 
Recorded on the 
Medication  Error  Page 
of the CRF  Recorded on the 
Adverse  Event  Page 
of the CRF  Reported on the CT SAE 
Report Form to [COMPANY_007] 
Safety  Within  24 Hours  of 
Awareness  
All (regardless  of whether 
associated with an AE)  Any AE or SAE  associated 
with the medication error  Only  if associated  with an 
SAE 
Medication  errors  include:  
• Medication  errors  involving  participant  exposure  to the study  intervention;  
• Potential  medication  errors  or uses outside  of what  is foreseen  in the protocol  that do 
or do not involve the study participant;  
• The administration of expi[INVESTIGATOR_214312];  
• The administration of an incorrect study  intervention;  
• The administration  of an incorrect  dosage;  
• The administration of study intervention that has undergone temperature excursion 
from  the specified  storage  range,  unless  it is determined  by [CONTACT_372010].  
Such  medication  errors  occurring  to a study  participant  are to be captured  on the medication 
error page of the CRF, which is a specific version of the AE page.  
Whether or not the medication error is accompanied by [CONTACT_1149], as determined by [CONTACT_1275],  the medication  error  is recorded  on the medication  error  page  of the CRF  and, if 
applicable,  any associated  AE(s),  serious  and nonserious,  are recorded  on the AE page  of the 
CRF.  
PF-[ADDRESS_465463] SAE  Report 
Form only when associated with an SAE.  
8.5. Pharmacokinetics  
8.5.1.  Plasma  for Analysis  of PF-07328948  Concentrations  
Blood samples of approximately  3 mL,  to provide approximately  1.2 mL of plasma, will be 
collected for measurement of plasma concentrations of PF -07328948 into appropriately 
labeled tubes containing K 2EDTA as specified in the SoA. Instructions for the collection 
including any potential additive information, processing, aliquoting, handling, storage, and 
shipment  of biological  samples  will be provided  in the laboratory  manual  or by [CONTACT_456]. 
The actual date and time (24 -hour clock time) of each sample will be recorded.  
The actual times may change, but the number of samples will remain the same. All efforts 
will be made  to obtain  the samples  at the exact  nominal  time relative  to dosing.  Collection  of 
samples up to and including 10 hours after dose administration that are obtained within  
10% of the nominal time relative to dosing (eg, within 6 minutes of a 60 -minute sample) will 
not be captured as a protocol deviation, as long as the exact time of the collection is noted on 
the source document and the CRF. Collection of samples more than 10 hours after dose 
administration that are obtained ≤[ADDRESS_465464] time of the collection is noted on 
the source  document  and the CRF.  This protocol  deviation  window  does not apply  to samples 
to be collected more than 10 hours after dose administration at outpatient/follow -up visits 
with visit windows.  
Samples  will be used to evaluate  the PK of PF-07328948.  Samples  collected  for analyses  of 
PF-[ADDRESS_465465] related to 
concerns  arising  during  or after the study,  for metabolite  identification,  and/or  evaluation  of 
the bioanalytical method, or for other internal exploratory purposes.  
 
Samples collected for measurement of plasma concentrations of PF -[ADDRESS_465466] be processed  and shipped  as indicated  in the instructions  provided  to 
the investigator site to maintain sample integrity. Any deviations from the PK sample 
handling  procedure  (eg, sample  collection  and processing  steps,  interim  storage  or shippi[INVESTIGATOR_15889]), including any actions taken, must be documented and reported to the sponsor. 
On a case -by-case basis, the sponsor may make a determination as to whether sample 
integrity has been compromised.  
PF-[ADDRESS_465467] 
be documented and approved by [CONTACT_372011], but will not constitute a protocol amendment. The IRB/EC will 
be informed of any safety issues that require alteration of the safety monitoring scheme or 
amendment of the ICD.  
8.6. Genetics  
8.6.1.  Specified  Genetics  
Specified  genetic  analyses  are not evaluated  in this study.  
8.6.2.  Retained  Research  Samples  for Genetics  
A 2-mL blood  sample  optimized  for DNA  isolation  Prep D1.5  will be collected  according  to 
the SoA, as local regulations and IRBs/ECs allow.  
Retained Research Samples may be used for research related to the study intervention(s). 
Genes  and other  analytes  (eg, proteins,  RNA,  nondrug  metabolites)  may be studied  using  the 
retained samples.  
See Appendix  5 for information  regarding  genetic  research.  Details  on processes  for 
collection and shipment of these samples can be found in the lab manual and other 
supporting documentation.  
8.7. Pharmacodynamics  
Collection  of samples  for pharmacodynamics  research  is also part of this study.  
The following  samples  for pharmacodynamics  research  are required  and will be collected 
from all participants in this study as specified in the SoA. 
• Retained  Prep B1.5  research sample  (Period  1 and  Period  4 only);  
• Retained  Prep B2.5  research  sample  (Period  1 and Period  4 only);  
• CCI  
 
8.7.1.  Biomarkers  
[IP_ADDRESS].  Specified  Gene  Expression  (RNA)  Research  
Specified gene expression (RNA) research is not included in this study.  
PF-07328948  
Protocol  C4921001  
Final  Protocol  Amendment  2, 24 Jan 2023  
PFIZER  CONFIDENTIAL  
Page  69  
 
CCI [IP_ADDRESS].  Specified  Protein  Research  
Specified protein research is not included in this study.  
[IP_ADDRESS].  Specified  Metabolomic  Research  
Specified metabolomic research is not included in this study.  
[IP_ADDRESS].  Retained  Research  Samples  for Biomarker  
These  Retained  Research  Samples  will be  collected  in this study:  
• 2 mL whole  blood  Prep B1.5  optimized  for plasma  (at each sampling  time as outlined 
in the SoA); 
• 2 mL whole  blood  Prep B2.5  optimized  for serum  (at each sampling  time as outlined 
in the SoA). 
Retained  Research  Samples  will be collected  as local  regulations  and IRB/ECs  allow 
according to the SoA. 
Retained Research Samples may be used for research related to the study intervention(s). 
Genes  and other  analytes  (eg, proteins,  RNA,  nondrug  metabolites)  may be studied  using  the 
retained samples.  
See Appendix  5 for information  regarding  genetic  research.  Details  on processes  for 
collection and shipment of these samples can be found in the lab manual and other 
supporting documentation.  
8.7.2.  Pharmacodynamics  Assessments  
 
Instructions for the collection, processing, handling, storage, and shippi[INVESTIGATOR_371990].  The actual  date and 
time (24 -hour clock time) of each sample will be recorded.  
The actual times may change, but the number of samples will remain the same. All efforts 
will be made  to obtain  the samples  at the exact  nominal  time relative  to dosing.  Collection  of 
samples up to and including 10 hours after dose administration that are obtained within  
10% of the nominal time relative to dosing (eg, within 6 minutes of a 60 -minute sample) will 
not be captured as a protocol deviation, as long as the exact time of the collection is noted on 
the source document and the CRF. Collection of samples more than 10 hours after dose 
administration that are obtained ≤[ADDRESS_465468] related to 
concerns  arising  during  or after the study,  for metabolite  identification  and/or  evaluation  of 
bioanalytical method, or for other internal exploratory purposes.  
Genetic  analyses  will not be performed  on these  plasma  unless  consent  for this was included 
in the informed consent. Participant confidentiality will be maintained.  
 
The PD samples must be processed and shipped as indicated in the instructions provided to 
the investigator site to maintain sample integrity. Any deviations from the PD sample 
handling  procedures  (eg, sample  collection  and processing  steps,  interim  storage,  or shippi[INVESTIGATOR_15889]), including any actions taken, must be documented and reported to the sponsor.  
On a case-by-case basis,  the sponsor  may make  a determination  as to whether  sample 
integrity has been compromised.  
PD concentration  information  that may unblind  the study  will not be reported  to investigator 
sites or blinded personnel until the study has been unblinded.  
Any changes  in the timing  or addition  of time points  for any planned  study  assessments  must 
be documented and approved by [CONTACT_372012], but will not constitute a protocol amendment. The IRB/EC will 
be informed of any safety issues that require alteration of the safety monitoring scheme or 
amendment of the ICD.  
 
 
 
8.8. Immunogenicity  Assessments  
Immunogenicity  assessments  are not included  in this study.  
CCI 
PF-07328948  
Protocol  C4921001  
Final  Protocol  Amendment  2, 24 Jan 2023  
PFIZER  CONFIDENTIAL  
Page  71  
 8.9. Health  Economics  
Health  economics/medical  resource  utilization  and health  economics  parameters  are not 
evaluated in this study.  
9. STATISTICAL  CONSIDERATIONS  
Detailed  methodology  for summary  and statistical  analyses  of the data collected  in this study 
is outlined here and further detailed in the SAP, which will be maintained by [CONTACT_456].  
The SAP may modify  what  is outlined  in the protocol  where  appropriate;  however,  any major 
modifications of the primary endpoint definitions or their analyses will also be reflected in a 
protocol amendment.  
9.1. Statistical  Hypothesis  
No formal  statistical  hypothesis testing will be performed in this study.  
9.2. Analysis Sets 
For purposes  of analysis,  the following  analysis  sets are defined:  
 
Participant  Analysis 
Set Description  
Enrolled  “Enrolled” means a participant’s agreement to participate in a 
clinical study following completion of the informed consent 
process  and randomization  to study  intervention.  A participant 
will be considered enrolled if the informed consent is not 
withdrawn prior to participating in any study activity after 
screening. Potential participants who are screened for the 
purpose of determining eligibility for the study, but do not 
participate in the study, are not considered enrolled, unless 
otherwise specified by [CONTACT_760].  
Safety  analysis  set All participants randomly assigned to study intervention and 
who take at least [ADDRESS_465469] 1 concentration  value  is reported  for any PD endpoint.  
PF-07328948  
Protocol  C4921001  
Final  Protocol  Amendment  2, 24 Jan 2023  
PFIZER  CONFIDENTIAL  
Page  72  
 9.3. Statistical Analyses  
The SAP will be developed and finalized before any analyses are performed and will 
describe  the analyses  and procedures  for accounting  for missing,  unused,  and spurious  data. 
This section is a summary of the planned statistical analyses of the primary, secondary and 
tertiary/exploratory endpoints.  
9.3.1.  Safety Endpoints  
All safety  analyses  will be performed  on the safety  analysis  set. 
AEs, ECGs, BP, pulse rate, respi[INVESTIGATOR_697], continuous cardiac monitoring, and safety 
laboratory data will be reviewed and summarized on an ongoing basis during the study to 
evaluate the safety of participants. Any clinical laboratory, ECG, BP, pulse rate, and 
respi[INVESTIGATOR_371991].  Safety  data will 
be presented in tabular and/or graphical format and summarized descriptively, where 
appropriate.  
Medical history and physical examination (including neurological examinations) as 
applicable, collected during the course of the study  will be considered source data and will 
not be required to be reported, unless otherwise noted. However, any untoward findings 
identified on physical and/or neurological examinations conducted during the active 
collection period will be captured as AEs, if those findings meet the definition of an AE. 
Data  collected  at screening  that are used for inclusion/exclusion  criteria,  such as laboratory 
data, ECGs, and vital signs, will be considered source data, and will not be required to be 
reported,  unless  otherwise  noted.  Demographic  data collected  at screening  will be reported.  
[IP_ADDRESS].  Electrocardiogram  Analyses  
Changes  from  baseline  for the ECG  parameters  (ie, QT interval,  heart  rate, QTcF  interval,  PR 
interval, and QRS complex) will be summarized by [CONTACT_22841].  
The number  (%) of participants  with maximum  postdose  QTcF  values  and maximum 
increases from baseline in the following categories will be tabulated by [CONTACT_3148]:  
 
Safety  QTcF  Assessment  
 
Degree  of Prolongation  Mild  (ms) Moderate  (ms) Severe  (ms) 
Absolute  value  >450 -480 >480 -500 >500  
Increase  from  baseline   30-60 >60 
If more than 1 ECG is collected at a nominal time after dose administration (for example, 
triplicate  ECGs),  the mean  of the replicate  measurements  will be used to represent  a single 
observation at that time point. If any of the 3 individual ECG tracings has a QTcF value  
>500  ms, but the mean  of the triplicates  is not >500  ms, the data from  the participant’s 
individual  tracing  will be described  in a safety  section  of the CSR  in order  to place  the 
>500 -ms value  in appropriate  clinical  context.  However,  values  from  individual  tracings 
within triplicate measurements that are >500 ms will not be included in the categorical  
PF-07328948  
Protocol  C4921001  
Final  Protocol  Amendment  2, 24 Jan 2023  
PFIZER  CONFIDENTIAL  
Page  73  
 analysis  unless  the average  from  the triplicate  measurements  is also >500  ms. Changes  from 
baseline will be defined as the change between the postdose QTcF value and the average of 
the pre -dose triplicate values at -1.0, -0.5, 0 hours pre -dose on Day 1.  
In addition, an attempt will be made to explore and characterize the relationship between 
plasma concentration and QT interval length using a PK/PD modeling approach. If a PK/PD 
relationship  is found,  the impact  of participant  factors  (covariates)  on the relationship  will be 
examined. The results of such analyses may not be included in the CSR.  
9.3.2.  PK Endpoints  
The PK concentration  and parameter  populations  are defined  in Section  9.2. 
[IP_ADDRESS].  Derivation  of PF-[ADDRESS_465470] Linear/Log  trapezoidal  method  
AUC inf* Area under the plasma 
concentration -time curve from 
time [ADDRESS_465471] + (Clast*/k el), where  Clast* is the predicted 
plasma concentration at the last quantifiable 
timepoint estimated from the log -linear 
regression analysis  
Cmax Maximum  plasma  concentration  Observed  directly  from  data 
Tmax Time  for Cmax Observed  directly  from  data as time of first 
occurrence  
t½ * Terminal  elimination  half-life Log e(2)/k el, where k el is the terminal phase rate 
constant  calculated  by a linear  regression  of the 
log-linear  concentration -time curve.  Only  those 
data points judged to describe the terminal  
log-linear  decline  will be used in the regression.  
CL/F*  Apparent  clearance  Dose/AUC inf 
Vz/F*  Apparent  volume  of distribution  Dose/(AUC inf∙kel) 
AUC last(dn) Dose -normalized  AUC last AUC last/Dose  
AUC inf(dn)*  Dose -normalized  AUC inf AUC inf/Dose  
Cmax(dn) Dose -normalized  Cmax Cmax/Dose  
*As data permits.  
PF-07328948  
Protocol  C4921001  
Final  Protocol  Amendment  2, 24 Jan 2023  
PFIZER  CONFIDENTIAL  
Page  74  
 [IP_ADDRESS].  Statistical  Methods  for PK Data  
Plasma concentrations of PF -07328948 will be summarized descriptively by [CONTACT_2715] (and 
fasting  condition,  if appropriate)  and nominal  PK sampling  time.  Individual  participant  and 
median profiles of the plasma concentration -time data will be plotted by [CONTACT_2715] (and fasting 
condition, if appropriate) using actual (for individual) and nominal (for median) times 
respectively. Median profiles will be presented on both linear and log scales.  
The plasma PK parameters will be summarized descriptively by [CONTACT_2715] (and fasting condition, 
if appropriate) as applicable. Dose -normalized AUC inf, AUC last, and C max will be plotted 
against  dose (and fasting  condition,  if appropriate)  using  a logarithmic  scale,  and will include 
individual  participant  values  and the geometric  means  for each dose.  These  plots  will be used 
to understand the relationship between the PK parameters and dose (and fasting condition, if 
appropriate).  
If the food effect  is assessed,  a mixed  effects  ANOVA  will be performed  separately  on the 
natural log transformed AUC inf, AUC last, and C max (dose -normalized prior to analysis, if 
appropriate) with fasting condition included as a fixed effect and participant as a random 
effect. Further details of this analysis will be provided in the SAP.  
Additional  PK analyses  may be performed  if deemed  appropriate,  and may not be included  in 
the CSR.  
9.3.3.  Tertiary/Exploratory Endpoint(s)  Analysis  
The analysis  of tertiary/exploratory  endpoints  will be detailed  in the SAP.  
9.3.4.  Other  Analyses  
Pharmacogenomic or biomarker data from Retained Research Samples may be collected 
during  or after the trial and retained  for future  analyses;  the results  of such analyses  are not 
planned to be included in the CSR.  
9.4. Interim  Analyses  
No formal  interim  analysis  will be conducted  for this study.  However,  as this is a 
sponsor -open  study,  the sponsor  will conduct  unblinded  reviews  of the data during  the course 
of the study for the purpose of safety and tolerability assessment, facilitating dose -escalation 
decisions, facilitating PK/PD modeling, and/or supporting clinical development.  
9.5. Sample Size Determination  
A sample size of approximately 24 healthy adult participants (up to 3 cohorts of 
approximately 8 participants each) has been chosen based on the need to minimize first 
exposure  to humans  of a new chemical  entity  and the requirement  to provide  adequate  safety, 
tolerability, PK and PD assessment at each dose level. At each dose level, approximately  
6 participants are planned to receive PF -07328948 and approximately 2 participants are 
planned  to receive  placebo  with all participants  at the end of the study  having  received  up to 
4 doses of PF -07328948 and up to 2 doses of placebo.  
PF-07328948  
Protocol  C4921001  
Final  Protocol  Amendment  2, 24 Jan 2023  
PFIZER  CONFIDENTIAL  
Page  75  
 10. SUPPORTING  DOCUMENTATION  AND  OPERATIONAL  CONSIDERATIONS  
10.1. Appendix  1: Regulatory,  Ethical,  and Study  Oversight  Considerations  
10.1.1.  Regulatory  and Ethical  Considerations  
This study  will be conducted in accordance with the protocol and with the following:  
• Consensus  ethical  principles  derived  from  international  guidelines,  including  the 
Declaration of Helsinki and CIOMS International Ethical Guidelines;  
• Applicable  ICH GCP  guidelines;  
• Applicable  laws and regulations,  including  applicable  privacy  laws.  
The protocol,  protocol  amendments,  ICD,  SRSD(s),  and other  relevant documents  
(eg, advertisements)  must  be reviewed  and approved  by [CONTACT_456],  submitted  to an IRB/EC 
by [CONTACT_093], and reviewed and approved by [CONTACT_1201]/EC before the study is initiated.  
Any amendments to the protocol will require IRB/EC approval before implementation of 
changes  made  to the study  design,  except  for changes  necessary  to eliminate  an immediate 
hazard to study participants.  
Protocols and any substantial amendments to the protocol will require health authority 
approval  prior  to initiation  except  for changes  necessary  to eliminate  an immediate  hazard  to 
study participants.  
The investigator  will be  responsible  for the following:  
• Providing  written  summaries  of the status  of the study  to the IRB/EC  annually  or 
more frequently in accordance with the requirements, policies, and procedures 
established by [CONTACT_1201]/EC;  
• Notifying  the IRB/EC  of SAEs  or other  significant  safety  findings  as required  by 
[CONTACT_1744]/EC procedures;  
• Providing oversight of the conduct of the study at the site and adherence to 
requirements  of 21 CFR,  ICH GCP guidelines,  the IRB/EC,  European  regulation 
536/2014  for clinical  studies,  European  Medical  Device  Regulation  2017/745  for 
clinical device research, and all other applicable local regulations.  
[IP_ADDRESS].  Reporting  of Safety  Issues  and Serious  Breaches  of the Protocol  or ICH  GCP  
In the event  of any prohibition  or restriction  imposed  (ie, clinical  hold)  by [CONTACT_22844], or if the investigator is aware of any new 
information that might influence the evaluation of the benefits and risks of the study 
intervention, [COMPANY_007] should be informed immediately.  
PF-[ADDRESS_465472],  and 
of any serious breaches of this protocol or of the ICH GCP guidelines that the investigator 
becomes aware of.  
10.1.2.  Financial Disclosure  
Not applicable.  
10.1.3.  informed  Consent  Process  
The investigator or the investigator’s representative will explain the nature of the study, 
including the risks and benefits, to the participant and answer all questions regarding the 
study.  The participant  should  be given  sufficient  time and opportunity  to ask questions  and to 
decide whether or not to participate in the trial.  
Participants must be informed that their participation is voluntary. Participants will be 
required  to sign a statement  of informed  consent  that meets  the requirements  of 21 CFR  50, 
local regulations, ICH guidelines, privacy and data protection requirements, where 
applicable, and the IRB/EC or study center.  
The investigator must ensure that each participant is fully informed about the nature and 
objectives  of the study,  the sharing  of data related  to the study,  and possible  risks  associated 
with participation, including the risks associated with the processing of the participant’s 
personal data.  
The participant  must  be informed  that their personal  study -related  data will be used by [CONTACT_219897]. The level  of disclosure  must  also be 
explained to the participant.  
The participant  must  be informed  that their medical  records  may be examined  by [CONTACT_11000], by 
[CONTACT_6667]/EC members, and by [CONTACT_6668].  
The investigator  further  must  ensure  that each study  participant  is fully  informed  about  their 
right to access and correct their personal data and to withdraw consent for the processing of 
their personal data.  
The medical record must include a statement that written informed consent was obtained 
before  the participant  was enrolled  in the study  and the date on which  the written  consent  was 
obtained. The authorized person obtaining the informed consent must also sign the ICD.  
Participants  must  be reconsented  to the most  current  version  of the IRB/EC -approved ICD(s) 
during their participation in the study as required per local regulations.  
A copy  of the ICD(s) must  be provided to the participant.  
PF-07328948  
Protocol  C4921001  
Final  Protocol  Amendment  2, 24 Jan 2023  
PFIZER  CONFIDENTIAL  
Page  77  
 Participants  who are rescreened  are required  to sign a new ICD.  
10.1.4.  Data  Protection  
All parties  will comply  with all applicable  laws,  including  laws regarding  the implementation 
of organizational and technical measures to ensure protection of participant data.  
Participants’  personal  data will be stored  at the study  site in encrypted  electronic  and/or  paper 
form and will be password -protected or secured in a locked room to ensure that only 
authorized study staff have access. The study site will implement appropriate technical and 
organizational measures to ensure that the personal data can be recovered in the event of 
disaster. In the event of a potential personal data breach, the study site  will be responsible for 
determining whether a personal data breach has in fact occurred and, if so, providing breach 
notifications as required by [CONTACT_2371].  
To protect the rights and freedoms of participants with regard to the processing of personal 
data, participants will be assigned a single, participant -specific numerical code. Any 
participant  records  or data sets that are transferred  to the sponsor  will contain  the numerical 
code; participant names  will not be transferred. All other identifiable data transferred to the 
sponsor will be identified by [CONTACT_20007], participant -specific code. The study site will 
maintain a confidential list of participants who participated in the study, linking each 
participant’s numerical code to their actual identity and medical record ID. In case of data 
transfer,  the sponsor  will protect  the confidentiality  of participants’  personal  data consistent 
with the clinical study agreement and applicable privacy laws.  
Information  technology  systems  used to collect,  process,  and store  study -related  data are 
secured by [CONTACT_46387], alteration, or unauthorized disclosure or access.  
The sponsor  maintains  standard  operating  procedures  on how to respond  in the event  of 
unauthorized access, use, or disclosure of sponsor information or systems.  
10.1.5.  Committees  Structure  
[IP_ADDRESS].  Data  Monitoring  Committee  
This study  will not use an E -DMC.  
10.1.6.  Dissemination of Clinical Study Data  
[COMPANY_007] fulfills its commitment to publicly disclose clinical study results through posting the 
results of studies on www.clinicaltrials.gov  (ClinicalTrials.gov), the EudraCT/CTIS, and/or 
www.pfizer.com,  and other  public  registries  and websites  in accordance  with applicable  local 
laws/regulations. In addition, [COMPANY_007] reports study  results outside of the requirements of local 
laws/regulations pursuant to its SOPs.  
PF-07328948  
Protocol  C4921001  
Final  Protocol  Amendment  2, 24 Jan 2023  
PFIZER  CONFIDENTIAL  
Page  78  
 In all cases, study results are reported by [CONTACT_4715], accurate, balanced, and 
complete  manner  and are reported  regardless  of the outcome  of the study  or the country  in 
which the study was conducted.  
www.clinicaltrials.gov  
[COMPANY_007]  posts  clinical  trial results  on www.clinicaltrials.gov  for [COMPANY_007] -sponsored  interventional 
studies (conducted in patients) that evaluate the safety and/or efficacy of a product,  
regardless of the geographical location in which the study is conducted. These results are 
submitted for posting in accordance with the format and timelines set forth by [CONTACT_20008].  
EudraCT/CTIS  
[COMPANY_007]  posts  clinical  trial results  on EudraCT/CTIS  for [COMPANY_007] -sponsored  interventional  studies 
in accordance with the format and timelines set forth by [CONTACT_20009].  
www.pfizer.com  
[COMPANY_007]  posts  CSR  synopses  and plain -language  study  results  summaries  on www.pfizer.com  
for [COMPANY_007] -sponsored interventional studies at the same time the  corresponding study  results 
are posted to www.clinicaltrials.gov.  CSR synopses will have personally identifiable 
information anonymized.  
Documents  within  marketing  applications  
[COMPANY_007]  complies  with applicable  local  laws/regulations  to publish  clinical  documents  included 
in marketing applications. Clinical documents include summary documents and CSRs 
including the protocol and protocol amendments, sample CRFs, and SAPs. Clinical 
documents will have personally identifiable information anonymized.  
Data  sharing  
[COMPANY_007] provides researchers secure access to participant -level data or full CSRs for the 
purposes  of “bona -fide scientific  research”  that contributes  to the scientific  understanding  of 
the disease, target, or compound class. [COMPANY_007] will make data from these trials available  
[ADDRESS_465473], including individuals 
requesting access for commercial/competitive or legal purposes.  
PF-07328948  
Protocol  C4921001  
Final  Protocol  Amendment  2, 24 Jan 2023  
PFIZER  CONFIDENTIAL  
Page  79  
 10.1.7.  Data Quality Assurance  
All participant  data relating  to the study  will be recorded  on printed  or electronic  CRF  unless 
transmitted  to the sponsor  or designee  electronically  (eg, laboratory  data).  The investigator  is 
responsible for verifying that data entries are accurate and correct by [CONTACT_18027].  
Guidance  on completion  of CRFs  will be provided  in the CRF  Completion  Requirements 
document.  
The investigator  must  ensure  that the CRFs  are securely  stored  at the study  site in encrypted 
electronic and/or paper form and are password -protected or secured in a locked room to 
prevent access by [CONTACT_20011].  
The investigator must permit study -related monitoring, audits, IRB/EC review, and 
regulatory agency inspections and provide direct access to source data documents. This 
verification  may also occur  after study  completion.  It is important  that the investigator(s)  and 
their relevant personnel are available during the monitoring visits and possible audits or 
inspections and that sufficient time is devoted to the process.  
Monitoring details describing strategy, including definition of study -critical data items and 
processes (eg, risk -based initiatives in operations and quality, such as risk management and 
mitigation strategies and analytical risk -based monitoring), methods, responsibilities, and 
requirements, including handling of noncompliance issues and monitoring techniques 
(central,  virtual,  or on-site monitoring),  are provided  in the data management  plan maintained 
and utilized by [CONTACT_36613].  
The sponsor  or designee  is responsible  for the data management  of this study,  including 
quality checking of the data.  
Records and documents, including signed ICDs, pertaining to the conduct of this study must 
be retained by [CONTACT_1732] [ADDRESS_465474]  ensure  that the records  continue  to be stored  securely  for as long as they are 
maintained.  
When  participant  data are to be deleted,  the investigator  will ensure  that all copi[INVESTIGATOR_219854].  
The investigator(s) will notify the sponsor or its agents immediately of any regulatory 
inspection notification in relation to the study. Furthermore, the investigator will cooperate 
with the sponsor  or its agents  to prepare  the investigator  site for the inspection  and will allow 
the sponsor or its agent, whenever feasible, to be present during the inspection. The 
investigator site and investigator will promptly resolve any discrepancies that are identified 
between the study data and the participant’s medical records. The investigator will promptly  
PF-[ADDRESS_465475] be available.  
Definition  of what  constitutes  source  data and its origin  can be found  in the Source 
Document Locator, which is maintained by [CONTACT_456]’s designee ([COMPANY_007] CRU).  
Description  of the use of the computerized  system  is documented  in the Data  Management 
Plan, which is maintained by [CONTACT_456]’s designee ([COMPANY_007] CRU).  
The investigator  must  maintain  accurate  documentation  (source  data)  that supports  the 
information entered in the CRF.  
The sponsor  or designee  will perform  monitoring  to confirm  that data entered  into the CRF 
by [CONTACT_372013],  complete,  and verifiable  from  source  documents; 
that the safety and rights of participants are being protected; and that the study is being 
conducted in accordance with the currently approved protocol and any other study 
agreements, ICH GCP guidelines, and all applicable regulatory requirements.  
10.1.9.  Study and Site Start and Closure  
The study  start date is the date on which  the clinical  study  will be open  for recruitment  of 
participants.  
The first act of recruitment  is the date of the first participant’s  first visit and will be the study 
start date.  
The sponsor designee reserves the right to close the study  site or terminate the study  at any 
time for any reason at the sole discretion of the sponsor, including (but not limited to) 
regulatory authority decision, change in opi[INVESTIGATOR_1100]/EC, or change in benefit -risk 
assessment. Study sites will be closed upon study completion. A study site is considered 
closed  when  all required  documents  and study  supplies  have  been  collected  and a study -site 
closure visit has been performed.  
The investigator  may initiate  study -site closure  at any time upon  notification  to the sponsor  if 
requested to do so by [CONTACT_22846]/EC or if such termination is required to protect the 
health of study participants.  
PF-07328948  
Protocol  C4921001  
Final  Protocol  Amendment  2, 24 Jan 2023  
PFIZER  CONFIDENTIAL  
Page  81  
 Reasons  for the early  closure  of a study  site by [CONTACT_219900]: 
• Failure  of the investigator  to comply  with the protocol,  the requirements  of the 
IRB/EC or local health authorities, the sponsor’s procedures, or the ICH GCP 
guidelines;  
• Inadequate  recruitment of  participants by  [CONTACT_093];  
• Discontinuation of further study  intervention development.  
If the study is prematurely terminated or suspended, the sponsor shall promptly inform the 
investigators,  the ECs/IRBs,  the regulatory  authorities,  and any CRO(s)  used in the study  of 
the reason for termination or suspension, as specified by [CONTACT_56859]. The investigator shall promptly inform the participant and should assure 
appropriate participant therapy and/or follow -up. 
Study  termination  is also provided  for in the clinical  study  agreement.  If there  is any conflict 
between the contract and this protocol, the contract will control as to termination rights.  
10.1.10.  Publication  Policy  
The investigator agrees to refer to the primary publication in any subsequent publications. 
[COMPANY_007] will not provide any financial compensation for the investigator’s  participation in the 
preparation  of the primary  congress  abstract,  poster,  presentation,  or primary  manuscript  for 
the study.  
Investigators are free to publish individual center results that they deem to be clinically 
meaningful after publication of the overall results of the study or [ADDRESS_465476]  to the other 
requirements described in this section.  
The investigator will provide [COMPANY_007] an opportunity to review any proposed publication or  
any other type of disclosure of the study results (collectively, “publication”) before it is 
submitted or otherwise disclosed and will submit all publications to [COMPANY_007] [ADDRESS_465477], remove any previously undisclosed 
confidential  information  before  disclosure,  except  for any study -intervention  or [COMPANY_007] -related 
information necessary for the appropriate scientific presentation or understanding of the  
study results. For joint publications, should there be disagreement regarding interpretation 
and/or presentation of specific analysis results, resolution of, and responsibility for, such 
disagreements will be the collective responsibility of all authors of the publication.  
PF-[ADDRESS_465478] 
access to the relevant statistical tables, figures, and reports (in their original format) required 
to develop the publication.  
10.1.11.  Sponsor’s  Medically  Qualified  Individual  
The contact  [CONTACT_219902]’s  MQI  for the study  is documented  in the study 
contact [CONTACT_336273].  
To facilitate access to their investigator and the sponsor’s MQI for study -related medical 
questions  or problems  from  nonstudy  healthcare  professionals,  participants  are provided  with 
an ECC at the time of informed consent. The ECC contains, at a minimum, (a) protocol and 
study intervention identifiers, (b) participant’s study identification number, and (c) site 
emergency phone number active 24 hours/day, [ADDRESS_465479], the established communication pathways 
between  the participant  and their investigator and site  staff,  and between  the investigator  and 
sponsor study team. The ECC is only  to be used by [CONTACT_219904],  as a means  of reaching  the investigator  or site staff related  to the care of a 
participant.  
PF-07328948  
Protocol  C4921001  
Final  Protocol  Amendment  2, 24 Jan 2023  
PFIZER  CONFIDENTIAL  
Page  83  
 10.2. Appendix  2: Clinical  Laboratory  Tests  
The following  safety  laboratory  tests will be performed  at times  defined  in the SoA section  of 
this protocol. Additional laboratory results may be reported on these samples as a result of  
the method of analysis or the type of analyzer used by [CONTACT_20019], or as derived 
from calculated values. These additional tests would not require additional collection of 
blood.  Unscheduled  clinical  laboratory  measurements  may be obtained  at any time during  the 
study to assess any perceived safety issues.  
 
Table  5. Protocol -Required  Safety  Laboratory  Assessments  
 
Hematology  Chemistry  Urinalysis  Other  
Hemoglobin 
Hematocrit 
RBC count 
Platelet  count 
WBC count  
Total  neutrophils  (Abs) 
Eosinophils (Abs) 
Monocytes (Abs) 
Basophils (Abs) 
Lymphocytes (Abs)  Urea  and creatinine 
eGFR (SCr)  
Glucose  (fasting) 
Calcium  
Sodium 
Potassium 
Chloride  
Total  CO 2 (bicarbonate) 
AST, ALT  
Total bilirubin 
Alkaline  phosphatase 
Uric acid  
Albumin 
Total  protein 
SCysf Local  dipstick:  
pHa 
Glucose  (qual) 
Protein (qual) 
Blood (qual) 
Ketones 
Nitrites  
Leukocyte  esterase  
Laboratory:  
Microscopy  and 
cultured Urine drug screeningb 
COVID -19 testing  (per 
CRU procedures)  
At screening  only:  
• FSHc 
• Hepatitis  B surface 
antigen  
• Hepatitis  B surface 
antibodye 
• Hepatitis  B core antibody  
• Hepatitis  C antibody  
• Human 
immunodeficiency  virus  
If Hb/RBC  abnormal:  
MCV,  MCH,  MCHC  
Neutrophils (%) 
Eosinophils (%) 
Basophils (%) 
Lymphocytes  (%) 
Monocytes (%) 
RBC  morphology  
RBC  distribution  width  For suspected  DILI:  
AST/ALT  
Total  bilirubin,  direct  and 
indirect bilirubin  
Alkaline phosphatase 
Total bile acids, GGT 
Total protein, albumin 
CK 
PT, INR 
Acetaminophen/paracetamol 
or 
protein adduct levels 
Hepatitis  serology  (even  if 
screening negative)    
 For suspected  DICI/DIKI:  
Creatinine (SCr) 
CystatinC (SCys) 
eGFR (SCr only and 
combined  SCr+SCys)  
 Spot (dipstick)  UACR  
PF-07328948  
Protocol  C4921001  
Final  Protocol  Amendment  2, 24 Jan 2023  
PFIZER  CONFIDENTIAL  
Page  84  
 Table  5. Protocol -Required  Safety  Laboratory  Assessments  
 
a. Can be performed  on dipstick  or pH-meter  device.  
b. The minimum  requirement  for drug screening  includes  cocaine,  THC,  opi[INVESTIGATOR_858]/opi[INVESTIGATOR_2438],  benzodiazepi[INVESTIGATOR_1651], 
and amphetamines (others are site - and study -specific).  
c. For confirmation  of postmenopausal  status  only.  
d. Urinary  culture  only if deemed  appropriate  by [CONTACT_093]  (eg, if UTI is suspected  and/or  urine 
dipstick is positive for nitrites or leukocyte esterase or both).  
e. HBsAb  will be tested  if HBsAg  and/or  HBcAb  is positive  
f. Baseline  (pre-dose)  only 
 
The investigator  must  review  the laboratory  report,  document  this review,  and record  any 
clinically relevant changes occurring during the study in the AE section of the CRF.  
Laboratory/analyte results that could unblind the study and have been collected for the 
purpose  of the study  will not be reported  to investigator  sites or other  blinded  personnel  until 
the study has been unblinded.  
Any remaining serum/plasma from samples collected for clinical safety laboratory 
measurements at baseline and at all times after dose administration may  be retained and 
stored for the duration of the study. Upon completion of the study, these retained safety 
samples  may be used for the assessment  of exploratory  safety  biomarkers  or unexpected 
safety findings. These data will not be included in the CSR. Samples to be used for this 
purpose will be shipped to either a [COMPANY_007] -approved BBS facility or other designated 
laboratory and retained for up to 1 year following the completion of the study.  
PF-07328948  
Protocol  C4921001  
Final  Protocol  Amendment  2, 24 Jan 2023  
PFIZER  CONFIDENTIAL  
Page  85  
 10.3. Appendix  3: Adverse  Events:  Definitions  and Procedures  for Recording, 
Evaluating, Follow -Up, and Reporting  
10.3.1.  Definition of AE 
 
AE Definition  
• An AE is any untoward medical occurrence in a patient or clinical study 
participant,  temporally  associated  with the use of study  intervention,  whether  or not 
considered related to the study intervention.  
• Note:  An AE can therefore  be any unfavorable  and unintended  sign (including  an 
abnormal laboratory finding), symptom, or disease (new or exacerbated) 
temporally associated with the use of study intervention.  
 
 
Events  Meeting  the AE Definition  
• Any abnormal  laboratory  test results  (hematology,  clinical  chemistry,  or urinalysis) 
or other  safety  assessments  (eg, ECG,  radiological  scans,  vital sign measurements), 
including those that worsen from baseline, considered clinically significant in the 
medical and scientific judgment of the investigator. Any abnormal laboratory test 
results that meet any of the conditions below must be recorded as an AE:  
• Is associated  with accompanying  symptoms;  
• Requires  additional  diagnostic  testing  or medical/surgical  intervention;  
• Leads  to a change  in study  dosing  (outside  of any protocol -specified  dose 
adjustments) or discontinuation from the study, significant additional 
concomitant drug treatment, or other therapy.  
• Exacerbation  of a chronic  or intermittent  preexisting  condition,  including  an 
increase in either frequency and/or intensity of the condition.  
• New  condition  detected  or diagnosed  after study  intervention  administration,  even 
though it may have been present before the start of the study.  
• Signs,  symptoms,  or the clinical  sequelae  of a suspected  drug-drug interaction.  
• Signs, symptoms, or the clinical sequelae of a suspected overdose of either study 
intervention  or a concomitant  medication.  Overdose  per se will not be reported  as 
an AE or SAE unless it is an intentional overdose taken with possible 
suicidal/self -harming intent. Such overdoses should be reported regardless of 
sequelae.  
PF-07328948  
Protocol  C4921001  
Final  Protocol  Amendment  2, 24 Jan 2023  
PFIZER  CONFIDENTIAL  
Page  86  
  
Events  NOT  Meeting  the AE Definition  
• Any clinically  significant abnormal laboratory  findings or other abnormal safety 
assessments  that are associated  with the underlying  disease,  unless  judged  by [CONTACT_11009]’s condition.  
• The disease/disorder  being  studied  or expected  progression,  signs,  or symptoms  of 
the disease/disorder being studied, unless more severe than expected for the 
participant’s condition.  
• Medical  or surgical  procedure  (eg, endoscopy,  appendectomy):  the condition  that 
leads to the procedure is the AE.  
• Situations  in which  an untoward  medical  occurrence  did not occur  (social  and/or 
convenience admission to a hospi[INVESTIGATOR_307]).  
• Anticipated  day-to-day fluctuations  of preexisting  disease(s)  or condition(s)  present 
or detected at the start of the study that do not worsen.  
10.3.2.  Definition of an  SAE  
 
An SAE  is defined  as any untoward  medical  occurrence  that,  at any dose,  meets  one 
or more of the criteria listed below:  
a.  Results in  death  
b. Is life -threatening  
The term “life-threatening”  in the definition  of “serious”  refers  to an event  in which  the 
participant  was at risk of death  at the time of the event.  It does not refer  to an event  that 
hypothetically might have caused death if it were more severe.  
c.  Requires  inpatient hospi[INVESTIGATOR_12993], hospi[INVESTIGATOR_12994] (usually 
involving  at least an overnight  stay)  at the hospi[INVESTIGATOR_371992]/or treatment that would not have been appropriate in the physician’s office or 
outpatient setting. Complications that occur during hospi[INVESTIGATOR_1084]. If a 
complication prolongs hospi[INVESTIGATOR_9236], the event is 
serious.  When in doubt as  to whether “hospi[INVESTIGATOR_059]” occurred or was necessary,  the 
AE should be considered serious.  
Hospi[INVESTIGATOR_54725] a preexisting  condition  that did not worsen 
from baseline is not considered an AE.  
PF-07328948  
Protocol  C4921001  
Final  Protocol  Amendment  2, 24 Jan 2023  
PFIZER  CONFIDENTIAL  
Page  87  
  
d. Results  in persistent  or significant disability/incapacity  
• The term disability  means  a substantial  disruption  of a person’s  ability  to conduct 
normal life functions.  
• This definition  is not intended  to include  experiences  of relatively  minor  medical 
significance, such as uncomplicated headache, nausea, vomiting, diarrhea, 
influenza, and accidental trauma (eg, sprained ankle), that may interfere with or 
prevent everyday life functions but do not constitute a substantial disruption.  
e.  Is a congenital  anomaly/birth  defect  
f. Is a suspected  transmission  via a [COMPANY_007]  product  of an infectious  agent,  pathogenic 
or non -pathogenic  
The event  may be suspected  from  clinical  symptoms  or laboratory  findings  indicating 
an infection in a participant exposed to a [COMPANY_007] product. The terms “suspected 
transmission” and “transmission” are considered synonymous. These cases are 
considered unexpected and handled as serious expedited cases by [CONTACT_372014]. Such cases are also considered for reporting as product defects, if 
appropriate.  
g. Other situations:  
• Medical  or scientific  judgment  should  be exercised  by [CONTACT_372015], such as significant 
medical events that may jeopardize the participant or may require medical or 
surgical intervention to prevent one of the other outcomes listed in the above 
definition. These events should usually be considered serious.  
• Examples  of such events  include  invasive  or malignant  cancers,  intensive  treatment 
in an emergency room or at home for allergic bronchospasm, blood dyscrasias or 
convulsions that do not result in hospi[INVESTIGATOR_059], or development of drug 
dependency or drug abuse.  
10.3.3.  Recording/Reporting  and Follow -Up of AEs and/or  SAEs  During  the Active 
Collection Period  
 
AE and SAE Recording/Reporting  
The table  below  summarizes  the requirements  for recording  AEs on the CRF  and for 
reporting SAEs on the CT SAE Report Form to [COMPANY_007] Safety throughout the active 
collection  period.  These  requirements  are delineated  for 3 types  of events:  (1) SAEs;  
(2) nonserious  AEs;  and (3) exposure  to the study  intervention  under  study  during 
pregnancy or breastfeeding, and occupational exposure.  
PF-[ADDRESS_465480] SAE 
Report Form for reporting of SAE information.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* EDP (with or without an associated AE or SAE): any pregnancy information is reported to [COMPANY_007] 
Safety  using  the CT SAE  Report  Form  and EDP  Supplemental  Form;  if the EDP  is associated  with 
an SAE, then the SAE is reported to [COMPANY_007] Safety using the CT SAE Report Form.  
** EDB  is reported  to [COMPANY_007]  Safety  using  the CT SAE  Report  Form, which  would  also include  details 
of any SAE that might be associated with the EDB.  
*** Environmental  or occupational  exposure:  AEs or SAEs  associated  with occupational  exposure 
are reported to [COMPANY_007] Safety using the CT SAE Report Form.  
• When  an AE or SAE  occurs,  it is the responsibility  of the investigator  to review  all 
documentation (eg, hospi[INVESTIGATOR_1088], laboratory reports, and diagnostic 
reports) related to the event.  
• The investigator  will then record  all relevant  AE or SAE  information  in the CRF.  Safety Event  Recorded  on the CRF  Reported on the CT SAE 
Report Form to [COMPANY_007] 
Safety  Within  24 Hours  of 
Awareness  
SAE All All 
Nonserious  AE All None  
Exposure to the study 
intervention  under  study 
during pregnancy or 
breastfeeding  All AEs/SAEs  associated 
with EDP or EDB  
 
Note: Instances of EDP or 
EDB  not associated  with an 
AE or SAE  are not captured 
in the CRF  All instances  of EDP  are 
reported  (whether  or not 
there is an associated 
SAE)*  
All instances  of EDB  are 
reported (whether or not 
there is an associated 
SAE)**  
Environmental or 
occupational  exposure  to 
the product under study 
to a nonparticipant (not 
involving EDP or EDB)  None.  Exposure  to a study 
non-participant is not 
collected on the CRF  The exposure  (whether  or 
not there is an associated 
AE or SAE) must be 
reported***  
 
PF-07328948  
Protocol  C4921001  
Final  Protocol  Amendment  2, 24 Jan 2023  
PFIZER  CONFIDENTIAL  
Page  89  
  
• It is not acceptable  for the investigator  to send photocopi[INVESTIGATOR_219860]’s 
medical records to [COMPANY_007] Safety in lieu of completion of the CT SAE Report 
Form/AE or SAE CRF page.  
• There may be instances when copi[INVESTIGATOR_240802]. In this case, all participant identifiers, with the 
exception  of the participant  number,  will be redacted  on the copi[INVESTIGATOR_240803].  
• The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms,  and/or  other  clinical  information.  Whenever  possible,  the diagnosis  (not 
the individual signs/symptoms) will be documented as the AE or SAE.  
Assessment of Intensity  
The investigator  will make  an assessment  of intensity  for each AE and SAE  reported 
during the study and assign it to 1 of the following categories:  
• Mild: A type of AE that is usually transient and may require only minimal 
treatment  or therapeutic  intervention.  The event  does not generally  interfere  with 
usual ADL.  
• Moderate: A type of AE that is usually alleviated with additional specific 
therapeutic  intervention.  The event  interferes  with usual  ADL,  causing  discomfort, 
but poses no significant or permanent risk of harm to the research participant.  
• Severe:  A type of AE that interrupts  usual  ADL,  or significantly  affects  clinical 
status, or may require intensive therapeutic intervention.  
An event  is defined  as “serious”  when  it meets  at least 1 of the predefined  outcomes  as 
described in the definition of an SAE, NOT when it is rated as severe.  
 
 
Assessment of Causality  
• The investigator  is obligated  to assess  the relationship  between  study  intervention 
and each occurrence of each AE or SAE. The investigator will use clinical 
judgment to determine the relationship.  
• A “reasonable possibility” of a relationship conveys that there are facts, evidence, 
and/or  arguments  to suggest  a causal  relationship,  rather  than a relationship  cannot 
be ruled out.  
PF-07328948  
Protocol  C4921001  
Final  Protocol  Amendment  2, 24 Jan 2023  
PFIZER  CONFIDENTIAL  
Page  90  
  
• Alternative  causes,  such as underlying  disease(s),  concomitant therapy,  and other 
risk factors,  as well as the temporal  relationship  of the event  to study  intervention 
administration, will be considered and investigated.  
• The investigator  will also consult  the IB and/or  product  information,  for marketed 
products, in their assessment.  
• For each AE or SAE,  the investigator must  document  in the medical  notes  that they 
have reviewed the AE or SAE and have provided an assessment of causality.  
• There may be situations in which an SAE has occurred and the investigator has 
minimal information to include in the initial report to the sponsor. However, it is 
very important that the investigator always make an assessment of causality 
for every  event  before  the initial  transmission  of the SAE  data  to the sponsor . 
• The investigator  may change  their opi[INVESTIGATOR_240804] -up 
information and send an SAE follow -up report with the updated causality 
assessment.  
• The causality  assessment  is one of the criteria  used when  determining  regulatory 
reporting requirements.  
• If the investigator does not know whether or not the study intervention caused the 
event,  then the event  will be handled  as “related  to study  intervention”  for reporting 
purposes, as defined by [CONTACT_456]. In addition, if the investigator determines that 
an SAE is associated with study procedures, the investigator must record this  
causal relationship in the source documents and CRF, and report such an 
assessment in the dedicated section of the CT SAE Report Form and in accordance 
with the SAE reporting requirements.  
 
 
Follow -Up of AEs and SAEs  
• The investigator  is obligated  to perform  or arrange  for the conduct  of supplemental 
measurements and/or evaluations, as medically indicated or as requested by [CONTACT_103], to elucidate the nature and/or causality of the AE or SAE as fully as 
possible. This may include additional laboratory tests or investigations, 
histopathological examinations, or consultation with other healthcare providers.  
• If a participant dies during participation in the study or during a recognized 
follow -up period,  the investigator  will provide  [COMPANY_007]  Safety  with a copy  of any 
postmortem findings, including histopathology.  
PF-07328948  
Protocol  C4921001  
Final  Protocol  Amendment  2, 24 Jan 2023  
PFIZER  CONFIDENTIAL  
Page  91  
  
• New  or updated  information  will be recorded  in the originally  submitted 
documents.  
• The investigator  will submit  any updated  SAE  data to the sponsor  within  [ADDRESS_465481]  
• The primary  mechanism  for reporting  an SAE  to [COMPANY_007]  Safety  will be the 
electronic DCT.  
• If the electronic  system  is unavailable,  then the site will use the paper  SAE  DCT 
(see next section) to report the event within 24 hours.  
• The site will enter  the SAE  data into the electronic  DCT  (eg, eSAE  or PSSA)  or 
paper form (as applicable) as soon as the data become available.  
• After  the study  is completed  at a given  site, the electronic  DCT  will be taken 
off-line to prevent the entry of new data or changes to existing data.  
• If a site receives  a report  of a new SAE  from  a study  participant  or receives  updated 
data on a previously  reported  SAE  after the electronic  DCT  has been  taken  off-line, 
then the site can report this information on a paper SAE form (see next section) or 
to [COMPANY_007] Safety by [CONTACT_756].  
 
 
SAE  Reporting  to [COMPANY_007]  Safety  via the CT SAE  Report  Form  
• Facsimile  transmission  of the CT SAE  Report  Form  is the preferred  method  to 
transmit this information to [COMPANY_007] Safety.  
• In circumstances  when  the facsimile  is not working,  an alternative  method  should 
be used, eg, secured (Transport Layer Security) or password -protected email. If 
none of  these methods  can be used,  notification by [CONTACT_9337] a 
copy of the CT SAE Report Form sent by [CONTACT_22855].  
• Initial notification via telephone does not replace the need for the investigator to 
complete  and sign the CT SAE  Report  Form  pages  within  the designated  reporting 
time frames.  
PF-07328948  
Protocol  C4921001  
Final  Protocol  Amendment  2, 24 Jan 2023  
PFIZER  CONFIDENTIAL  
Page  92  
 10.4. Appendix  4: Contraceptive  and Barrier  Guidance  
10.4.1.  Male  Participant  Reproductive  Inclusion  Criteria  
Male  participants  are eligible  to participate  if they agree  to the following  requirements  during 
the intervention  period  and for at least [ADDRESS_465482] dose of study  intervention,  which 
corresponds to the time needed to eliminate reproductive safety risk of the study 
intervention(s):  
• Refrain  from  donating  sperm. 
PLUS either : 
• Be abstinent  from  heterosexual  intercourse  as their preferred  and usual  lifestyle 
(abstinent on a long -term and persistent basis) and agree to remain abstinent.  
OR 
• Must  agree  to use contraception/barrier  as detailed  below:  
• Agree to use a male condom, and should also be advised of the benefit for a 
female  partner  to use a highly  effective  method  of contraception,  as a condom 
may break  or leak,  when  having  sexual  intercourse  with a WOCBP  who is not 
currently pregnant.  
• In addition  to male  condom  use, a highly  effective  method  of contraception  may be 
considered in WOCBP partners of male participants (refer to the list of highly 
effective methods below in Section 10.4.4 ). 
10.4.2.  Female  Participant  Reproductive  Inclusion  Criteria  
The criteria  below  are part of inclusion  criterion  1 (Age  and Sex; Section  5.1) and specify  the 
reproductive requirements for including female participants. Refer to Section 10.4.[ADDRESS_465483] of contraceptive methods permitted in the study.  
A female  participant  is eligible  to participate  if she is not pregnant  or breastfeeding  and is not 
a WOCBP (see definition in Section 10.4.3).  
The investigator  is responsible  for review  of medical  history,  menstrual  history,  and recent 
sexual activity to decrease the risk for inclusion of a woman with an early undetected 
pregnancy.  
10.4.3.  Woman  of Childbearing  Potential  
A woman  is considered  fertile  following  menarche  and until becoming  postmenopausal 
unless permanently sterile (see below).  
PF-07328948  
Protocol  C4921001  
Final  Protocol  Amendment  2, 24 Jan 2023  
PFIZER  CONFIDENTIAL  
Page  93  
 If fertility  is unclear  (eg, amenorrhea  in adolescents  or athletes)  and a menstrual  cycle  cannot 
be confirmed before the first dose of study intervention, additional evaluation should be 
considered.  
Women  in the following  categories  are not considered  WOCBP:  
1. Premenopausal  female  with 1 of the following:  
• Documented  hysterectomy;  
• Documented bilateral salpi[INVESTIGATOR_1656];  
• Documented  bilateral  oophorectomy.  
For individuals with permanent infertility due to a medical cause other than the above 
(eg, mullerian  agenesis,  androgen  insensitivity),  investigator  discretion  should  be applied 
to determining study entry.  
Note:  Documentation  for any of the above  categories  can come  from  the site personnel’s 
review of the participant’s medical records, medical examination, or medical history 
interview.  The method  of documentation  should  be recorded  in the participant’s  medical 
record for the study.  
2. Postmenopausal  female.  
• A postmenopausal  state is defined  as no menses  for 12 months  without  an 
alternative medical cause. In addition:  
• A high FSH level in the postmenopausal range must be used to confirm a 
postmenopausal  state in women  under  60 years  old and not using  hormonal 
contraception or HRT.  
• A female on HRT and whose menopausal status is in doubt must discontinue 
HRT  to allow  confirmation  of postmenopausal  status  before  study  enrollment.  
10.4.4.  Contraception  Methods  
Contraceptive  use by [CONTACT_219910]/regulations 
regarding the use of contraceptive methods for those participating in clinical trials.  
The following  contractive  methods  are appropriate  for this study:  
Highly  Effective  Methods  That Have  Low User  Dependency  (for WOCBP  partners  of male  
participants)  
1. Implantable  progestogen -only hormone  contraception  associated  with inhibition  of 
ovulation.  
PF-07328948  
Protocol  C4921001  
Final  Protocol  Amendment  2, 24 Jan 2023  
PFIZER  CONFIDENTIAL  
Page  94  
 2. Intrauterine  device.  
3. Intrauterine  hormone -releasing  system.  
4. Bilateral  tubal  occlusion.  
5. Vasectomized  partner:  
• Vasectomized  partner  is a highly  effective  contraceptive  method  provided  that the 
partner is the sole sexual partner of the WOCBP and the absence of sperm has 
been confirmed. If not, an additional highly effective method of contraception 
should be used. The spermatogenesis cycle is approximately 90 days.  
Highly  Effective  Methods  That Are User  Dependent  (for WOCBP  partners  of male  
participants)  
6. Combined  (estrogen - and progestogen -containing)  hormonal  contraception  associated 
with inhibition of ovulation:  
• Oral;  
• Intravaginal;  
• Transdermal.  
7. Progestogen -only hormone  contraception  associated  with inhibition  of ovulation:  
• Oral;  
• Injectable.  
Sexual Abstinence  
8. Sexual abstinence is considered a highly effective method only if defined as 
refraining from heterosexual intercourse during the entire period of risk associated 
with the study  intervention.  The reliability  of sexual  abstinence  needs  to be evaluated 
in relation to the duration of the study and the preferred and usual lifestyle of the 
participant.  
PF-07328948  
Protocol  C4921001  
Final  Protocol  Amendment  2, 24 Jan 2023  
PFIZER  CONFIDENTIAL  
Page  95  
 10.5. Appendix  5: Genetics 
Use/Analysis of DNA  
• Genetic variation may impact a participant’s response to study intervention, 
susceptibility to, and severity and progression of disease. Therefore, where local 
regulations  and IRBs/ECs  allow,  a blood  sample  will be collected  for DNA  analysis.  
• The scope  of the genetic  research  may be narrow  (eg, 1 or more  candidate  genes)  or 
broad (eg, the entire genome), as appropriate to the scientific question under 
investigation.  
• The samples may  be analyzed as part of a multistudy  assessment of genetic factors 
involved  in the response  to study  intervention  or study  interventions  of this class  to 
understand treatments for the disease(s) under study or the disease(s) themselves.  
• The results of genetic analyses may be reported in the CSR or in a separate study 
summary,  or may be used for internal  decision  making  without  being  included  in a 
study report.  
• The sponsor  will store  the DNA  samples  in a secure  storage  space  with adequate 
measures to protect confidentiality.  
• The samples  will be retained  as indicated:  
• Retained  samples  will be stored  indefinitely  or for another  period  as per local 
requirements.  
• Participants  may withdraw  their consent  for the storage  and/or  use of their Retained 
Research Samples at any time by [CONTACT_7328] a request to the investigator; in this case, 
any remaining material will be destroyed. Data already  generated from the samples 
will be retained to protect the integrity of existing analyses.  
• Samples  for genetic  research  will be labeled  with a code.  The key between  the code 
and the participant’s personally  identifying information (eg, name, address) will be 
held securely at the study site.  
PF-07328948  
Protocol  C4921001  
Final  Protocol  Amendment  2, 24 Jan 2023  
PFIZER  CONFIDENTIAL  
Page  96  
 10.6. Appendix  6: Liver  Safety:  Suggested  Actions  and Follow -Up Assessments 
Potential Cases of Drug -Induced Liver Injury  
Humans exposed to a drug who show no sign of liver injury (as determined by  [CONTACT_20023])  are termed  “tolerators,”  while  those  who show  transient  liver injury  but adapt 
are termed “adaptors.” In some participants, transaminase elevations are a harbinger of a 
more serious potential outcome. These participants fail to adapt and therefore are 
“susceptible” to progressive and serious liver injury, commonly referred to as DILI. 
Participants who experience a transaminase elevation above 3 × ULN should be monitored 
more frequently to determine if they are “adaptors” or are “susceptible.”  
In the majority  of DILI  cases,  elevations  in AST  and/or  ALT  precede  T bili elevations 
(>2 × ULN) by [CONTACT_22857]. The increase in T bili typi[INVESTIGATOR_22774]/ALT is/are still elevated above 3 × ULN (ie, AST/ALT and T bili values will be  
elevated  within  the same  laboratory  sample).  In rare instances,  by [CONTACT_29623] T bili elevations 
are detected, AST/ALT values might have decreased. This occurrence is still regarded as a 
potential DILI. Therefore, abnormal elevations in either AST OR ALT in addition to T bili 
that meet the criteria outlined below are considered potential DILI (assessed per Hy’s law 
criteria) cases and should always be considered important medical events, even before all 
other possible causes of liver injury have been excluded.  
The threshold of laboratory abnormalities for a potential DILI case depends on the 
participant’s  individual  baseline  values  and underlying  conditions.  Participants  who present 
with the following laboratory abnormalities should be evaluated further as potential DILI 
(Hy’s law) cases to definitively determine the etiology of the abnormal laboratory values:  
• Participants  with AST/ALT  and T bili baseline  values  within  the normal  range  who 
subsequently present with AST OR ALT values ≥3 × ULN AND a T bili value  
≥2 × ULN  with no evidence  of hemolysis  and an alkaline  phosphatase  value  
<2 × ULN or not available.  
• For participants  with baseline  AST  OR ALT  OR T bili values  above  the ULN,  the 
following threshold values are used in the definition mentioned above, as needed, 
depending on which values are above the ULN at baseline:  
• Preexisting AST or ALT baseline values above the normal range: AST or ALT 
values  ≥2 times  the baseline  values  AND  ≥3 × ULN;  or ≥8 × ULN  (whichever  is 
smaller).  
• Preexisting  values  of T bili above  the normal  range:  T bili level  increased  from 
baseline value by [CONTACT_219911] ≥1 × ULN or if the value reaches ≥3 × ULN 
(whichever is smaller).  
PF-[ADDRESS_465484]/ALT and T bili separated by [CONTACT_726] a few weeks should be assessed 
individually  based  on clinical  judgment;  any case where  uncertainty  remains  as to whether  it 
represents a potential Hy’s law case should be reviewed with the sponsor.  
The participant should return to the investigator site and be evaluated as soon as possible, 
preferably  within  [ADDRESS_465485] and ALT and T bili for suspected Hy’s law 
cases, additional laboratory tests should include albumin, CK, direct and indirect bilirubin, 
GGT, PT/INR, total bile acids, and alkaline phosphatase. Consideration should also be given 
to drawing a separate tube of clotted blood and an anticoagulated tube of blood for further 
testing, as needed, for further contemporaneous analyses at the time of the recognized initial 
abnormalities to determine etiology. A detailed history, including relevant information, such 
as review of ethanol, acetaminophen/paracetamol (either by [CONTACT_20025] a coformulated 
product in prescription or over -the-counter medications), recreational drug, or supplement 
(herbal)  use and consumption,  family  history,  sexual  history,  travel  history,  history  of contact 
[CONTACT_4490] a jaundiced person, surgery, blood transfusion, history of liver or allergic disease, and 
potential occupational exposure to chemicals, should be collected. Further testing for acute 
hepatitis  A, B, C, D, and E infection,  liver imaging  (eg, biliary  tract),  and collection  of serum 
samples for acetaminophen/paracetamol drug and/or protein adduct levels may  be warranted.  
All cases demonstrated on repeat testing as meeting the laboratory  criteria of AST/ALT and 
T bili elevation defined above should be considered potential DILI (Hy’s law) cases if no 
other  reason  for the LFT abnormalities  has yet  been  found.  Such  potential  DILI  (Hy’s  law) 
cases are to be reported as SAEs, irrespective of availability of all the results of the 
investigations performed to determine etiology of the LFT abnormalities.  
A potential DILI (Hy’s law) case becomes a confirmed case only after all results of 
reasonable  investigations  have  been  received  and have  excluded  an alternative  etiology.  
PF-07328948  
Protocol  C4921001  
Final  Protocol  Amendment  2, 24 Jan 2023  
PFIZER  CONFIDENTIAL  
Page  98  
 10.7. Appendix  7: Kidney  Safety:  Monitoring  Guidelines  
10.7.1.  Laboratory  Assessment  of Change  in Kidney  Function  and Detection  of Kidney 
Injury  
Standard kidney safety monitoring requires assessment of baseline and postbaseline serum 
creatinine (SCr measurement to estimate glomerular filtration rate [SCr -based eGFR] or 
eCrCl]. Baseline and postbaseline serum SCys makes it feasible to distinguish AKI from 
other causes of SCr increase. If SCr increase is confirmed after baseline, then reflex 
measurement  of SCys  is indicated  to estimate  the combined  SCr-SCys  eGFR  calculation  (for 
adults only).  
Regardless of whether kidney function monitoring tests are required as a routine safety 
monitoring  procedure  in the study,  if the investigator  or sponsor  deems  it necessary  to further 
assess kidney safety and quantify kidney function, then these test results should be managed 
and followed per standard of care.  
10.7.2.  Age-Specific  Kidney  Function  Calculation  Recommendations  
[IP_ADDRESS].  Adults  (18 Years  and Above) —2021  CKD -EPI [INVESTIGATOR_185560]  
 
2021  CKD -EPI 
[INVESTIGATOR_371993] 
(mg/dL)  SCys  
(mg/L)  Recommended  eGFR  Equation  
Female  if ≤0.7 NA eGFR  = 143  × (SCr/0.7)-0.241 × (0.9938)Age 
Female  if >0.7 NA eGFR  = 143  × (SCr/0.7)-1.200 × (0.9938)Age 
Male  if ≤0.9 NA eGFR  = 142  × (SCr/0.9)-0.302 × (0.9938)Age 
Male  if >0.9 NA eGFR  = 142 ×  (SCr/0.9)-1.200 × (0.9938)Age 
2021  CKD -EPI 
[CONTACT_114263]-SCys 
Combined  SCr 
(mg/dL)  SCys  
(mg/L)  Recommended  eGFR  Equation  
Female  if ≤0.7 if ≤0.8 eGFR  = 130 × (SCr/0.7)-0.219 × (SCys/0.8)-0.323 × (0.9961)Age 
Female  if ≤0.7 if >0.8 eGFR  = 130 × (SCr/0.7)-0.219 × (SCys/0.8)-0.778 × (0.9961)Age 
Female  if >0.7 if ≤0.8 eGFR  = 130 × (SCr/0.7)-0.544 × (SCys/0.8)-0.323 × (0.9961)Age 
Female  if >0.7 if >0.8 eGFR  = 130 × (SCr/0.7)-0.544 × (SCys/0.8)-0.778 × (0.9961)Age 
Male  if ≤0.9 if ≤0.8 eGFR  = 135 × (SCr/0.9)-0.144 × (SCys/0.8)-0.323 × (0.9961)Age 
Male  if ≤0.9 if >0.8 eGFR  = 135 × (SCr/0.9)-0.144 × (SCys/0.8)-0.778 × (0.9961)Age 
Male  if >0.9 if ≤0.8 eGFR  = 135 × (SCr/0.9)-0.544 × (SCys/0.8)-0.323 × (0.9961)Age 
Male  if >0.9 if >0.8 eGFR  = 135 × (SCr/0.9)-0.544 × (SCys/0.8)-0.778 × (0.9961)Age 
Source:9 
10.7.3.  Adverse  Event  Grading  for Kidney  Safety  Laboratory  Abnormalities  
AE grading  for decline  in kidney  function  (ie, eGFR  or eCrCl)  will be according  to KDIGO 
criteria.10 
PF-07328948  
Protocol  C4921001  
Final  Protocol  Amendment  2, 24 Jan 2023  
PFIZER  CONFIDENTIAL  
Page  99  
 10.8. Appendix  8: ECG  Findings  of Potential  Clinical  Concern  
 
ECG  Findings That  May  Qualify  as AEs 
• Marked  sinus  bradycardia  (rate <40 bpm)  lasting  minutes.  
• New  PR interval  prolongation >280 ms. 
• New prolongation of QTcF to >480 ms (absolute) or by  ≥60 ms from baseline.  
• New -onset  atrial  flutter  or fibrillation,  with controlled  ventricular  response  rate: ie, 
rate <120 bpm.  
• New -onset  type I second -degree  (Wenckebach)  AV block  of >30 seconds’ 
duration.  
• Frequent  PVCs,  triplets,  or short  intervals  (<30  seconds)  of consecutive  ventricular 
complexes.  
ECG  Findings  That  May  Qualify  as SAEs  
• QTcF prolongation >500 ms. 
• New  ST-T changes  suggestive  of myocardial  ischemia.  
• New -onset  LBBB  (QRS  complex>120  ms). 
• New -onset  right  bundle  branch  block  (QRS  complex>120  ms). 
• Symptomatic  bradycardia.  
• Asystole:  
• In awake,  symptom -free participants  in sinus  rhythm,  with documented  periods 
of asystole  ≥3.0 seconds  or any escape  rate <40 bpm,  or with an escape  rhythm 
that is below the AV node.  
• In awake,  symptom -free participants  with atrial  fibrillation  and bradycardia 
with [ADDRESS_465486] 5 seconds or longer.  
• Atrial  flutter  or fibrillation,  with rapid  ventricular  response  rate: rapid  = rate 
>120  bpm.  
• Sustained  supraventricular  tachycardia  (rate >120  bpm)  (“sustained”  = short 
duration with relevant symptoms or lasting >1 minute).  
PF-07328948  
Protocol  C4921001  
Final  Protocol  Amendment  2, 24 Jan 2023  
PFIZER  CONFIDENTIAL  
Page  100  
  
• Ventricular  rhythms  >30 seconds’  duration,  including  idioventricular  rhythm  (HR 
<40 bpm),  accelerated  idioventricular  rhythm  (HR >40 bpm to <100  bpm),  and 
monomorphic/polymorphic ventricular tachycardia (HR >100 bpm [such as 
torsades de pointes]).  
• Type II  second -degree  (Mobitz II)  AV block.  
• Complete  (third -degree)  heart  block.  
ECG  Findings That  Qualify as  SAEs  
• Change  in pattern  suggestive  of new myocardial  infarction.  
• Sustained  ventricular  tachyarrhythmias  (>30  seconds’  duration).  
• Second - or third -degree  AV block  requiring  pacemaker  placement.  
• Asystolic  pauses  requiring  pacemaker  placement.  
• Atrial flutter or fibrillation with rapid ventricular response requiring cardioversion.  
• Ventricular  fibrillation/flutter.  
• At the discretion  of the investigator,  any arrhythmia  classified  as an adverse 
experience.  
The enumerated list of major events of potential clinical concern are recommended as “alerts” or 
notifications  from  the core ECG  laboratory  to the investigator  and [COMPANY_007]  study  team,  and not to be 
considered as all -inclusive of what to be reported as AEs/SAEs.  
PF-07328948  
Protocol  C4921001  
Final  Protocol  Amendment  2, 24 Jan 2023  
PFIZER  CONFIDENTIAL  
Page  101  
 10.9. Appendix  9: Protocol  Amendment  History  
The protocol  amendment  summary  of changes  table  for the current  amendment  is located 
directly before the TOC. The protocol amendment summary of changes tables for past 
amendment(s) can be found below:  
Amendment  1 (29 September  2022)  
Overall  Rationale  for the Amendment:  use precautionary  sentinel  dosing  in dose 
escalation to mitigate potential unpredicted risks in FIH study  
 
Section  # and Name  [CONTACT_372018] 1.1 (Synopsis),  
Section  1.2 (Schema),  
Section 4.1 (Overall  
Design),  Section  6.6.1 
(Dose Escalation and 
Stoppi[INVESTIGATOR_1869])  Added description 
wording of 
precautionary  sentinel 
dosing in Overall 
Design of synopsis, 
Schema and Overall 
Design.  To describe 
sentinel  dosing  Substantial  
Section 2.3 
(Benefit/Risk 
Assessment),  Mentioned the use of 
precautionary  sentinel 
dosing.  To describe 
sentinel  dosing  Substantial  
Section  4.2 (Scientific 
Rationale for Study 
Design)  Added the scientific 
rationale for 
precautionary  sentinel 
dosing.  To provide 
rationale for 
precautionary 
sentinel dosing  Substantial  
Title  page  and 
Section 1.1 (Synopsis)  Added  US IND number  To provide the 
US IND number  Nonsubstantial  
PF-07328948  
Protocol  C4921001  
Final  Protocol  Amendment  2, 24 Jan 2023  
PFIZER  CONFIDENTIAL  
Page  102  
 10.10.  Appendix  10: Abbreviations  
The following is a list of abbreviations that may  be used in the protocol.  
 
Abbreviation  Term  
Abs absolute  
ADL  activity/activities  of daily  living  
AE adverse  event  
AKI acute  kidney  injury  
ALT  alanine aminotransferase  
ANOVA  analysis  of variance  
AST aspartate aminotransferase  
AUC  area under  the plasma  concentration -time curve  
AUC 24,u unbound AUC over [ADDRESS_465487] quantifiable concentration  
Cmax maximum concentration  
Cmax,u  unbound  Cmax 
CO 2 carbon  dioxide  (bicarbonate)  
COVID -[ADDRESS_465488]  European  Union  Drug  Regulating  Authorities  Clinical  Trials 
(European Clinical Trials Database)  
F bioavailability  
fa fraction  absorbed  
fg fraction escapi[INVESTIGATOR_371994] -stimulating  hormone  
fu fraction  unbound  
GCP  Good  Clinical  Practice  
GGT  gamma -glutamyl  transferase  
GLP Good Laboratory  Practice  
Hb hemoglobin  
PF-[ADDRESS_465489]  idiosyncratic  drug reaction  
IB Investigator’s  Brochure  
IC50 half maximal  inhibitory  concentration  
ICD informed  consent  document  
ICH International  Council  for Harmonisation  of Technical 
Requirements for Pharmaceuticals for Human Use  
ID identification  
Ile isoleucine  
IMP investigational  medicinal  product  
IND Investigational  New  Drug  
INR international  normalized  ratio 
IPAL  Investigational Product Accountability  Log 
IRB Institutional  Review  Board  
IV intravenous(ly)  
K Proportionality  constant  for Bedside  and Modified  Schwartz 
Equations (kidney function)  
K2EDTA  K2 dipotassium  ethylenediaminetetraacetic  acid 
KDIGO  Kidney  Disease Improving Global Outcomes  
KIC ketoleucine  
KIV ketovaline  
KMV  ketoisoleucine  
LBBB  left bundle  branch  block  
Leu namely  leucine  
LFT liver function  test 
LVSP  peak  left ventricular  systolic  pressure  
MCH  mean corpuscular hemoglobin  
MCHC  mean  corpuscular  hemoglobin  concentration  
MCV  mean corpuscular volume  
MMTT  mixed meal tolerance test 
MQI  medically  qualified individual  
NA not applicable  
NAFLD  non-alcoholic  fatty liver disease  
NASH  non-alcoholic  steatohepatitis  
NHP  nonhuman  primate  
PF-[ADDRESS_465490]  level  
OATP  organic -anion -transporting  polypeptides  
 CCI     
PBPK  physiologically  based  pharmacokinetic  
PCRU  [COMPANY_007] Clinical Research Unit 
PD pharmacodynamic(s)  
PE physical  examination  
PI [INVESTIGATOR_63168](s)  
PO by [CONTACT_372016]'s Serious Adverse Event Submission  Assistant  
PT prothrombin time 
PVC  premature  ventricular  contraction/complex  
QTc corrected  QT interval  
QTcF  QTc corrected  using  Fridericia’s  formula  
qual qualitative  
RBC  red blood  cell 
RNA  ribonucleic  acid 
RRCK  Ralph Russ canine kidney  
SAD  single  ascending  dose 
SAE serious  adverse  event  
SAP Statistical  Analysis  Plan 
SARS -CoV-[ADDRESS_465491] operating procedure  
SPF sun protection  factor  
SRSD  single  reference  safety  document  
S[LOCATION_003]R  Suspected  Unexpected  Serious  Adverse  Reaction  
t½ terminal  elimination  half-life 
T bili total bilirubin  
THC  tetrahydrocannabinol  
UACR  urine  albumin/creatinine  ratio 
UGT  uridine  5'-diphospho -glucuronosyltransferase  
ULN  upper  limit  of normal  
US United  States  
PF-[ADDRESS_465492] infection  
UV ultraviolet  
Val valine  
Vss volume of distribution at steady  state 
WBC  white  blood  cell 
WOCBP  woman/women  of childbearing  potential  
PF-[ADDRESS_465493]  of Branched -Chain  Amino  Acids 
Promotes Heart Failure. Circulation. 2016;133(21):2038 -2049.  
2 Uddin  GM, Zhang  L, Shah  S, et al. Impaired  branched  chain  amino  acid oxidation 
contributes to cardiac insulin resistance in heart failure. Cardiovasc Diabetol. 
2019;18(1):86. Published [ADDRESS_465494]. 2013;9(11):[ADDRESS_465495] CB, An J, Bain JR, et al. A branched -chain amino acid -related metabolic 
signature  [CONTACT_372019]. 
Cell Metab 2009;9(4):[ADDRESS_465496] and after exercise. Int  J Sport  Nutr 
Exerc Metab. 2012;22(6):452 -462. 
6 Varma  MV, Steyn  SJ, Allerton  C, et al. Predicting  Clearance  Mechanism  in Drug 
Discovery: Extended Clearance Classification System (ECCS). Pharm Res. 
2015;32(12):3785 -3802.  
7 Muscelli  E, Frascerra  S, Casolaro  A, et al. The amino  acid response  to a mixed  meal  in 
patients with type 2 diabetes: effect of sitagliptin treatment. Diabetes Obes Metab. 
2014;16(11):1140 -1147.  
8 Gaggini  M, Carli  F, Rosso  C, et al. Altered  amino  acid concentrations  in NAFLD: 
Impact of obesity and insulin resistance. Hepatology. 2018;67(1):145 -158. 
9 Inker LA, Eneanya ND, Coresh J, et al. New Creatinine - and Cystatin C -Based 
Equations  to Estimate  GFR  without  Race.  N Engl  J Med.  2021;385(19):1737 -1749.  
10 KDIGO  guidelines.  KDIGO  website.  Available  from:  https://kdigo.org/guidelines/. 
Accessed: 29 Aug 2022.  